<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Pfizer Inc. (PFE) Q4 2025 Earnings Call February 3, 2026 10:00 AM EST<br><br>Company Participants<br><br>Francesca DeMartino - Chief Investor Relations Officer<br>Albert Bourla - Chairman of the Board & CEO<br>Chris Boshoff - Chief Scientific Officer and President of Research & Development<br>David Denton - Executive VP & CFO<br>Aamir Malik - Executive VP & Chief U.S.</td><td># í™”ì´ì (Pfizer Inc.) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br>2026ë…„ 2ì›” 3ì¼ ì˜¤ì „ 10ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>í”„ë€ì²´ìŠ¤ì¹´ ë“œë§ˆë¥´í‹°ë…¸ (Francesca DeMartino) - ìµœê³  íˆ¬ìì ê´€ê³„ ì±…ì„ì<br>ì•Œë²„íŠ¸ ë¶€ë¥¼ë¼ (Albert Bourla) - ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO<br>í¬ë¦¬ìŠ¤ ë³´ì‡¼í”„ (Chris Boshoff) - ìµœê³  ê³¼í•™ ì±…ì„ì ê²¸ ì—°êµ¬ê°œë°œ ë¶€ë¬¸ ì‚¬ì¥<br>ë°ì´ë¹„ë“œ ë´íŠ¼ (David Denton) - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br>ì•„ë¯¸ë¥´ ë§ë¦­ (Aamir Malik) - ì „ë¬´ì´ì‚¬ ê²¸ ë¯¸êµ­ ì‚¬ì—…ë¶€ ëŒ€í‘œ</td></tr>
<tr><td>Commercial Officer<br>Alexandre de Germay - Executive VP & Chief International Commercial Officer<br><br>Conference Call Participants<br><br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Vamil Divan - Guggenheim Securities, LLC, Research Division<br>Steve Scala - TD Cowen, Research Division<br>Geoffrey Meacham - Citigroup Inc., Research Division<br>Terence Flynn - Morgan Stanley, Research Division<br>Akash Tewari - Jefferies LLC, Research Division<br>Asad Haider - Goldman Sachs Group, Inc., Research Division<br>Courtney Breen - Bernstein Institutional Services LLC, Research Division<br>Umer Raffat - Evercore ISI Institutional Equities, Research Division<br>Jason Gerberry - BofA Securities, Research Division<br>Michael Yee<br>Alexandria Hammond - Wolfe Research, LLC<br>Mohit Bansal - Wells Fargo Securities, LLC, Research Division<br>Evan Seigerman - BMO Capital Markets Equity Research<br>David Risinger - Leerink Partners LLC, Research Division<br>Louise Chen - Scotiabank Global Banking and Markets, Research Division<br><br>Presentation<br><br>Operator<br><br>Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call.</td><td>ìƒì—… ë‹´ë‹¹ ì„ì›<br>Alexandre de Germay - ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³  êµ­ì œìƒì—…ì±…ì„ì<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>Christopher Schott - JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Vamil Divan - Guggenheim Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Steve Scala - TD Cowen, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Geoffrey Meacham - Citigroup Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Terence Flynn - Morgan Stanley, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Akash Tewari - Jefferies LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Asad Haider - Goldman Sachs Group, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Courtney Breen - Bernstein Institutional Services LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Umer Raffat - Evercore ISI Institutional Equities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Jason Gerberry - BofA Securities, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Michael Yee<br>Alexandria Hammond - Wolfe Research, LLC<br>Mohit Bansal - Wells Fargo Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Evan Seigerman - BMO Capital Markets ì£¼ì‹ ë¦¬ì„œì¹˜<br>David Risinger - Leerink Partners LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Louise Chen - Scotiabank Global Banking and Markets, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì—¬ëŸ¬ë¶„. í™”ì´ìì˜ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am. Francesca DeMartino<br>Chief Investor Relations Officer<br><br>Good morning, and welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the fourth quarter and full year 2025 via a press release that is available on our website at pfizer.com. I'm joined today by Dr. Albert Bourla, our Chairman and CEO; Dr.</td><td>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, í™”ì´ì ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ì €ëŠ” ìµœê³  íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ì„ì›ì¸ í”„ë€ì²´ìŠ¤ì¹´ ë“œë§ˆë¥´í‹°ë…¸ì…ë‹ˆë‹¤. í™”ì´ì íŒ€ì„ ëŒ€í‘œí•˜ì—¬ ì°¸ì„í•´ ì£¼ì‹  ì—¬ëŸ¬ë¶„ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì€ pfizer.comì—ì„œ ì˜¤ë””ì˜¤ ì›¹ìºìŠ¤íŠ¸ë¡œ ì œê³µë˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì•„ì¹¨ ì¼ì° ë‹¹ì‚¬ëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì„ ë³´ë„ìë£Œë¥¼ í†µí•´ ë°œí‘œí–ˆìœ¼ë©°, ì´ëŠ” ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ pfizer.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ ì•¨ë²„íŠ¸ ë¶€ë¥¼ë¼ íšŒì¥ ê²¸ CEOì™€...<br><br>[Note: The transcript appears to be incomplete as it cuts off mid-sentence. I've translated up to the point where the text ends.]</td></tr>
<tr><td>Chris Boshoff, our Scientific Officer -- Chief Scientific Officer; and Dave Denton, our CFO. Albert, Chris and Dave have some prepared remarks, and we will then open the call for questions. Members of our leadership team will be available for the Q&A session. Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures. I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning and the disclosures in our SEC filings, which are all available on the IR website on pfizer.com.</td><td>í¬ë¦¬ìŠ¤ ë³´ì‡¼í”„ ìµœê³ ê³¼í•™ì±…ì„ì(Chief Scientific Officer)ì™€ ë°ì´ë¸Œ ë´íŠ¼ ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)ê°€ í•¨ê»˜í•©ë‹ˆë‹¤. ì•Œë²„íŠ¸, í¬ë¦¬ìŠ¤, ë°ì´ë¸Œê°€ ì¤€ë¹„ëœ ë°œì–¸ì„ ë¨¼ì € í•˜ê³ , ì´í›„ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ê² ìŠµë‹ˆë‹¤. ê²½ì˜ì§„ì´ ì§ˆì˜ì‘ë‹µ ì„¸ì…˜ì— ì°¸ì—¬í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì‹œì‘í•˜ê¸° ì „ì—, ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì„ í•˜ê²Œ ë˜ë©° íŠ¹ì • ë¹„-GAAP ì¬ë¬´ì§€í‘œë“¤ì„ ë…¼ì˜í•  ê²ƒì„ì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ í”„ë ˆì  í…Œì´ì…˜, ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œí•œ ë³´ë„ìë£Œ, ê·¸ë¦¬ê³  SEC ì œì¶œ ì„œë¥˜ì˜ ë©´ì±…ì¡°í•­ì„ ì½ì–´ë³´ì‹¤ ê²ƒì„ ê¶Œì¥ë“œë¦½ë‹ˆë‹¤. ì´ ëª¨ë“  ìë£ŒëŠ” pfizer.comì˜ íˆ¬ììê´€ê³„(IR) ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date and we undertake no obligation to update or revise any of the statements. With that, I will turn the call over to Albert. Albert Bourla<br>Chairman of the Board & CEO<br><br>Thank you, Francesca. So 2025 was a very good year for Pfizer. I'm very pleased with strong execution to deliver and, frankly, over-deliver on our financial commitments. We exceeded expectations for revenues and adjusted diluted EPS while also returning $9.8 billion to shareholders via our quarterly dividend.</td><td>ì•ˆë…•í•˜ì„¸ìš”. ì „ë¬¸ ê¸ˆìœµ ë²ˆì—­ê°€ì…ë‹ˆë‹¤. í•´ë‹¹ ì‹¤ì ë°œí‘œ ë‚´ìš©ì„ í•œêµ­ì–´ë¡œ ë²ˆì—­í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>---<br><br>ë³¸ ì»¨í¼ëŸ°ìŠ¤ ì½œì˜ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì€ ìƒë‹¹í•œ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì„ ë‚´í¬í•˜ê³  ìˆìœ¼ë©°, ì»¨í¼ëŸ°ìŠ¤ ì½œ ì›ë˜ ë‚ ì§œ ê¸°ì¤€ìœ¼ë¡œë§Œ ìœ íš¨í•©ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì´ëŸ¬í•œ ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•˜ê±°ë‚˜ ìˆ˜ì •í•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ì•Œë²„íŠ¸ì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì•Œë²„íŠ¸ ë¶€ë¥¼ë¼(Albert Bourla)<br>ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, í”„ë€ì²´ìŠ¤ì¹´. 2025ë…„ì€ í™”ì´ìì—ê²Œ ë§¤ìš° ì¢‹ì€ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ì €ëŠ” ì¬ë¬´ ì•½ì†ì„ ì´í–‰í•˜ê³ , ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ê·¸ ì´ìƒì„ ë‹¬ì„±í•œ ê°•ë ¥í•œ ì‹¤í–‰ë ¥ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë§¤ì¶œ(revenues)ê³¼ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(adjusted diluted EPS) ëª¨ë‘ì—ì„œ ê¸°ëŒ€ì¹˜ë¥¼ ì´ˆê³¼í–ˆìœ¼ë©°, ë¶„ê¸° ë°°ë‹¹ê¸ˆ(quarterly dividend)ì„ í†µí•´ 98ì–µ ë‹¬ëŸ¬ë¥¼ ì£¼ì£¼ë“¤ì—ê²Œ í™˜ì›í–ˆìŠµë‹ˆë‹¤.<br><br>---<br><br>ì°¸ê³ ì‚¬í•­:<br>- Forward-looking statements: ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ  (ì¬ë¬´ì œí‘œ ë° IR ìë£Œì—ì„œ í‘œì¤€ì ìœ¼ë¡œ ì‚¬ìš©ë˜ëŠ” ìš©ì–´)<br>- Adjusted diluted EPS: ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ (ì¼íšŒì„± í•­ëª©ì„ ì œì™¸í•œ ì£¼ë‹¹ìˆœì´ìµ)<br>- Quarterly dividend: ë¶„ê¸° ë°°ë‹¹ê¸ˆ</td></tr>
<tr><td>We grew overall operational revenue for full year 2025 when excluding COVID-19 products, achieved solid double-digit growth in recently launched and acquired products and expanded adjusted gross margins. Strategic actions in 2025 helped us resolve significant uncertainty, including achieving greater clarity on pricing and tariffs and demonstrating the underlying resilience of our business to deliver EPS despite the lowest-ever COVID-19 season. We achieved four key approvals, eight critical readouts and initiated 11 pivotal studies. And our Metsera, YaoPharma and 3SBio deals helped strengthen our robust pipeline. Overall, 2025 reinforced how well Pfizer can execute.</td><td>2025ë…„ ì „ì²´ ìš´ì˜ ë§¤ì¶œì€ ì½”ë¡œë‚˜19 ì œí’ˆì„ ì œì™¸í•˜ê³ ë„ ì„±ì¥í–ˆìœ¼ë©°, ìµœê·¼ ì¶œì‹œ ë° ì¸ìˆ˜í•œ ì œí’ˆë“¤ì—ì„œ ê²¬ê³ í•œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆê³  ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì„ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. 2025ë…„ì˜ ì „ëµì  ì¡°ì¹˜ë“¤ì€ ê°€ê²© ì±…ì •ê³¼ ê´€ì„¸ì— ëŒ€í•œ ëª…í™•ì„± í™•ë³´, ê·¸ë¦¬ê³  ì—­ëŒ€ ìµœì € ìˆ˜ì¤€ì˜ ì½”ë¡œë‚˜19 ì‹œì¦Œì—ë„ ë¶ˆêµ¬í•˜ê³  ì£¼ë‹¹ìˆœì´ìµ(EPS)ì„ ë‹¬ì„±í•˜ë©° ìš°ë¦¬ ì‚¬ì—…ì˜ ê·¼ë³¸ì ì¸ íšŒë³µë ¥ì„ ì…ì¦í•˜ëŠ” ë“± ìƒë‹¹í•œ ë¶ˆí™•ì‹¤ì„±ì„ í•´ì†Œí•˜ëŠ” ë° ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 4ê±´ì˜ ì£¼ìš” ìŠ¹ì¸ì„ íšë“í–ˆê³ , 8ê±´ì˜ ì¤‘ìš”í•œ ì„ìƒê²°ê³¼ë¥¼ ë°œí‘œí–ˆìœ¼ë©°, 11ê±´ì˜ í”¼ë²—(pivotal) ì„ìƒì‹œí—˜ì„ ê°œì‹œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Metsera, YaoPharma, 3SBioê³¼ì˜ ê±°ë˜ëŠ” ìš°ë¦¬ì˜ íƒ„íƒ„í•œ íŒŒì´í”„ë¼ì¸ì„ ê°•í™”í•˜ëŠ” ë° ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ 2025ë…„ì€ í™”ì´ìê°€ ì–¼ë§ˆë‚˜ ì˜ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ”ì§€ë¥¼ ì¬í™•ì¸ì‹œì¼œ ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We strengthened a foundation, positioning us for growth towards the end of the decade, continued impact for patient and long-term shareholder value. We have once again defined strategic priorities for the year ahead, which we presented at JPMorgan. 2026 is an important year in a pivotal investment period as we strive for industry-leading growth after several key products lose patent for regulatory exclusivity in the next few years. Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years. They have transformative potential for Pfizer, and we are focused on maximizing the value of in-line product portfolios and accelerating pipeline development.</td><td>ìš°ë¦¬ëŠ” ê¸°ë°˜ì„ ê°•í™”í•˜ì—¬ 2020ë…„ëŒ€ ë§ê¹Œì§€ ì„±ì¥í•  ìˆ˜ ìˆëŠ” ì…ì§€ë¥¼ ë§ˆë ¨í–ˆìœ¼ë©°, í™˜ìë“¤ì„ ìœ„í•œ ì§€ì†ì ì¸ ì˜í–¥ë ¥ê³¼ ì¥ê¸° ì£¼ì£¼ê°€ì¹˜ë¥¼ ì¶”êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. JPëª¨ê±´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ë°œí‘œí•œ ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” ë‹¤ì‹œ í•œë²ˆ ë‚´ë…„ë„ ì „ëµì  ìš°ì„ ìˆœìœ„ë¥¼ ì •ë¦½í–ˆìŠµë‹ˆë‹¤. 2026ë…„ì€ ì¤‘ìš”í•œ í•´ì…ë‹ˆë‹¤. í–¥í›„ ëª‡ ë…„ê°„ ì—¬ëŸ¬ í•µì‹¬ ì œí’ˆë“¤ì´ íŠ¹í—ˆ ë° ê·œì œ ë…ì ê¶Œì„ ìƒì‹¤í•˜ëŠ” ì‹œì  ì´í›„ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì„±ì¥ì„ ë‹¬ì„±í•˜ê¸° ìœ„í•œ ì¤‘ì¶”ì  íˆ¬ì ê¸°ê°„ì— í•´ë‹¹í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì‹œì  (Seagen), ë©”íŠ¸ì„¸ë¼(Metsera), ë°”ì´ì˜¤í—¤ì´ë¸(Biohaven)ì€ ìµœê·¼ ëª‡ ë…„ê°„ ê°€ì¥ ì¤‘ìš”í•œ ì „ëµì  ì¸ìˆ˜ì˜€ìŠµë‹ˆë‹¤. ì´ë“¤ì€ í™”ì´ìì— í˜ì‹ ì  ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ìš°ë¦¬ëŠ” í˜„ì¬ íŒë§¤ ì¤‘ì¸ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê°€ì¹˜ë¥¼ ê·¹ëŒ€í™”í•˜ê³  íŒŒì´í”„ë¼ì¸ ê°œë°œì„ ê°€ì†í™”í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We made continued progress last year, integrating legacy Seagen products into our commercial portfolio. I'm also pleased with notable advances in our development programs, including a recent FDA approval for Padcev in combination with pembro for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy. We are encouraged by the opportunity to build on this with an expected regulatory decision for patients with cisplatin-eligible MIBC. If successful we will substantially expand the U.S.</td><td>ì €í¬ëŠ” ì‘ë…„ì— ë ˆê±°ì‹œ Seagen ì œí’ˆë“¤ì„ ìƒì—… í¬íŠ¸í´ë¦¬ì˜¤ì— í†µí•©í•˜ëŠ” ë° ìˆì–´ ì§€ì†ì ì¸ ì§„ì „ì„ ì´ë£¨ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ ê°œë°œ í”„ë¡œê·¸ë¨ì—ì„œ ì£¼ëª©í•  ë§Œí•œ ì§„ì „ì„ ì´ë£¬ ê²ƒì— ëŒ€í•´ì„œë„ ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì‹œìŠ¤í”Œë¼í‹´ í•¨ìœ  í™”í•™ìš”ë²•ì´ ì í•©í•˜ì§€ ì•Šì€ ê·¼ìœ¡ ì¹¨ìœ¤ì„± ë°©ê´‘ì•” í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ Padcevê³¼ í¨ë¸Œë¡œ ë³‘ìš©ìš”ë²•ì— ëŒ€í•œ ìµœê·¼ FDA ìŠ¹ì¸ì´ í¬í•¨ë©ë‹ˆë‹¤. ì €í¬ëŠ” ì‹œìŠ¤í”Œë¼í‹´ ì ê²© ê·¼ìœ¡ ì¹¨ìœ¤ì„± ë°©ê´‘ì•” í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ê·œì œ ë‹¹êµ­ì˜ ê²°ì •ì„ í†µí•´ ì´ë¥¼ ë”ìš± ë°œì „ì‹œí‚¬ ìˆ˜ ìˆëŠ” ê¸°íšŒì— ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë§Œì•½ ì„±ê³µí•œë‹¤ë©´ ë¯¸êµ­ ì‹œì¥ì„ ì‹¤ì§ˆì ìœ¼ë¡œ í™•ëŒ€í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>addressable population with up to approximately 22,500 additional patients across both cis-eligible and cis-ineligible muscle-invasive bladder cancer, up from about 19,000 patients in metastatic urothelial cancer. We have a clear strategy aiming for Pfizer leadership in the next generation of therapies for chronic weight management with a highly differentiated Metsera pipeline portfolio, our YaoPharma exclusive global collaboration and licensing agreement and other Pfizer programs such as our oral GIPR antagonist candidate. Since closing our Biohaven acquisition a few years ago, we have globally scaled a leading migraine portfolio.</td><td>ëŒ€ìƒ í™˜ìêµ°ì€ ì‹œìŠ¤í”Œë¼í‹´ ì ê²© ë° ë¶€ì ê²© ê·¼ìœ¡ì¹¨ìœ¤ì„± ë°©ê´‘ì•”ì„ í•©ì³ ì•½ 22,500ëª…ì˜ ì¶”ê°€ í™˜ìë¡œ í™•ëŒ€ë˜ë©°, ì´ëŠ” ì „ì´ì„± ìš”ë¡œìƒí”¼ì•”ì˜ ì•½ 19,000ëª… í™˜ìì—ì„œ ì¦ê°€í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì°¨ë³„í™”ëœ Metsera íŒŒì´í”„ë¼ì¸ í¬íŠ¸í´ë¦¬ì˜¤, YaoPharmaì™€ì˜ ë…ì ì  ê¸€ë¡œë²Œ í˜‘ë ¥ ë° ë¼ì´ì„ ì‹± ê³„ì•½, ê·¸ë¦¬ê³  ê²½êµ¬ìš© GIPR ê¸¸í•­ì œ í›„ë³´ë¬¼ì§ˆê³¼ ê°™ì€ ê¸°íƒ€ í™”ì´ì í”„ë¡œê·¸ë¨ì„ í†µí•´ ì°¨ì„¸ëŒ€ ë§Œì„± ì²´ì¤‘ ê´€ë¦¬ ì¹˜ë£Œì œ ë¶„ì•¼ì—ì„œ í™”ì´ìì˜ ë¦¬ë”ì‹­ì„ ëª©í‘œë¡œ í•˜ëŠ” ëª…í™•í•œ ì „ëµì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ìˆ˜ë…„ ì „ Biohaven ì¸ìˆ˜ë¥¼ ì™„ë£Œí•œ ì´í›„, ìš°ë¦¬ëŠ” ì„ ë„ì ì¸ í¸ë‘í†µ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì „ ì„¸ê³„ì ìœ¼ë¡œ í™•ëŒ€í•´ ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>It strengthened our product mix to drive significant impact both for patients and our commercial performance. Nurtec has a strong market leadership position in the oral CGRP class in 2025. In Q4, we captured 83% of new CGRP writer volume and remain the leader in new patient starts. I expect 2026 to be also a very rich year for key catalysts and we intend to deliver on our critical R&D milestones. This year, we anticipate progress with approximately 20 recently initiated and planned key pivotal studies, with 10 of them in the Metsera portfolio and four with our anti-PD-1 VEGF bispecific.</td><td>ì´ëŠ” í™˜ìë“¤ê³¼ ìš°ë¦¬ì˜ ìƒì—…ì  ì„±ê³¼ ëª¨ë‘ì— ìƒë‹¹í•œ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆë„ë¡ ì œí’ˆ ë¯¹ìŠ¤ë¥¼ ê°•í™”í–ˆìŠµë‹ˆë‹¤. Nurtecì€ 2025ë…„ ê²½êµ¬ìš© CGRP í´ë˜ìŠ¤ì—ì„œ ê°•ë ¥í•œ ì‹œì¥ ì„ ë„ì  ì§€ìœ„ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ì‹ ê·œ CGRP ì²˜ë°© ë¬¼ëŸ‰ì˜ 83%ë¥¼ í™•ë³´í–ˆìœ¼ë©°, ì‹ ê·œ í™˜ì ì‹œì‘ ë¶€ë¬¸ì—ì„œë„ ì„ ë‘ë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €ëŠ” 2026ë…„ë„ ì£¼ìš” ì´‰ë§¤ì œë“¤ì´ í’ë¶€í•œ í•œ í•´ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ìš°ë¦¬ì˜ í•µì‹¬ R&D ë§ˆì¼ìŠ¤í†¤ì„ ë‹¬ì„±í•  ê³„íšì…ë‹ˆë‹¤. ì˜¬í•´ ìš°ë¦¬ëŠ” ìµœê·¼ ì°©ìˆ˜í–ˆê±°ë‚˜ ê³„íš ì¤‘ì¸ ì•½ 20ê°œì˜ ì£¼ìš” í”¼ë³´íƒˆ ì„ìƒì‹œí—˜ì—ì„œ ì§„ì „ì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ê·¸ ì¤‘ 10ê°œëŠ” Metsera í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ, 4ê°œëŠ” ìš°ë¦¬ì˜ í•­-PD-1 VEGF ì´ì¤‘íŠ¹ì´í•­ì²´ë¡œ ì§„í–‰ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Among eight expected key readouts, we anticipate, one for SV, our novel, potential first-in-class, integrin beta 6-targeting vedotin ADC. The readout will be in second-line-plus non-squamous metastatic non-small cell lung cancer, which affects about 50,000 patients in the U.S. and more than 200,000 patients globally. We are also expecting key Phase III readouts for Elrexfio in double-class exposed relapsed, refractory multiple myeloma and for our Lyme disease vaccine candidate. The foundation of our strategy in obesity and adjacent condition is targeting breakthrough medicines in what could be a $150 billion market.</td><td>8ê°œì˜ ì£¼ìš” ì„ìƒ ê²°ê³¼ ë°œí‘œ ì¤‘, ìš°ë¦¬ëŠ” SVì— ëŒ€í•œ í•œ ê±´ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. SVëŠ” ë‹¹ì‚¬ì˜ í˜ì‹ ì ì´ê³  ì ì¬ì ì¸ ë™ì¢… ìµœì´ˆ(first-in-class) ì¸í…Œê·¸ë¦° ë² íƒ€6 í‘œì  ë² ë„í‹´ ADCì…ë‹ˆë‹¤. ì´ë²ˆ ê²°ê³¼ëŠ” 2ì°¨ ì¹˜ë£Œ ì´ìƒì˜ ë¹„í¸í‰ ì „ì´ì„± ë¹„ì†Œì„¸í¬íì•”ì— ëŒ€í•œ ê²ƒìœ¼ë¡œ, ì´ëŠ” ë¯¸êµ­ì—ì„œ ì•½ 5ë§Œ ëª…, ì „ ì„¸ê³„ì ìœ¼ë¡œëŠ” 20ë§Œ ëª… ì´ìƒì˜ í™˜ìì—ê²Œ ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ì§ˆí™˜ì…ë‹ˆë‹¤. ë˜í•œ ì´ì¤‘ ê³„ì—´ ë…¸ì¶œ ì¬ë°œì„±, ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì— ëŒ€í•œ Elrexfioì™€ ë¼ì„ë³‘ ë°±ì‹  í›„ë³´ë¬¼ì§ˆì— ëŒ€í•œ ì£¼ìš” 3ìƒ ì„ìƒ ê²°ê³¼ë„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¹„ë§Œ ë° ì¸ì ‘ ì§ˆí™˜ì— ëŒ€í•œ ìš°ë¦¬ ì „ëµì˜ í•µì‹¬ì€ 1,500ì–µ ë‹¬ëŸ¬ ê·œëª¨ê°€ ë  ìˆ˜ ìˆëŠ” ì‹œì¥ì—ì„œ íšê¸°ì ì¸ ì˜ì•½í’ˆì„ ëª©í‘œë¡œ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Earlier today, we announced encouraging results from our VESPER-3 study, which previously was known as Metsera-097i (sic) [ MET-097i ], the ultra-long acting investigational next-generation injectable GLP-1 receptor agonist. In a few moments, Chris Boshoff, our Chief Scientific Officer, will walk through additional details and our plans for advancing our obesity portfolio this year. Oncology is another source of strength, and I'm excited by opportunities for significant progress in 2026 that would build on our established presence in breast, in genitourinary, in thoracic and gastrointestinal cancer and of course, blood cancer.</td><td>ì˜¤ëŠ˜ ì´ˆ, ìš°ë¦¬ëŠ” ì´ì „ì— Metsera-097i [MET-097i]ë¡œ ì•Œë ¤ì¡Œë˜ VESPER-3 ì—°êµ¬ì—ì„œ ê³ ë¬´ì ì¸ ê²°ê³¼ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ˆì¥ê¸° ì§€ì†í˜• ì°¨ì„¸ëŒ€ ì£¼ì‚¬í˜• GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œì…ë‹ˆë‹¤. ì ì‹œ í›„, ìš°ë¦¬ì˜ ìµœê³ ê³¼í•™ì±…ì„ìì¸ Chris Boshoffê°€ ì¶”ê°€ ì„¸ë¶€ì‚¬í•­ê³¼ ì˜¬í•´ ë¹„ë§Œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë°œì „ì‹œí‚¤ê¸° ìœ„í•œ ìš°ë¦¬ì˜ ê³„íšì„ ì„¤ëª…í•  ê²ƒì…ë‹ˆë‹¤. ì¢…ì–‘í•™ì€ ë˜ ë‹¤ë¥¸ ê°•ì ì˜ ì›ì²œì´ë©°, ìœ ë°©ì•”, ë¹„ë‡¨ìƒì‹ê¸°ì•”, í‰ë¶€ì•”, ìœ„ì¥ê´€ì•”, ê·¸ë¦¬ê³  ë¬¼ë¡  í˜ˆì•¡ì•” ë¶„ì•¼ì—ì„œ ìš°ë¦¬ì˜ í™•ê³ í•œ ì…ì§€ë¥¼ ê¸°ë°˜ìœ¼ë¡œ 2026ë…„ì— ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£° ìˆ˜ ìˆëŠ” ê¸°íšŒì— ëŒ€í•´ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In addition to promising programs, such as the SV, our Oncology team is moving quickly with a robust program for '4404, the bispecific antibody licensed last year from 3SBio. We have seven near-term planned or recently started trials for '4404, including two large global Phase III studies, anchoring our efforts to establish this investigational medicine as a potential backbone therapy across multiple tumor types. We're also pleased that the FDA has granted HYMPAVZI Breakthrough Therapy Designation for investigation in younger pediatric patients aged 6 to 11 in hemophilia B with or without inhibitors.</td><td>SVì™€ ê°™ì€ ìœ ë§í•œ í”„ë¡œê·¸ë¨ ì™¸ì—ë„, ë‹¹ì‚¬ì˜ ì¢…ì–‘í•™ íŒ€ì€ ì‘ë…„ì— 3SBioë¡œë¶€í„° ë¼ì´ì„ ìŠ¤ë¥¼ ì·¨ë“í•œ ì´ì¤‘íŠ¹ì´í•­ì²´ '4404ì— ëŒ€í•œ ê°•ë ¥í•œ í”„ë¡œê·¸ë¨ì„ ì‹ ì†í•˜ê²Œ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” '4404ì— ëŒ€í•´ 7ê±´ì˜ ë‹¨ê¸° ê³„íš ë˜ëŠ” ìµœê·¼ ì‹œì‘ëœ ì„ìƒì‹œí—˜ì„ ì§„í–‰ ì¤‘ì´ë©°, ì—¬ê¸°ì—ëŠ” 2ê±´ì˜ ëŒ€ê·œëª¨ ê¸€ë¡œë²Œ 3ìƒ ì—°êµ¬ê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ ì—°êµ¬ ì¤‘ì¸ ì˜ì•½í’ˆì„ ë‹¤ì–‘í•œ ì¢…ì–‘ ìœ í˜•ì— ê±¸ì³ ì ì¬ì ì¸ ê¸°ë°˜ ì¹˜ë£Œì œë¡œ í™•ë¦½í•˜ë ¤ëŠ” ë‹¹ì‚¬ì˜ ë…¸ë ¥ì„ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ FDAê°€ ì–µì œì œ ìœ ë¬´ì™€ ê´€ê³„ì—†ì´ í˜ˆìš°ë³‘ Bë¥¼ ì•“ê³  ìˆëŠ” 6ì„¸ì—ì„œ 11ì„¸ ì‚¬ì´ì˜ ì†Œì•„ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ì—°êµ¬ì— ëŒ€í•´ HYMPAVZIì— í˜ì‹ ì¹˜ë£Œì œ ì§€ì •(Breakthrough Therapy Designation)ì„ ë¶€ì—¬í•œ ê²ƒì„ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>That's an important innovative medicine today, and we are investigating the full potential of HYMPAVZI to support more patients living with hemophilia. Our third strategic priority is investing to maximize post-2028 growth. We are committed to fully supporting a robust and accelerated approach to R&D, the successful commercial launch of new products and bolt-on business development while maintaining our robust dividend. And finally, we are scaling artificial intelligence across R&D, manufacturing, commercial and patient engagement to improve productivity and accelerate innovation. We have been setting the foundation with AI-ready data, agentic workflows and compute capacity.</td><td>ì´ëŠ” ì˜¤ëŠ˜ë‚  ì¤‘ìš”í•œ í˜ì‹  ì˜ì•½í’ˆì´ë©°, ìš°ë¦¬ëŠ” í˜ˆìš°ë³‘ì„ ì•“ê³  ìˆëŠ” ë” ë§ì€ í™˜ìë“¤ì„ ì§€ì›í•˜ê¸° ìœ„í•´ HYMPAVZIì˜ ëª¨ë“  ì ì¬ë ¥ì„ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì„¸ ë²ˆì§¸ ì „ëµì  ìš°ì„ ìˆœìœ„ëŠ” 2028ë…„ ì´í›„ ì„±ì¥ì„ ê·¹ëŒ€í™”í•˜ê¸° ìœ„í•œ íˆ¬ìì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê²¬ê³ í•œ ë°°ë‹¹ê¸ˆì„ ìœ ì§€í•˜ë©´ì„œ ê°•ë ¥í•˜ê³  ê°€ì†í™”ëœ R&D ì ‘ê·¼ë°©ì‹, ì‹ ì œí’ˆì˜ ì„±ê³µì ì¸ ìƒì—…ì  ì¶œì‹œ, ê·¸ë¦¬ê³  ì†Œê·œëª¨ ì‚¬ì—…ê°œë°œ(bolt-on business development)ì„ ì „í­ì ìœ¼ë¡œ ì§€ì›í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ìƒì‚°ì„±ì„ í–¥ìƒì‹œí‚¤ê³  í˜ì‹ ì„ ê°€ì†í™”í•˜ê¸° ìœ„í•´ R&D, ì œì¡°, ìƒì—…í™” ë° í™˜ì ì°¸ì—¬ ì „ë°˜ì— ê±¸ì³ ì¸ê³µì§€ëŠ¥ì„ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” AI í™œìš© ê°€ëŠ¥ ë°ì´í„°(AI-ready data), ì—ì´ì „íŠ¸ ì›Œí¬í”Œë¡œìš°(agentic workflows) ë° ì»´í“¨íŒ… ì—­ëŸ‰ìœ¼ë¡œ ê¸°ë°˜ì„ êµ¬ì¶•í•´ ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>To meet the growing AI demand over the next 2 years, we are expanding to more than 1,200 GPUs, largely driven by R&D application of AI. In R&D, we are embedding AI across discovery, development, regulatory and medical to increase productivity and accelerate the pipeline and time lines. AI is optimizing supply planning and manufacturing, contributing to our Manufacturing Optimization Program goals. In commercial, AI is helping to accelerate new product launches, delivering insights for dynamic targeting and supporting personalized messaging and real-time marketing content.</td><td>AI ìˆ˜ìš” ì¦ê°€ì— ëŒ€ì‘í•˜ê¸° ìœ„í•´ í–¥í›„ 2ë…„ê°„ GPUë¥¼ 1,200ê°œ ì´ìƒìœ¼ë¡œ í™•ëŒ€í•  ê³„íšì´ë©°, ì´ëŠ” ì£¼ë¡œ R&D ë¶„ì•¼ì˜ AI í™œìš©ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. R&D ë¶€ë¬¸ì—ì„œëŠ” ì‹ ì•½ ë°œê²¬, ê°œë°œ, ê·œì œ, ì˜í•™ ì „ë°˜ì— ê±¸ì³ AIë¥¼ ë‚´ì¬í™”í•˜ì—¬ ìƒì‚°ì„±ì„ ë†’ì´ê³  íŒŒì´í”„ë¼ì¸ê³¼ ê°œë°œ ì¼ì •ì„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. AIëŠ” ê³µê¸‰ ê³„íšê³¼ ì œì¡° ê³µì •ì„ ìµœì í™”í•˜ì—¬ ì œì¡° ìµœì í™” í”„ë¡œê·¸ë¨(Manufacturing Optimization Program) ëª©í‘œ ë‹¬ì„±ì— ê¸°ì—¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒì—… ë¶€ë¬¸ì—ì„œëŠ” AIê°€ ì‹ ì œí’ˆ ì¶œì‹œ ê°€ì†í™”, ë™ì  íƒ€ê²ŸíŒ…ì„ ìœ„í•œ ì¸ì‚¬ì´íŠ¸ ì œê³µ, ê°œì¸í™”ëœ ë©”ì‹œì§• ë° ì‹¤ì‹œê°„ ë§ˆì¼€íŒ… ì½˜í…ì¸  ì§€ì›ì— í™œìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So with that and after I described the four priorities, which describe the full picture of what we plan to do in 2026, I will turn it over to Chris to discuss for the news of the day, which are the Metsera long-acting announcement of VESPER-3. Chris? Chris Boshoff<br>Chief Scientific Officer and President of Research & Development<br><br>Thank you, Albert. It is my pleasure to discuss the VESPER-3 study results today and provide more color to our press release this morning. These data are an important advancement in our obesity portfolio because they increase significantly our confidence in the Phase III monthly dosing study that we expect to start later this year.</td><td>ê·¸ëŸ¼ ì´ì œ 2026ë…„ì— ìš°ë¦¬ê°€ ê³„íší•˜ê³  ìˆëŠ” ì „ì²´ ê·¸ë¦¼ì„ ì„¤ëª…í•˜ëŠ” ë„¤ ê°€ì§€ ìš°ì„ ìˆœìœ„ë¥¼ ë§ì”€ë“œë ¸ìœ¼ë‹ˆ, ì˜¤ëŠ˜ì˜ ì£¼ìš” ì†Œì‹ì¸ Metsera ì¥ê¸°ì§€ì†í˜• ì œí’ˆì˜ VESPER-3 ë°œí‘œì— ëŒ€í•´ Chrisì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. Chris?<br><br>Chris Boshoff<br>ìµœê³ ê³¼í•™ì±…ì„ì ê²¸ ì—°êµ¬ê°œë°œ ë¶€ë¬¸ ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Albert. ì˜¤ëŠ˜ VESPER-3 ì„ìƒì‹œí—˜ ê²°ê³¼ë¥¼ ë…¼ì˜í•˜ê³  ì˜¤ëŠ˜ ì•„ì¹¨ ë³´ë„ìë£Œì— ëŒ€í•´ ë” ìì„¸íˆ ì„¤ëª…í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì´ë²ˆ ë°ì´í„°ëŠ” ìš°ë¦¬ ë¹„ë§Œ í¬íŠ¸í´ë¦¬ì˜¤ì— ìˆì–´ ì¤‘ìš”í•œ ì§„ì „ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì˜¬í•´ í›„ë°˜ì— ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ì›” 1íšŒ íˆ¬ì—¬ 3ìƒ ì„ìƒì‹œí—˜ì— ëŒ€í•œ ìš°ë¦¬ì˜ í™•ì‹ ì„ í¬ê²Œ ë†’ì—¬ì£¼ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>To start, I'd like to review how the structure of PF'3944 drives its long half-life. Prior GLP-1 receptor agonists that rely on albumin binding to extend half-life require dissociation from the albumin protein for optimal receptor engagement. '3944 binds the GLP-1 receptor while still bound to albumin due to lipidation at the terminal end of the amino acid chain rather than in the middle. This allows for reduced clearance without reduced receptor engagement, resulting in a half-life exceeding other agents that require albumin dissociation for binding. A key differentiator of '3944 is its extended half-life, which supports monthly dosing.</td><td>ë¨¼ì €, PF'3944ì˜ êµ¬ì¡°ê°€ ì–´ë–»ê²Œ ê¸´ ë°˜ê°ê¸°ë¥¼ ìœ ë„í•˜ëŠ”ì§€ ê²€í† í•˜ê³ ì í•©ë‹ˆë‹¤. ë°˜ê°ê¸° ì—°ì¥ì„ ìœ„í•´ ì•Œë¶€ë¯¼ ê²°í•©ì— ì˜ì¡´í•˜ëŠ” ê¸°ì¡´ GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œë“¤ì€ ìµœì ì˜ ìˆ˜ìš©ì²´ ê²°í•©ì„ ìœ„í•´ ì•Œë¶€ë¯¼ ë‹¨ë°±ì§ˆë¡œë¶€í„° ë¶„ë¦¬ë˜ì–´ì•¼ í•©ë‹ˆë‹¤. ë°˜ë©´ '3944ëŠ” ì•„ë¯¸ë…¸ì‚° ì‚¬ìŠ¬ ì¤‘ê°„ì´ ì•„ë‹Œ ë§ë‹¨ì— ì§€ì§ˆí™”ë˜ì–´ ìˆì–´, ì•Œë¶€ë¯¼ì— ê²°í•©ëœ ìƒíƒœì—ì„œë„ GLP-1 ìˆ˜ìš©ì²´ì™€ ê²°í•©í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ìˆ˜ìš©ì²´ ê²°í•©ë ¥ ê°ì†Œ ì—†ì´ ì²­ì†Œìœ¨(clearance)ì„ ë‚®ì¶œ ìˆ˜ ìˆìœ¼ë©°, ê²°ê³¼ì ìœ¼ë¡œ ê²°í•©ì„ ìœ„í•´ ì•Œë¶€ë¯¼ ë¶„ë¦¬ê°€ í•„ìš”í•œ ë‹¤ë¥¸ ì•½ë¬¼ë“¤ë³´ë‹¤ ê¸´ ë°˜ê°ê¸°ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. '3944ì˜ í•µì‹¬ ì°¨ë³„í™” ìš”ì†ŒëŠ” ì›” 1íšŒ íˆ¬ì—¬ë¥¼ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” ì—°ì¥ëœ ë°˜ê°ê¸°ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Furthermore, given '3944's length of 41 amino acids, the molecule is considered a biologic and would be eligible for regulatory review via the BLA pathway. The right side of the slide shows previously reported data from the Phase IIb VESPER-1 study, evaluating '3944 dosed weekly and without titration. These data show dose-dependent placebo-adjusted weight loss of up to 14.1% at week 28, demonstrating the molecule's potential to deliver efficacy that is competitive with the standard of care and potentially best-in-class among mono-agonists. In our currently ongoing weekly Phase III study of '3944, VESPER-4, we are also testing a higher dose of 2.4 milligrams weekly.</td><td>ë˜í•œ, '3944ì˜ ì•„ë¯¸ë…¸ì‚° ê¸¸ì´ê°€ 41ê°œì„ì„ ê³ ë ¤í•  ë•Œ, ì´ ë¶„ìëŠ” ìƒë¬¼í•™ì  ì œì œë¡œ ë¶„ë¥˜ë˜ì–´ BLA ê²½ë¡œë¥¼ í†µí•œ ê·œì œ ì‹¬ì‚¬ ëŒ€ìƒì´ ë©ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ ì˜¤ë¥¸ìª½ì€ '3944ë¥¼ ì£¼ 1íšŒ íˆ¬ì—¬í•˜ê³  ìš©ëŸ‰ ì ì • ì—†ì´ í‰ê°€í•œ Phase IIb VESPER-1 ì—°êµ¬ì˜ ê¸°ì¡´ ë³´ê³  ë°ì´í„°ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì´ ë°ì´í„°ëŠ” 28ì£¼ì°¨ì— ìœ„ì•½ ëŒ€ë¹„ ìµœëŒ€ 14.1%ì˜ ìš©ëŸ‰ ì˜ì¡´ì  ì²´ì¤‘ ê°ì†Œë¥¼ ë‚˜íƒ€ë‚´ë©°, ì´ëŠ” í•´ë‹¹ ë¶„ìê°€ í‘œì¤€ ì¹˜ë£Œì œì™€ ê²½ìŸë ¥ ìˆê³  ë‹¨ì¼ ì‘ìš©ì œ ì¤‘ì—ì„œëŠ” ì ì¬ì ìœ¼ë¡œ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì˜ íš¨ëŠ¥ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì„ ì…ì¦í•©ë‹ˆë‹¤. í˜„ì¬ ì§„í–‰ ì¤‘ì¸ '3944ì˜ ì£¼ 1íšŒ íˆ¬ì—¬ Phase III ì—°êµ¬ì¸ VESPER-4ì—ì„œëŠ” ì£¼ 1íšŒ 2.4ë°€ë¦¬ê·¸ë¨ì˜ ë” ë†’ì€ ìš©ëŸ‰ë„ ì‹œí—˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With VESPER-3, we aim to achieve two key objectives: first, to demonstrate that we could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain '3944's efficacy while reducing the dosing frequency 4-fold. And second, to demonstrate that '3944 could switch to a 4-fold equivalent monthly dose while maintaining a well-tolerated and favorable safety profile. Today, I will walk you through these data, which demonstrate we've successfully achieved both. The VESPER-3 Phase IIb study was designed to evaluate '3944 with monthly maintenance dosing, following a titration period of up to 12 weeks.</td><td>VESPER-3 ì—°êµ¬ë¥¼ í†µí•´ ìš°ë¦¬ëŠ” ë‘ ê°€ì§€ í•µì‹¬ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê³ ì í–ˆìŠµë‹ˆë‹¤. ì²«ì§¸, ì£¼ 1íšŒ íˆ¬ì—¬ì—ì„œ ì›” 1íšŒ í”¼í•˜ì£¼ì‚¬ë¡œ ì „í™˜í•  ë•Œ ì§€ì†ì ì¸ ì²´ì¤‘ ê°ì†Œë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆìŒì„ ì…ì¦í•˜ê³ , íˆ¬ì—¬ ë¹ˆë„ë¥¼ 4ë¶„ì˜ 1ë¡œ ì¤„ì´ë©´ì„œë„ '3944ì˜ íš¨ëŠ¥ì„ ìœ ì§€í•  ìˆ˜ ìˆìŒì„ ë³´ì—¬ì£¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ë‘˜ì§¸, '3944ê°€ 4ë°°ì— í•´ë‹¹í•˜ëŠ” ì›” 1íšŒ ìš©ëŸ‰ìœ¼ë¡œ ì „í™˜í•˜ë©´ì„œë„ ë‚´ì•½ì„±ì´ ìš°ìˆ˜í•˜ê³  ì–‘í˜¸í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ìœ ì§€í•  ìˆ˜ ìˆìŒì„ ì…ì¦í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ëŠ” ì´ ë‘ ê°€ì§€ ëª©í‘œë¥¼ ì„±ê³µì ìœ¼ë¡œ ë‹¬ì„±í–ˆìŒì„ ë³´ì—¬ì£¼ëŠ” ë°ì´í„°ë¥¼ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. VESPER-3 2bìƒ ì„ìƒì‹œí—˜ì€ ìµœëŒ€ 12ì£¼ê°„ì˜ ìš©ëŸ‰ ì ì • ê¸°ê°„ ì´í›„ ì›” 1íšŒ ìœ ì§€ ìš©ëŸ‰ìœ¼ë¡œ '3944ë¥¼ í‰ê°€í•˜ë„ë¡ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This study compares four different dosing regimens versus placebo with a prespecified interim tolerability analysis at week 12 and a primary reporting milestone at week 28. Arm 1 and Arm 3 are low and medium dose regimens that we plan to advance to Phase III, and these two study arms are the focus of the data we are sharing today. Starting with our first objective, I'm pleased to share that we observed robust, statistically significant weight loss across all doses tested. At week 28, placebo-adjusted weight loss was 10% and 12.3% for our planned low and medium Phase III doses, respectively. These results are shown in the blue bars and represent the trial's efficacy estimate.</td><td>ë³¸ ì—°êµ¬ëŠ” 4ê°€ì§€ íˆ¬ì—¬ ìš©ë²•ì„ ìœ„ì•½ê³¼ ë¹„êµí•˜ë©°, 12ì£¼ì°¨ì— ì‚¬ì „ ì§€ì •ëœ ì¤‘ê°„ ë‚´ì•½ì„± ë¶„ì„ê³¼ 28ì£¼ì°¨ì— 1ì°¨ ë³´ê³  ì‹œì ì„ ë‘ê³  ìˆìŠµë‹ˆë‹¤. Arm 1ê³¼ Arm 3ì€ 3ìƒìœ¼ë¡œ ì§„í–‰í•  ê³„íšì¸ ì €ìš©ëŸ‰ ë° ì¤‘ê°„ìš©ëŸ‰ ìš©ë²•ì´ë©°, ì´ ë‘ ì—°êµ¬êµ°ì´ ì˜¤ëŠ˜ ê³µìœ í•˜ëŠ” ë°ì´í„°ì˜ í•µì‹¬ì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ ëª©í‘œë¶€í„° ë§ì”€ë“œë¦¬ë©´, ëª¨ë“  ì‹œí—˜ ìš©ëŸ‰ì—ì„œ ê°•ë ¥í•˜ê³  í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•œ ì²´ì¤‘ ê°ì†Œë¥¼ ê´€ì°°í–ˆë‹¤ëŠ” ì ì„ ê¸°ì˜ê²Œ ë³´ê³ ë“œë¦½ë‹ˆë‹¤. 28ì£¼ì°¨ì— ìœ„ì•½ ëŒ€ë¹„ ì²´ì¤‘ ê°ì†ŒëŠ” ê³„íšëœ 3ìƒ ì €ìš©ëŸ‰ê³¼ ì¤‘ê°„ìš©ëŸ‰ì—ì„œ ê°ê° 10%ì™€ 12.3%ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ëŠ” íŒŒë€ìƒ‰ ë§‰ëŒ€ë¡œ í‘œì‹œë˜ì–´ ìˆìœ¼ë©° ì„ìƒì‹œí—˜ì˜ ìœ íš¨ì„± ì¶”ì •ì¹˜ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>In the teal bars are our model predictions of the potential efficacy we would expect with monthly maintenance dosing of '3944 in the study of adults with obesity or overweight and without type 2 diabetes, similar to VESPER-3. A model-based meta-analysis approach was used to generate these predictions. This approach uses a mathematical model to capture the weight loss trajectory over time and the dose-response relationship. This model was built, taking into account the observed data from the VESPER-3 trial, the available data from other '3944 clinical studies and data from published trials of other weight loss.</td><td>ì²­ë¡ìƒ‰ ë§‰ëŒ€ëŠ” VESPER-3ì™€ ìœ ì‚¬í•˜ê²Œ ë¹„ë§Œ ë˜ëŠ” ê³¼ì²´ì¤‘ì´ë©´ì„œ ì œ2í˜• ë‹¹ë‡¨ë³‘ì´ ì—†ëŠ” ì„±ì¸ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ì—°êµ¬ì—ì„œ '3944ì˜ ì›” 1íšŒ ìœ ì§€ ìš©ëŸ‰ íˆ¬ì—¬ ì‹œ ì˜ˆìƒë˜ëŠ” ì ì¬ì  íš¨ëŠ¥ì— ëŒ€í•œ ì €í¬ ëª¨ë¸ ì˜ˆì¸¡ì¹˜ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì˜ˆì¸¡ì¹˜ë¥¼ ìƒì„±í•˜ê¸° ìœ„í•´ ëª¨ë¸ ê¸°ë°˜ ë©”íƒ€ë¶„ì„(model-based meta-analysis) ì ‘ê·¼ë²•ì„ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤. ì´ ì ‘ê·¼ë²•ì€ ì‹œê°„ ê²½ê³¼ì— ë”°ë¥¸ ì²´ì¤‘ ê°ì†Œ ì¶”ì´ì™€ ìš©ëŸ‰-ë°˜ì‘ ê´€ê³„ë¥¼ í¬ì°©í•˜ê¸° ìœ„í•´ ìˆ˜í•™ì  ëª¨ë¸ì„ í™œìš©í•©ë‹ˆë‹¤. ì´ ëª¨ë¸ì€ VESPER-3 ì„ìƒì‹œí—˜ì—ì„œ ê´€ì°°ëœ ë°ì´í„°, ë‹¤ë¥¸ '3944 ì„ìƒì—°êµ¬ì—ì„œ í™•ë³´í•œ ë°ì´í„°, ê·¸ë¦¬ê³  ê¸°íƒ€ ì²´ì¤‘ ê°ì†Œ ê´€ë ¨ ê³µê°œëœ ì„ìƒì‹œí—˜ ë°ì´í„°ë¥¼ ì¢…í•©ì ìœ¼ë¡œ ê³ ë ¤í•˜ì—¬ êµ¬ì¶•ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>For the low and medium dose regimens, we see excellent concordance between our VESPER-3 clinical data in blue and our model predictions in teal. Applying the same model to project the potential efficacy of the planned Phase III high-dose regimen of 9.6 milligrams monthly, we predict placebo-adjusted weight loss of nearly 16% at week 28. Note, the high dose is already being studied in the VESPER-4 Phase III study as a 2.4-milligram weekly dose. Collectively, our clinical data model predictions show that '3944 can deliver robust weight loss after switching to monthly administration and suggest that we can potentially achieve increased efficacy with a higher dose.</td><td>ì €ìš©ëŸ‰ ë° ì¤‘ê°„ ìš©ëŸ‰ íˆ¬ì—¬êµ°ì˜ ê²½ìš°, íŒŒë€ìƒ‰ìœ¼ë¡œ í‘œì‹œëœ VESPER-3 ì„ìƒ ë°ì´í„°ì™€ ì²­ë¡ìƒ‰ìœ¼ë¡œ í‘œì‹œëœ ëª¨ë¸ ì˜ˆì¸¡ì¹˜ ê°„ì— íƒì›”í•œ ì¼ì¹˜ë„ë¥¼ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë™ì¼í•œ ëª¨ë¸ì„ ì ìš©í•˜ì—¬ ê³„íš ì¤‘ì¸ 3ìƒ ê³ ìš©ëŸ‰ íˆ¬ì—¬êµ°ì¸ ì›” 1íšŒ 9.6ë°€ë¦¬ê·¸ë¨ì˜ ì ì¬ì  íš¨ëŠ¥ì„ ì˜ˆì¸¡í•œ ê²°ê³¼, 28ì£¼ì°¨ì— ìœ„ì•½ ëŒ€ë¹„ ì•½ 16%ì˜ ì²´ì¤‘ ê°ì†Œë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ, ê³ ìš©ëŸ‰ íˆ¬ì—¬êµ°ì€ ì´ë¯¸ VESPER-4 3ìƒ ì—°êµ¬ì—ì„œ ì£¼ 1íšŒ 2.4ë°€ë¦¬ê·¸ë¨ ìš©ëŸ‰ìœ¼ë¡œ ì—°êµ¬ê°€ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ì¢…í•©ì ìœ¼ë¡œ, ìš°ë¦¬ì˜ ì„ìƒ ë°ì´í„° ëª¨ë¸ ì˜ˆì¸¡ì€ '3944ê°€ ì›” 1íšŒ íˆ¬ì—¬ë¡œ ì „í™˜í•œ í›„ì—ë„ ê°•ë ¥í•œ ì²´ì¤‘ ê°ì†Œ íš¨ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆìœ¼ë©°, ë” ë†’ì€ ìš©ëŸ‰ìœ¼ë¡œ íš¨ëŠ¥ ì¦ëŒ€ë¥¼ ì ì¬ì ìœ¼ë¡œ ë‹¬ì„±í•  ìˆ˜ ìˆìŒì„ ì‹œì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Moreover, VESPER-3 data do not show a weight-loss plateau reached at week 28, projecting continued weight loss is expected as the study continues through week 64. With these results, we are confident that '3944 has the potential to deliver efficacy that is competitive with the standard of care and potentially best-in-class among mono-agonists with a differentiated monthly dosing format. Next, I'll turn your attention to the second objective of VESPER-3 demonstrating a well-tolerated and favorable safety profile for '3944 when switching to a 4-fold equivalent monthly dose. Similar to our first objective, I'm pleased to report that here too, '3944 delivered.</td><td>ë”ìš±ì´, VESPER-3 ë°ì´í„°ëŠ” 28ì£¼ì°¨ì— ì²´ì¤‘ ê°ì†Œ ì •ì²´ê¸°(plateau)ì— ë„ë‹¬í•˜ì§€ ì•Šì•˜ìŒì„ ë³´ì—¬ì£¼ë©°, ì—°êµ¬ê°€ 64ì£¼ì°¨ê¹Œì§€ ê³„ì†ë¨ì— ë”°ë¼ ì§€ì†ì ì¸ ì²´ì¤‘ ê°ì†Œê°€ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” '3944ê°€ í‘œì¤€ ì¹˜ë£Œì œ(standard of care)ì™€ ê²½ìŸë ¥ ìˆëŠ” íš¨ëŠ¥ì„ ì œê³µí•  ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ì°¨ë³„í™”ëœ ì›” 1íšŒ íˆ¬ì—¬ ë°©ì‹ì„ ê°–ì¶˜ ë‹¨ì¼ ì‘ìš©ì œ(mono-agonist) ì¤‘ì—ì„œ ì ì¬ì ìœ¼ë¡œ ë™ê¸‰ ìµœê³ (best-in-class)ê°€ ë  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, VESPER-3ì˜ ë‘ ë²ˆì§¸ ëª©í‘œì¸ 4ë°° ìš©ëŸ‰ì— í•´ë‹¹í•˜ëŠ” ì›” 1íšŒ íˆ¬ì—¬ë¡œ ì „í™˜ ì‹œ '3944ì˜ ìš°ìˆ˜í•œ ë‚´ì•½ì„±(tolerability)ê³¼ ì–‘í˜¸í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ ì…ì¦ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ëª©í‘œì™€ ë§ˆì°¬ê°€ì§€ë¡œ, ì—¬ê¸°ì„œë„ '3944ê°€ ì„±ê³µì ì¸ ê²°ê³¼ë¥¼ ë‹¬ì„±í–ˆìŒì„ ê¸°ì˜ê²Œ ë³´ê³ ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>In VESPER-3, '3944 has displayed a well-tolerated and favorable safety profile that is consistent with what has been observed with weekly GLP-1 receptor agonists. Observed gastrointestinal treatment-emergent adverse events were predominantly mild or moderate with no more than one instance of severe nausea or vomiting in any dose group and no instances of severe diarrhea. Treatment discontinuation rates for VESPER-3 weekly and monthly phases both show a compelling profile. Across the dose regimens planned for inclusion in Phase III, five participants discontinued due to adverse events in each of the weekly and monthly phases.</td><td>VESPER-3 ì—°êµ¬ì—ì„œ '3944ëŠ” ì£¼ 1íšŒ íˆ¬ì—¬ GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œì—ì„œ ê´€ì°°ëœ ê²ƒê³¼ ì¼ê´€ë˜ê²Œ ìš°ìˆ˜í•œ ë‚´ì•½ì„±ê³¼ ì–‘í˜¸í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ê´€ì°°ëœ ìœ„ì¥ê´€ê³„ ì¹˜ë£Œ ê´€ë ¨ ì´ìƒë°˜ì‘ì€ ëŒ€ë¶€ë¶„ ê²½ì¦ ë˜ëŠ” ì¤‘ë“±ë„ì˜€ìœ¼ë©°, ì–´ë–¤ ìš©ëŸ‰êµ°ì—ì„œë„ ì¤‘ì¦ ì˜¤ì‹¬ ë˜ëŠ” êµ¬í† ê°€ 1ê±´ì„ ì´ˆê³¼í•˜ì§€ ì•Šì•˜ê³ , ì¤‘ì¦ ì„¤ì‚¬ ì‚¬ë¡€ëŠ” ì „í˜€ ì—†ì—ˆìŠµë‹ˆë‹¤. VESPER-3ì˜ ì£¼ê°„ ë° ì›”ê°„ íˆ¬ì—¬ ë‹¨ê³„ ëª¨ë‘ì—ì„œ ì¹˜ë£Œ ì¤‘ë‹¨ìœ¨ì€ ë§¤ìš° ìš°ìˆ˜í•œ í”„ë¡œíŒŒì¼ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. 3ìƒ ì„ìƒì‹œí—˜ì— í¬í•¨ë  ì˜ˆì •ì¸ ìš©ëŸ‰ ìš”ë²• ì „ë°˜ì— ê±¸ì³, ì£¼ê°„ ë° ì›”ê°„ íˆ¬ì—¬ ë‹¨ê³„ ê°ê°ì—ì„œ ì´ìƒë°˜ì‘ìœ¼ë¡œ ì¸í•´ ì¹˜ë£Œë¥¼ ì¤‘ë‹¨í•œ ì°¸ê°€ìëŠ” 5ëª…ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>There were no discontinuations due to adverse events in the placebo group. We're encouraged by these results as they serve as an important proof of concept for the delivery of our 4-fold equivalent monthly dose that maintains competitive tolerability, particularly given the study protocol did not limit down titration. The totality of tolerability data support our plans to evaluate a higher monthly dose of 9.6 milligrams in Phase III, which is the monthly equivalent to the 2.4 milligram weekly dose currently being studied in the ongoing VESPER-4 trial. Today's encouraging results bolster our expansive obesity program.</td><td>ìœ„ì•½êµ°ì—ì„œëŠ” ì´ìƒë°˜ì‘ìœ¼ë¡œ ì¸í•œ íˆ¬ì•½ ì¤‘ë‹¨ ì‚¬ë¡€ê°€ ì—†ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ëŠ” ê²½ìŸë ¥ ìˆëŠ” ë‚´ì•½ì„±ì„ ìœ ì§€í•˜ë©´ì„œ 4ë°° ìš©ëŸ‰ì— í•´ë‹¹í•˜ëŠ” ì›” 1íšŒ íˆ¬ì—¬ë¥¼ ì…ì¦í•˜ëŠ” ì¤‘ìš”í•œ ê°œë… ì¦ëª…ìœ¼ë¡œì„œ ê³ ë¬´ì ì´ë©°, íŠ¹íˆ ì„ìƒì‹œí—˜ í”„ë¡œí† ì½œì´ ìš©ëŸ‰ ê°ëŸ‰ì„ ì œí•œí•˜ì§€ ì•Šì•˜ë‹¤ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ ë”ìš± ê·¸ë ‡ìŠµë‹ˆë‹¤. ì „ë°˜ì ì¸ ë‚´ì•½ì„± ë°ì´í„°ëŠ” 3ìƒì—ì„œ ì›” 1íšŒ 9.6ë°€ë¦¬ê·¸ë¨ì˜ ë” ë†’ì€ ìš©ëŸ‰ì„ í‰ê°€í•˜ë ¤ëŠ” ì €í¬ ê³„íšì„ ë’·ë°›ì¹¨í•˜ë©°, ì´ëŠ” í˜„ì¬ ì§„í–‰ ì¤‘ì¸ VESPER-4 ì„ìƒì‹œí—˜ì—ì„œ ì—°êµ¬ë˜ê³  ìˆëŠ” ì£¼ 1íšŒ 2.4ë°€ë¦¬ê·¸ë¨ ìš©ëŸ‰ì— í•´ë‹¹í•˜ëŠ” ì›” 1íšŒ ìš©ëŸ‰ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ì˜ ê³ ë¬´ì ì¸ ê²°ê³¼ëŠ” ì €í¬ì˜ ê´‘ë²”ìœ„í•œ ë¹„ë§Œ í”„ë¡œê·¸ë¨ì„ ê°•í™”ì‹œì¼œ ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>This year, we plan to advance 20-plus obesity trials, including 10 Phase III studies of '3944 that span chronic weight management, obesity-associated comorbidities and opportunities to increase patient optionality and access. We are targeting the first of a series of potential approvals in 2028. Looking to our early-stage programs, we are enthusiastic about Phase II studies with our ultra-long-acting amylin analog, which we believe has the potential for class-leading efficacy and combinability with '3944 in a monthly dosing format. We previously reported positive early data from the single ascending dose combination study, which showed well-tolerated starting doses and additive weight loss.</td><td>ì˜¬í•´ ìš°ë¦¬ëŠ” 20ê°œ ì´ìƒì˜ ë¹„ë§Œ ì„ìƒì‹œí—˜ì„ ì§„í–‰í•  ê³„íšì´ë©°, ì—¬ê¸°ì—ëŠ” ë§Œì„± ì²´ì¤‘ ê´€ë¦¬, ë¹„ë§Œ ê´€ë ¨ ë™ë°˜ì§ˆí™˜, ê·¸ë¦¬ê³  í™˜ì ì„ íƒê¶Œ ë° ì ‘ê·¼ì„± í™•ëŒ€ ê¸°íšŒë¥¼ ì•„ìš°ë¥´ëŠ” '3944ì˜ 10ê°œ 3ìƒ ì„ìƒì‹œí—˜ì´ í¬í•¨ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2028ë…„ì— ì¼ë ¨ì˜ ì ì¬ì  ìŠ¹ì¸ ì¤‘ ì²« ë²ˆì§¸ë¥¼ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ˆê¸° ë‹¨ê³„ í”„ë¡œê·¸ë¨ì„ ì‚´í´ë³´ë©´, ìš°ë¦¬ëŠ” ì´ˆì¥ê¸° ì§€ì†í˜• ì•„ë°€ë¦° ìœ ì‚¬ì²´ì˜ 2ìƒ ì„ìƒì‹œí—˜ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì›” 1íšŒ íˆ¬ì—¬ í˜•íƒœë¡œ '3944ì™€ ë³‘ìš© ì‹œ ë™ê¸‰ ìµœê³  ìˆ˜ì¤€ì˜ íš¨ëŠ¥ê³¼ ë³‘ìš© ê°€ëŠ¥ì„±ì„ ê°€ì§ˆ ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ì „ì— ë‹¨ì¼ ìš©ëŸ‰ ì¦ëŸ‰ ë³‘ìš© ì—°êµ¬ì—ì„œ ê¸ì •ì ì¸ ì´ˆê¸° ë°ì´í„°ë¥¼ ë³´ê³ í•œ ë°” ìˆìœ¼ë©°, ì´ëŠ” ë‚´ì•½ì„±ì´ ìš°ìˆ˜í•œ ì‹œì‘ ìš©ëŸ‰ê³¼ ì¶”ê°€ì ì¸ ì²´ì¤‘ ê°ì†Œ íš¨ê³¼ë¥¼ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We plan to show updated combination data later this year. We continue to advance our potentially first-in-class oral GIPR antagonist that is in Phase II and additional Phase I studies of agents with diverse modalities and mechanisms. These include an injectable ultra-long-acting GIPR agonist, a potential quarterly dosed injectable GLP-1 receptor agonist and oral candidates. To summarize, today's results are clear. VESPER-3 achieved its two main objectives: reinforcing '3944's potential potent and tolerable monthly profile.</td><td>ì˜¬í•´ í›„ë°˜ì— ì—…ë°ì´íŠ¸ëœ ë³‘ìš© ë°ì´í„°ë¥¼ ê³µê°œí•  ê³„íšì…ë‹ˆë‹¤. í˜„ì¬ 2ìƒ ì„ìƒì‹œí—˜ ì¤‘ì¸ ì ì¬ì  first-in-class ê²½êµ¬ìš© GIPR ê¸¸í•­ì œì™€ ë‹¤ì–‘í•œ ê¸°ì „ê³¼ ëª¨ë‹¬ë¦¬í‹°ë¥¼ ê°€ì§„ ì•½ë¬¼ë“¤ì˜ ì¶”ê°€ 1ìƒ ì„ìƒì‹œí—˜ì„ ê³„ì† ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì£¼ì‚¬í˜• ì´ˆì¥ê¸° ì§€ì†í˜• GIPR ì‘ìš©ì œ, ë¶„ê¸°ë³„ íˆ¬ì—¬ ê°€ëŠ¥í•œ ì£¼ì‚¬í˜• GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œ, ê·¸ë¦¬ê³  ê²½êµ¬ìš© í›„ë³´ë¬¼ì§ˆë“¤ì´ í¬í•¨ë©ë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ì˜¤ëŠ˜ ë°œí‘œëœ ê²°ê³¼ëŠ” ëª…í™•í•©ë‹ˆë‹¤. VESPER-3ëŠ” ë‘ ê°€ì§€ ì£¼ìš” ëª©í‘œë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤: '3944ì˜ ê°•ë ¥í•˜ê³  ë‚´ì•½ì„±ì´ ìš°ìˆ˜í•œ ì›” 1íšŒ íˆ¬ì—¬ í”„ë¡œíŒŒì¼ì˜ ì ì¬ë ¥ì„ ì…ì¦í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>The ultra-long-acting GLP-1 receptor agonist serves as a foundation to our differentiated investigational obesity portfolio, delivering robust weight loss with no plateau observed at week 28 in VESPER-3, while also maintaining competitive tolerability when switching to a 4-fold equivalent monthly dose. We are primed to execute across an expansive Phase III program of '3944, targeting potential approval starting in 2028. And we are pursuing differentiated combination approaches with earlier-stage agents that have the potential to deliver greater optionality to address the diverse unmet needs of patients. With that, I'll turn it back to Albert.</td><td>ì´ ì´ˆì¥ê¸° ì‘ìš© GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œëŠ” ì°¨ë³„í™”ëœ ë¹„ë§Œ ì¹˜ë£Œ ì„ìƒ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê¸°ë°˜ ì—­í• ì„ í•˜ë©°, VESPER-3 ì—°êµ¬ì—ì„œ 28ì£¼ì°¨ì—ë„ ì •ì²´ê¸°(plateau) ì—†ì´ ê°•ë ¥í•œ ì²´ì¤‘ ê°ì†Œë¥¼ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ë™ì‹œì— 4ë°°ì— í•´ë‹¹í•˜ëŠ” ì›” 1íšŒ íˆ¬ì—¬ëŸ‰ìœ¼ë¡œ ì „í™˜í•  ë•Œë„ ê²½ìŸë ¥ ìˆëŠ” ë‚´ì•½ì„±ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” 2028ë…„ë¶€í„° ì ì¬ì  ìŠ¹ì¸ì„ ëª©í‘œë¡œ '3944ì˜ ê´‘ë²”ìœ„í•œ 3ìƒ í”„ë¡œê·¸ë¨ì„ ì‹¤í–‰í•  ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì´ˆê¸° ë‹¨ê³„ ì•½ë¬¼ë“¤ê³¼ì˜ ì°¨ë³„í™”ëœ ë³‘ìš© ì ‘ê·¼ë²•ì„ ì¶”ì§„í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” í™˜ìë“¤ì˜ ë‹¤ì–‘í•œ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•˜ê¸° ìœ„í•œ ë” í° ì„ íƒê¶Œì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ë‹¤ì‹œ Albertì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla<br>Chairman of the Board & CEO<br><br>Thank you, Chris. And I just wanted to say that today's results provide a compelling validation of our unique, proprietary ultra-long-acting peptide platform. For the first time, we have shown that the GLP-1 receptor agonist peptides can be administered monthly while maintaining the potential for competitive efficacy and safety. We are pleased with this important milestone for the platform that reinforces both the differentiation of our technology and the significant long-term value creation opportunity that represents. And with that now, I will turn it over to Dave, he will discuss the excellent results of the quarter. So Dave?</td><td>ì•Œë²„íŠ¸ ë¶€ë¥¼ë¼<br>ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, í¬ë¦¬ìŠ¤. ì˜¤ëŠ˜ì˜ ê²°ê³¼ëŠ” ìš°ë¦¬ì˜ ë…ìì ì´ê³  ê³ ìœ í•œ ì´ˆì¥ê¸° ì‘ìš© í©íƒ€ì´ë“œ í”Œë«í¼ì— ëŒ€í•œ ì„¤ë“ë ¥ ìˆëŠ” ê²€ì¦ì„ ì œê³µí•œë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì²˜ìŒìœ¼ë¡œ GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œ í©íƒ€ì´ë“œê°€ ê²½ìŸë ¥ ìˆëŠ” íš¨ëŠ¥ê³¼ ì•ˆì „ì„±ì˜ ì ì¬ë ¥ì„ ìœ ì§€í•˜ë©´ì„œ ì›” 1íšŒ íˆ¬ì—¬ë  ìˆ˜ ìˆìŒì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ ê¸°ìˆ ì˜ ì°¨ë³„í™”ì™€ ê·¸ê²ƒì´ ë‚˜íƒ€ë‚´ëŠ” ì¤‘ìš”í•œ ì¥ê¸° ê°€ì¹˜ ì°½ì¶œ ê¸°íšŒë¥¼ ëª¨ë‘ ê°•í™”í•˜ëŠ” ì´ í”Œë«í¼ì˜ ì¤‘ìš”í•œ ì´ì •í‘œì— ëŒ€í•´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ì œ ë°ì´ë¸Œì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ê·¸ê°€ ì´ë²ˆ ë¶„ê¸°ì˜ ìš°ìˆ˜í•œ ì‹¤ì ì— ëŒ€í•´ ë…¼ì˜í•  ê²ƒì…ë‹ˆë‹¤. ë°ì´ë¸Œ?</td></tr>
<tr><td>David Denton<br>Executive VP & CFO<br><br>Great. Thank you, Chris and Albert, and good morning, everyone. Let me begin today by highlighting that our strong financial performance for both the fourth quarter and the full year directly reflects our continued disciplined execution of our key strategic priorities. We resolved certain and significant uncertainties in our business and made strategic investments aimed at driving revenue growth later this decade and beyond. Looking ahead, Pfizer is approaching an exciting phase, where recently launched and acquired products and a strong pipeline are anticipated to spur growth towards the end of this decade.</td><td>ë°ì´ë¹„ë“œ ë´í„´<br>ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, í¬ë¦¬ìŠ¤ì™€ ì•Œë²„íŠ¸. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ë¨¼ì € 4ë¶„ê¸°ì™€ ì—°ê°„ ì‹¤ì  ëª¨ë‘ì—ì„œ ë‚˜íƒ€ë‚œ ìš°ë¦¬ì˜ ê°•ë ¥í•œ ì¬ë¬´ ì„±ê³¼ê°€ í•µì‹¬ ì „ëµì  ìš°ì„ ìˆœìœ„ì— ëŒ€í•œ ì§€ì†ì ì´ê³  ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ì„ ì§ì ‘ì ìœ¼ë¡œ ë°˜ì˜í•˜ê³  ìˆë‹¤ëŠ” ì ì„ ê°•ì¡°í•˜ê³ ì í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‚¬ì—…ì˜ íŠ¹ì •í•œ ì¤‘ëŒ€ ë¶ˆí™•ì‹¤ì„±ë“¤ì„ í•´ì†Œí–ˆìœ¼ë©°, ì´ë²ˆ 10ë…„ëŒ€ í›„ë°˜ê³¼ ê·¸ ì´í›„ì˜ ë§¤ì¶œ ì„±ì¥ì„ ê²¬ì¸í•˜ê¸° ìœ„í•œ ì „ëµì  íˆ¬ìë¥¼ ì‹¤í–‰í–ˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ í™”ì´ìëŠ” ìµœê·¼ ì¶œì‹œ ë° ì¸ìˆ˜í•œ ì œí’ˆë“¤ê³¼ ê°•ë ¥í•œ íŒŒì´í”„ë¼ì¸ì´ ì´ë²ˆ 10ë…„ëŒ€ ë§ì„ í–¥í•´ ì„±ì¥ì„ ì´‰ì§„í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” í¥ë¯¸ì§„ì§„í•œ êµ­ë©´ì— ì ‘ì–´ë“¤ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With that said, this morning, I'll provide our full year and fourth quarter -- full year and fourth quarter 2025 results, then I'll touch on our cost improvement initiatives as well as our capital allocation priorities. I'll finish with a few comments on our '26 guidance, which we are reaffirming today. For the full year 2025, we recorded revenues of $62.6 billion versus $63.6 billion last year, representing a 2% operational decline. Importantly, our operational revenue growth when excluding contributions from our COVID-19 products was 6%. Full year 2025 adjusted gross margins expanded to 76%, in line with our expectations.</td><td>ì´ì œ ì˜¤ëŠ˜ ì•„ì¹¨ 2025ë…„ ì—°ê°„ ë° 4ë¶„ê¸° ì‹¤ì ì„ ë§ì”€ë“œë¦° í›„, ë¹„ìš© ê°œì„  ì´ë‹ˆì…”í‹°ë¸Œì™€ ìë³¸ ë°°ë¶„ ìš°ì„ ìˆœìœ„ì— ëŒ€í•´ ì–¸ê¸‰í•˜ê² ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì˜¤ëŠ˜ ì¬í™•ì¸í•˜ëŠ” 2026ë…„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ëª‡ ê°€ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>2025ë…„ ì—°ê°„ ë§¤ì¶œì€ ì „ë…„ë„ 636ì–µ ë‹¬ëŸ¬ ëŒ€ë¹„ 626ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬, ì‹¤ì§ˆ ê¸°ì¤€ìœ¼ë¡œ 2% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€, ì½”ë¡œë‚˜19 ì œí’ˆ ê¸°ì—¬ë¶„ì„ ì œì™¸í•œ ì‹¤ì§ˆ ë§¤ì¶œ ì„±ì¥ë¥ ì€ 6%ì˜€ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. 2025ë…„ ì—°ê°„ ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ ì˜ˆìƒëŒ€ë¡œ 76%ë¡œ í™•ëŒ€ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We will continue to drive cost improvements going forward across our manufacturing network. And on the bottom line, we reported full year 2025 diluted EPS of $1.36, versus $1.41 last year and adjusted diluted earnings per share of $3.22 versus $3.11 LY, ahead of expectations. Pfizer's recently launched and acquired set of products delivered $10.2 billion in revenues for the full year of '25 while growing approximately 14% operationally versus last year. We plan to continue to invest behind these two product groups to drive their future performance to enable the company to partially offset our LOEs over the next several years.</td><td>ì•ìœ¼ë¡œë„ ì œì¡° ë„¤íŠ¸ì›Œí¬ ì „ë°˜ì— ê±¸ì³ ì›ê°€ ê°œì„ ì„ ì§€ì†ì ìœ¼ë¡œ ì¶”ì§„í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ìˆœì´ìµ ì¸¡ë©´ì—ì„œëŠ” 2025 íšŒê³„ì—°ë„ í¬ì„ì£¼ë‹¹ìˆœì´ìµ(diluted EPS)ì´ ì „ë…„ë„ 1.41ë‹¬ëŸ¬ ëŒ€ë¹„ 1.36ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì¡°ì • í¬ì„ì£¼ë‹¹ìˆœì´ìµ(adjusted diluted EPS)ì€ ì „ë…„ë„ 3.11ë‹¬ëŸ¬ ëŒ€ë¹„ 3.22ë‹¬ëŸ¬ë¡œ ì˜ˆìƒì¹˜ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. í™”ì´ìì˜ ìµœê·¼ ì¶œì‹œ ë° ì¸ìˆ˜ ì œí’ˆêµ°ì€ 2025 íšŒê³„ì—°ë„ì— 102ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì „ë…„ ëŒ€ë¹„ ì‹¤ì§ˆ ê¸°ì¤€ìœ¼ë¡œ ì•½ 14% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. í–¥í›„ ìˆ˜ë…„ê°„ íŠ¹í—ˆë§Œë£Œ(LOE)ë¡œ ì¸í•œ ë§¤ì¶œ ê°ì†Œë¥¼ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„í•  ìˆ˜ ìˆë„ë¡, ì´ ë‘ ì œí’ˆêµ°ì˜ ë¯¸ë˜ ì„±ê³¼ë¥¼ ê²¬ì¸í•˜ê¸° ìœ„í•´ ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>Now turning to the fourth quarter of '25, we recorded revenues of $17.6 billion, a decrease of 3% operationally versus the same period of LY, largely driven by an approximate 40% operational year-over-year decline in our COVID products. The decline was primarily due to Comirnaty receiving a narrow recommendation for vaccines in the U.S. and Paxlovid, which experienced reduced demand from lower infection rates. Having said that, our non-COVID product performance was solid, growing 9% operationally versus the same period of last year. Our results demonstrate the effectiveness of our refined commercial strategy.</td><td>ì´ì œ '25ë…„ 4ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ì„œ, ìš°ë¦¬ëŠ” 176ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì˜ì—… ê¸°ì¤€ 3% ê°ì†Œí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ COVID ì œí’ˆêµ°ì˜ ì˜ì—… ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ ì•½ 40% ê°ì†Œì— ê¸°ì¸í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°ì†ŒëŠ” ì£¼ë¡œ Comirnatyê°€ ë¯¸êµ­ì—ì„œ ì œí•œì ì¸ ë°±ì‹  ê¶Œê³ ë¥¼ ë°›ì•˜ê³ , Paxlovidì˜ ê²½ìš° ê°ì—¼ë¥  ê°ì†Œë¡œ ì¸í•œ ìˆ˜ìš” ê°ì†Œë¥¼ ê²½í—˜í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, ë¹„COVID ì œí’ˆ ì‹¤ì ì€ ê²¬ì¡°í•˜ì—¬ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì˜ì—… ê¸°ì¤€ 9% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ìš°ë¦¬ì˜ ì •êµí™”ëœ ìƒì—… ì „ëµì˜ íš¨ê³¼ì„±ì„ ì…ì¦í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We saw solid contributions across our product portfolio, primarily driven by Abrysvo, Eliquis, Prevnar and the Vyndaqel family. Adjusted gross margin for the fourth quarter was approximately 71%, primarily reflecting the product mix in the quarter, including lower Comirnaty sales versus fourth quarter of '24 as well as continued strong cost management. Future improvements in our manufacturing footprint remained a top priority going forward. As a reminder, over the past 2 years, our adjusted gross margins have generally remained in the mid- to upper 70s, excluding Comirnaty, which has a 50-50 profit split with our partner, BioNTech.</td><td>ìš°ë¦¬ëŠ” ì£¼ë¡œ Abrysvo, Eliquis, Prevnar ë° Vyndaqel ì œí’ˆêµ°ì— í˜ì…ì–´ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ê²¬ì¡°í•œ ê¸°ì—¬ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ ì•½ 71%ë¡œ, ì´ëŠ” ì£¼ë¡œ 24ë…„ 4ë¶„ê¸° ëŒ€ë¹„ ë‚®ì€ Comirnaty ë§¤ì¶œì„ í¬í•¨í•œ ë¶„ê¸° ì œí’ˆ ë¯¹ìŠ¤ì™€ ì§€ì†ì ì¸ ê°•ë ¥í•œ ì›ê°€ ê´€ë¦¬ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. í–¥í›„ ì œì¡° ì„¤ë¹„ì˜ ê°œì„ ì€ ì•ìœ¼ë¡œë„ ìµœìš°ì„  ê³¼ì œë¡œ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ, ì§€ë‚œ 2ë…„ê°„ ìš°ë¦¬ì˜ ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ íŒŒíŠ¸ë„ˆì‚¬ BioNTechì™€ 50ëŒ€ 50ìœ¼ë¡œ ì´ìµì„ ë¶„ë°°í•˜ëŠ” Comirnatyë¥¼ ì œì™¸í•˜ë©´ ì¼ë°˜ì ìœ¼ë¡œ 70% ì¤‘í›„ë°˜ëŒ€ë¥¼ ìœ ì§€í•´ ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We achieved approximately $600 million in savings from Phase 1 of our Manufacturing Optimization Program through 2025 with additional savings expected in '26 and '27. Total adjusted operating expenses were $7.4 billion for the fourth quarter of '25, in line with last year. But looking at the components, adjusted SI&A expenses decreased 5% operationally, primarily driven by focused investments and ongoing productivity improvements that drove a decrease in marketing and promotional spend for various products and lower spending in corporate enabling functions.</td><td>2025ë…„ê¹Œì§€ ì œì¡° ìµœì í™” í”„ë¡œê·¸ë¨ 1ë‹¨ê³„ë¥¼ í†µí•´ ì•½ 6ì–µ ë‹¬ëŸ¬ì˜ ë¹„ìš© ì ˆê°ì„ ë‹¬ì„±í–ˆìœ¼ë©°, 2026ë…„ê³¼ 2027ë…„ì—ë„ ì¶”ê°€ ì ˆê°ì´ ì˜ˆìƒë©ë‹ˆë‹¤. 2025ë…„ 4ë¶„ê¸° ì´ ì¡°ì • ì˜ì—…ë¹„ìš©ì€ 74ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ìˆ˜ì¤€ì„ ìœ ì§€í–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì„¸ë¶€ í•­ëª©ì„ ì‚´í´ë³´ë©´, ì¡°ì • íŒë§¤ê´€ë¦¬ë¹„ëŠ” ìš´ì˜ ê¸°ì¤€ìœ¼ë¡œ 5% ê°ì†Œí–ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ ì§‘ì¤‘ì ì¸ íˆ¬ìì™€ ì§€ì†ì ì¸ ìƒì‚°ì„± ê°œì„ ì— ë”°ë¥¸ ê²ƒìœ¼ë¡œ, ë‹¤ì–‘í•œ ì œí’ˆì˜ ë§ˆì¼€íŒ… ë° íŒì´‰ ë¹„ìš© ê°ì†Œì™€ ì „ì‚¬ ì§€ì› ê¸°ëŠ¥ì˜ ì§€ì¶œ ê°ì†Œê°€ ì£¼ìš” ìš”ì¸ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Adjusted R&D expense increased 4% operationally, primarily driven by the increase in spending in oncology and obesity product candidates, partially offset by a net decrease in spending due to pipeline focus and optimization, including the expansion of our digital capabilities. Now turning to the bottom line. In the fourth quarter, our reported diluted GAAP performance was a loss per share of $0.29. Our adjusted diluted earnings per share performance was a profit of $0.66, ahead of our expectations due to our overall gross margin and cost management performance.</td><td>ì¡°ì • R&D ë¹„ìš©ì€ ìš´ì˜ ê¸°ì¤€ 4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ í•­ì•”ì œì™€ ë¹„ë§Œ ì¹˜ë£Œì œ í›„ë³´ë¬¼ì§ˆì— ëŒ€í•œ ì§€ì¶œ ì¦ê°€ì— ê¸°ì¸í•˜ë©°, ë””ì§€í„¸ ì—­ëŸ‰ í™•ëŒ€ë¥¼ í¬í•¨í•œ íŒŒì´í”„ë¼ì¸ ì§‘ì¤‘ ë° ìµœì í™”ë¡œ ì¸í•œ ìˆœ ì§€ì¶œ ê°ì†Œë¶„ì´ ì¼ë¶€ ìƒì‡„í–ˆìŠµë‹ˆë‹¤. ì´ì œ ë‹¹ê¸°ìˆœì´ìµì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë³´ê³  ê¸°ì¤€ í¬ì„ GAAP ì‹¤ì ì€ ì£¼ë‹¹ 0.29ë‹¬ëŸ¬ ì†ì‹¤ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ ì‹¤ì ì€ 0.66ë‹¬ëŸ¬ í‘ìë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì „ë°˜ì ì¸ ë§¤ì¶œì´ì´ìµë¥ ê³¼ ë¹„ìš© ê´€ë¦¬ ì„±ê³¼ ë•ë¶„ì— ë‹¹ì‚¬ì˜ ì˜ˆìƒì¹˜ë¥¼ ìƒíšŒí•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>In support of our goal to enhance R&D productivity and focus on high-impact medicines, our fourth quarter GAAP results reflect strategic decisions in our development plans and updated long-range revenue forecast for certain products and pipeline assets. As a result, we recorded approximately $4.4 billion of noncash intangible asset impairments related to several medicines in development as well as in-line products. It is important to note that one of the asset indications we deprioritized was disitamab vedotin in bladder cancer is largely the result of the recently strong study readouts, expanded indications and related higher long-term revenue projections for Padcev.</td><td>R&D ìƒì‚°ì„±ì„ í–¥ìƒì‹œí‚¤ê³  ì˜í–¥ë ¥ì´ í° ì˜ì•½í’ˆì— ì§‘ì¤‘í•˜ë ¤ëŠ” ëª©í‘œë¥¼ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•´, 4ë¶„ê¸° GAAP ì‹¤ì ì—ëŠ” ê°œë°œ ê³„íšì˜ ì „ëµì  ì˜ì‚¬ê²°ì •ê³¼ íŠ¹ì • ì œí’ˆ ë° íŒŒì´í”„ë¼ì¸ ìì‚°ì— ëŒ€í•œ ì¥ê¸° ë§¤ì¶œ ì „ë§ ì—…ë°ì´íŠ¸ê°€ ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼, ê°œë°œ ì¤‘ì¸ ì—¬ëŸ¬ ì˜ì•½í’ˆê³¼ ê¸°ì¡´ íŒë§¤ ì œí’ˆë“¤ê³¼ ê´€ë ¨í•˜ì—¬ ì•½ 44ì–µ ë‹¬ëŸ¬ì˜ ë¹„í˜„ê¸ˆ ë¬´í˜•ìì‚° ì†ìƒì°¨ì†ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ ìš°ë¦¬ê°€ ìš°ì„ ìˆœìœ„ë¥¼ ë‚®ì¶˜ ìì‚° ì ì‘ì¦ ì¤‘ í•˜ë‚˜ì¸ ë°©ê´‘ì•”ì—ì„œì˜ ë””ì‹œíƒ€ë§™ ë² ë„í‹´(disitamab vedotin)ì˜ ê²½ìš°, ìµœê·¼ Padcevì˜ ê°•ë ¥í•œ ì„ìƒì‹œí—˜ ê²°ê³¼, ì ì‘ì¦ í™•ëŒ€, ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨ëœ ì¥ê¸° ë§¤ì¶œ ì „ë§ ìƒí–¥ ì¡°ì •ì— ì£¼ë¡œ ê¸°ì¸í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Padcev is an asset we will continue to invest behind and thus diminishing the value of DV in bladder cancer. I will also mention, while impairment decisions are based on current valuations of individual assets, overall, the Seagen portfolio is progressing ahead of our expectations. These decisions highlight our focus on delivering future growth as well as innovation. We are on track to deliver the majority of the anticipated $7.2 billion in total net cost savings from our productivity programs by the end of 2026.</td><td>PadcevëŠ” ìš°ë¦¬ê°€ ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•  ìì‚°ì´ë©°, ì´ì— ë”°ë¼ ë°©ê´‘ì•”ì—ì„œ DVì˜ ê°€ì¹˜ê°€ ê°ì†Œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë§ì”€ë“œë¦¬ìë©´, ì†ìƒì°¨ì† ê²°ì •ì€ ê°œë³„ ìì‚°ì˜ í˜„ì¬ ê°€ì¹˜í‰ê°€ì— ê¸°ë°˜í•˜ì§€ë§Œ, ì „ë°˜ì ìœ¼ë¡œ Seagen í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ìš°ë¦¬ì˜ ì˜ˆìƒì„ ì•ì„œê°€ë©° ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ì •ë“¤ì€ ë¯¸ë˜ ì„±ì¥ê³¼ í˜ì‹  ì‹¤í˜„ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì§‘ì¤‘ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2026ë…„ ë§ê¹Œì§€ ìƒì‚°ì„± í”„ë¡œê·¸ë¨ì„ í†µí•´ ì˜ˆìƒë˜ëŠ” ì´ 72ì–µ ë‹¬ëŸ¬ì˜ ìˆœë¹„ìš© ì ˆê°ì•¡ ì¤‘ ëŒ€ë¶€ë¶„ì„ ë‹¬ì„±í•  ê³„íšëŒ€ë¡œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect additional savings of $700 million in '26 and $200 million in '27 from Phase 1 of the Manufacturing Optimization Program for a total of $1.5 billion in savings by the end of '27. In addition, we exceeded our savings targets through '25 from our cost realignment program and as previously communicated, the R&D savings achieved in '25 under the cost realignment program is expected to be reinvested in '26 and is reflected in our '26 R&D guidance range. We remain committed to achieving the expected $5.7 billion of total net savings from our cost realignment program by the end of '26, at which time we will have met our savings commitment under the program.</td><td>ì œì¡° ìµœì í™” í”„ë¡œê·¸ë¨ 1ë‹¨ê³„ë¥¼ í†µí•´ '26ë…„ì— 7ì–µ ë‹¬ëŸ¬, '27ë…„ì— 2ì–µ ë‹¬ëŸ¬ì˜ ì¶”ê°€ ì ˆê°ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, '27ë…„ ë§ê¹Œì§€ ì´ 15ì–µ ë‹¬ëŸ¬ì˜ ì ˆê° íš¨ê³¼ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ë˜í•œ, ë¹„ìš© ì¬ì¡°ì • í”„ë¡œê·¸ë¨ì„ í†µí•´ '25ë…„ê¹Œì§€ì˜ ì ˆê° ëª©í‘œë¥¼ ì´ˆê³¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì•ì„œ ê³µì§€í•œ ë°”ì™€ ê°™ì´ ë¹„ìš© ì¬ì¡°ì • í”„ë¡œê·¸ë¨ í•˜ì—ì„œ '25ë…„ì— ë‹¬ì„±í•œ R&D ì ˆê°ì•¡ì€ '26ë…„ì— ì¬íˆ¬ìë  ì˜ˆì •ì´ë©° ì´ëŠ” '26ë…„ R&D ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” '26ë…„ ë§ê¹Œì§€ ë¹„ìš© ì¬ì¡°ì • í”„ë¡œê·¸ë¨ì„ í†µí•´ ì˜ˆìƒë˜ëŠ” ì´ ìˆœì ˆê°ì•¡ 57ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìœ¼ë©°, ê·¸ ì‹œì ì— í”„ë¡œê·¸ë¨ í•˜ì˜ ì ˆê° ëª©í‘œë¥¼ ì™„ìˆ˜í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Going forward, we will continue to focus on identifying further productivity opportunities and efficiencies. Now let me quickly touch upon our capital allocation strategy, which is designed to enhance long-term shareholder value. Our strategy consists of maintaining and over the long term, growing our dividend; reinvesting in our business at the appropriate level of financial return and in the future, the potential to make value-enhancing share repurchases.</td><td>ì•ìœ¼ë¡œë„ ìš°ë¦¬ëŠ” ì¶”ê°€ì ì¸ ìƒì‚°ì„± í–¥ìƒ ê¸°íšŒì™€ íš¨ìœ¨ì„±ì„ ì§€ì†ì ìœ¼ë¡œ ë°œêµ´í•˜ëŠ” ë° ì§‘ì¤‘í•  ê²ƒì…ë‹ˆë‹¤. ì´ì œ ì¥ê¸°ì ì¸ ì£¼ì£¼ê°€ì¹˜ ì œê³ ë¥¼ ìœ„í•´ ì„¤ê³„ëœ ìš°ë¦¬ì˜ ìë³¸ë°°ë¶„ ì „ëµì— ëŒ€í•´ ê°„ëµíˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ì „ëµì€ ë°°ë‹¹ì„ ìœ ì§€í•˜ê³  ì¥ê¸°ì ìœ¼ë¡œ ì„±ì¥ì‹œí‚¤ëŠ” ê²ƒ, ì ì ˆí•œ ì¬ë¬´ì  ìˆ˜ìµë¥  ìˆ˜ì¤€ì—ì„œ ì‚¬ì—…ì— ì¬íˆ¬ìí•˜ëŠ” ê²ƒ, ê·¸ë¦¬ê³  í–¥í›„ ê°€ì¹˜ë¥¼ ì œê³ í•˜ëŠ” ìì‚¬ì£¼ ë§¤ì…ì„ ì‹¤í–‰í•  ê°€ëŠ¥ì„±ìœ¼ë¡œ êµ¬ì„±ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And in '25, we returned $9.8 billion to shareholders via the quarterly dividend; invested $10.4 billion in internal R&D and invested approximately $8.8 billion in business development transactions, primarily reflecting the Metsera acquisition and the 3SBio licensing deal. And as a reminder, our leverage is expected to end 2025 at near our 2.7x target following the close of the Metsera transaction. However, given the next few years of LOE headwinds, we expect the leverage to remain at this current level or slightly higher through the LOE period. Additionally, the planned sale of our stake in ViiV will further improve our balance sheet.</td><td>ê·¸ë¦¬ê³  2025ë…„ì—ëŠ” ë¶„ê¸° ë°°ë‹¹ì„ í†µí•´ 98ì–µ ë‹¬ëŸ¬ë¥¼ ì£¼ì£¼ë“¤ì—ê²Œ í™˜ì›í–ˆìœ¼ë©°, ë‚´ë¶€ R&Dì— 104ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí–ˆê³ , ì‚¬ì—…ê°œë°œ ê±°ë˜ì— ì•½ 88ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ Metsera ì¸ìˆ˜ì™€ 3SBio ë¼ì´ì„ ì‹± ê³„ì•½ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì°¸ê³ ë¡œ, Metsera ê±°ë˜ ì™„ë£Œ í›„ 2025ë…„ ë§ ë‹¹ì‚¬ì˜ ë ˆë²„ë¦¬ì§€ëŠ” ëª©í‘œì¹˜ì¸ 2.7ë°° ìˆ˜ì¤€ì— ê·¼ì ‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ í–¥í›„ ëª‡ ë…„ê°„ íŠ¹í—ˆë§Œë£Œ(LOE) ì—­í’ì„ ê³ ë ¤í•  ë•Œ, ë ˆë²„ë¦¬ì§€ëŠ” LOE ê¸°ê°„ ë™ì•ˆ í˜„ì¬ ìˆ˜ì¤€ì´ê±°ë‚˜ ì•½ê°„ ë†’ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë˜í•œ ViiV ì§€ë¶„ ë§¤ê° ê³„íšì€ ë‹¹ì‚¬ì˜ ì¬ë¬´ìƒíƒœí‘œë¥¼ ë”ìš± ê°œì„ ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>When including the ViiV proceeds, we have approximately $7 billion in BD capacity. Now let me turn quickly to our full year '26 guidance, again, which remains unchanged. We expect total company full year '26 revenues to be in the range of $59.5 billion to $62.5 billion and full year '26 adjusted diluted earnings per share to be in the range of $2.80 to $3 a share, which reflects our expectations of strong contributions across our product portfolio; mid-70s adjusted gross margin; continued focus on strong cost management, all while prioritizing investments in our business to drive growth by the end of this decade.</td><td>ViiV ë§¤ê° ëŒ€ê¸ˆì„ í¬í•¨í•˜ë©´, ìš°ë¦¬ëŠ” ì•½ 70ì–µ ë‹¬ëŸ¬ì˜ ì‚¬ì—…ê°œë°œ(BD) ì—¬ë ¥ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë³€ë™ ì—†ì´ ìœ ì§€ë˜ëŠ” 2026 íšŒê³„ì—°ë„ ì „ì²´ ê°€ì´ë˜ìŠ¤ë¡œ ë¹ ë¥´ê²Œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2026 íšŒê³„ì—°ë„ ì „ì‚¬ ë§¤ì¶œì´ 595ì–µ ë‹¬ëŸ¬ì—ì„œ 625ì–µ ë‹¬ëŸ¬ ë²”ìœ„ì— ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, 2026 íšŒê³„ì—°ë„ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 2.80ë‹¬ëŸ¬ì—ì„œ 3ë‹¬ëŸ¬ ë²”ìœ„ì— ìˆì„ ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì´ëŠ” ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì¹œ ê°•ë ¥í•œ ê¸°ì—¬, 70% ì¤‘ë°˜ëŒ€ì˜ ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ , ê°•ë ¥í•œ ë¹„ìš© ê´€ë¦¬ì— ëŒ€í•œ ì§€ì†ì ì¸ ì§‘ì¤‘ì„ ë°˜ì˜í•˜ëŠ” ë™ì‹œì—, ì´ë²ˆ 10ë…„ëŒ€ ë§ê¹Œì§€ ì„±ì¥ì„ ê²¬ì¸í•˜ê¸° ìœ„í•œ ì‚¬ì—… íˆ¬ìë¥¼ ìš°ì„ ì‹œí•˜ëŠ” ê²ƒì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤.</td></tr>
<tr><td>Our COVID products are expected to trend lower again in '26 with revenues of approximately $5 billion. We continue to expect stable revenue contributions from our non-COVID product portfolio, which incorporates an expectation of approximately $1.5 billion in revenue compression due to products impacted by anticipated generic entry in '26. Revenues at the midpoint, excluding COVID and LOE products are expected to grow approximately 4% operationally year-over-year. And lastly, I will mention that we will continue to monitor currency fluctuation as the year progresses.</td><td>ë‹¹ì‚¬ì˜ ì½”ë¡œë‚˜19 ì œí’ˆì€ 2026ë…„ì—ë„ ë‹¤ì‹œ ê°ì†Œ ì¶”ì„¸ë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ë§¤ì¶œì€ ì•½ 50ì–µ ë‹¬ëŸ¬ ìˆ˜ì¤€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ë¹„ì½”ë¡œë‚˜19 ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê²½ìš° ì•ˆì •ì ì¸ ë§¤ì¶œ ê¸°ì—¬ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 2026ë…„ ì˜ˆìƒë˜ëŠ” ì œë„¤ë¦­ ì§„ì…ì˜ ì˜í–¥ì„ ë°›ëŠ” ì œí’ˆë“¤ë¡œ ì¸í•œ ì•½ 15ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œ ê°ì†Œë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì½”ë¡œë‚˜19 ì œí’ˆê³¼ íŠ¹í—ˆë§Œë£Œ(LOE) ì œí’ˆì„ ì œì™¸í•œ ì¤‘ê°„ê°’ ê¸°ì¤€ ë§¤ì¶œì€ ì „ë…„ ëŒ€ë¹„ ì•½ 4%ì˜ ì‹¤ì§ˆ ì„±ì¥ë¥ ì„ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì—°ì¤‘ í™˜ìœ¨ ë³€ë™ì„ ì§€ì†ì ìœ¼ë¡œ ëª¨ë‹ˆí„°ë§í•  ê²ƒì„ì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>In closing, let me continue to emphasize that over the next few years, our focus is on investing in key assets and managing upcoming LOEs, mainly from 2026 to 2028. At the end of the decade, growth is expected to be driven by our advancing R&D pipeline, the business development initiatives we've already executed and the ongoing progress of products we've recently launched or acquired. Our goal is to invest strategically, balancing cost savings with funding high-value products, designed to ensure long-term and sustainable growth potential for our shareholders. And with that, I'll turn it back to Albert and begin the Q&A.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì ì€, í–¥í›„ ëª‡ ë…„ê°„ ìš°ë¦¬ì˜ ì´ˆì ì€ í•µì‹¬ ìì‚°ì— ëŒ€í•œ íˆ¬ìì™€ ë‹¤ê°€ì˜¤ëŠ” íŠ¹í—ˆë§Œë£Œ(LOE) ê´€ë¦¬ì— ìˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ 2026ë…„ë¶€í„° 2028ë…„ ì‚¬ì´ì— ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. 2020ë…„ëŒ€ ë§ì—ëŠ” ì§„í–‰ ì¤‘ì¸ R&D íŒŒì´í”„ë¼ì¸, ì´ë¯¸ ì‹¤í–‰í•œ ì‚¬ì—…ê°œë°œ ì´ë‹ˆì…”í‹°ë¸Œ, ê·¸ë¦¬ê³  ìµœê·¼ ì¶œì‹œí•˜ê±°ë‚˜ ì¸ìˆ˜í•œ ì œí’ˆë“¤ì˜ ì§€ì†ì ì¸ ì§„ì „ì´ ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ìš°ë¦¬ì˜ ëª©í‘œëŠ” ë¹„ìš© ì ˆê°ê³¼ ê³ ë¶€ê°€ê°€ì¹˜ ì œí’ˆì— ëŒ€í•œ íˆ¬ì ê°„ì˜ ê· í˜•ì„ ë§ì¶”ë©° ì „ëµì ìœ¼ë¡œ íˆ¬ìí•˜ëŠ” ê²ƒì´ë©°, ì´ëŠ” ì£¼ì£¼ ì—¬ëŸ¬ë¶„ì„ ìœ„í•œ ì¥ê¸°ì ì´ê³  ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ ì ì¬ë ¥ì„ í™•ë³´í•˜ê¸° ìœ„í•´ ì„¤ê³„ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ Albertì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê³  ì§ˆì˜ì‘ë‹µì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla<br>Chairman of the Board & CEO<br><br>Thank you, David, and congratulations for an excellent quarter. Now operator, please assemble the queue.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, David. ê·¸ë¦¬ê³  í›Œë¥­í•œ ë¶„ê¸° ì‹¤ì ì„ ì¶•í•˜í•©ë‹ˆë‹¤. ì´ì œ ì˜¤í¼ë ˆì´í„°ë‹˜, ì§ˆë¬¸ ëŒ€ê¸°ì—´ì„ êµ¬ì„±í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Pfizer Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>**ì£¼ìš” ì¬ë¬´ ì„±ê³¼ ë° ê°€ì´ë˜ìŠ¤**<br>- 2025ë…„ ë§¤ì¶œ $626ì–µ(ì „ë…„ ëŒ€ë¹„ -2% ìš´ì˜ ê¸°ì¤€), ì¡°ì • EPS $3.22ë¡œ ê°€ì´ë˜ìŠ¤ ìƒíšŒ ë‹¬ì„±. COVID ì œí’ˆ ì œì™¸ ì‹œ ìš´ì˜ ë§¤ì¶œ 6% ì„±ì¥í•˜ë©° ê¸°ì € ì‚¬ì—… ê²¬ì¡°í•¨ ì…ì¦<br>- 2026ë…„ ê°€ì´ë˜ìŠ¤ ì¬í™•ì¸: ë§¤ì¶œ $595~625ì–µ, ì¡°ì • EPS $2.80~3.00. COVID ì œí’ˆ ë§¤ì¶œì€ ì•½ $50ì–µìœ¼ë¡œ ê°ì†Œ ì˜ˆìƒ, ë¹„COVID í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ì•ˆì •ì  ê¸°ì—¬ ì „ë§<br>- ì¡°ì • ë§¤ì¶œì´ì´ìµë¥  76%ë¡œ í™•ëŒ€, ì œì¡° ìµœì í™” í”„ë¡œê·¸ë¨ í†µí•´ 2027ë…„ê¹Œì§€ ì´ $15ì–µ ì ˆê° ëª©í‘œ. ë°°ë‹¹ìœ¼ë¡œ $98ì–µ ì£¼ì£¼í™˜ì›, ë ˆë²„ë¦¬ì§€ëŠ” 2.7ë°° ëª©í‘œ ìˆ˜ì¤€ ìœ ì§€<br><br>**ë¹„ë§Œì¹˜ë£Œì œ íŒŒì´í”„ë¼ì¸ í•µì‹¬ ì§„ì „**<br>- VESPER-3 ì„ìƒì—ì„œ ì›” 1íšŒ íˆ¬ì—¬ GLP-1 ìˆ˜ìš©ì²´ ì‘ìš©ì œ PF-3944ê°€ 28ì£¼ì°¨ ìœ„ì•½ ëŒ€ë¹„ 10~12.3% ì²´ì¤‘ ê°ì†Œ ë‹¬ì„±, ê³ ìš©ëŸ‰ ëª¨ë¸ ì˜ˆì¸¡ì¹˜ëŠ” 16% ë„ë‹¬. ë‚´ì•½ì„± ìš°ìˆ˜í•˜ë©° 2028ë…„ ì²« ìŠ¹ì¸ ëª©í‘œë¡œ 10ê°œ ì´ìƒ 3ìƒ ì—°êµ¬ ì§„í–‰ ì¤‘<br>- ì´ˆì¥ê¸° ì‘ìš© ì•„ë°€ë¦° ìœ ì‚¬ì²´ ë³‘ìš©ìš”ë²• 2ìƒ ë°ì´í„° ì—°ë‚´ ê³µê°œ ì˜ˆì •, ê²½êµ¬ GIPR ê¸¸í•­ì œ ë“±</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question will come from Chris Schott with JPMorgan.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ JPëª¨ê±´ì˜ í¬ë¦¬ìŠ¤ ì‡¼íŠ¸ ì• ë„ë¦¬ìŠ¤íŠ¸ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division Just had maybe a two-parter on the VESPER-3 data. I guess, first, can you just elaborate any more on the tolerability you saw here? And maybe just specifically, is there anything more you can say about vomit rates or any differences you saw between the mild or moderate dosing arms? And then just maybe bigger picture, if we consider the two doses that are moving forward from VESPER-3, it seems like you have a drug that clearly had solid weight loss, it's got monthly dosing. At the same time, that weight loss might be a bit below what you saw with the weekly or Zepbound. I just wanted to get your views on what role you see that type of profile playing in the market.</td><td>**Christopher Schott:** VESPER-3 ë°ì´í„°ì— ëŒ€í•´ ë‘ ê°€ì§€ ì§ˆë¬¸ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë¨¼ì €, ì—¬ê¸°ì„œ ê´€ì°°ëœ ë‚´ì•½ì„±ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? íŠ¹íˆ êµ¬í†  ë°œìƒë¥ ì´ë‚˜ ê²½ì¦ ë˜ëŠ” ì¤‘ë“±ë„ ìš©ëŸ‰êµ° ê°„ì— ê´€ì°°ëœ ì°¨ì´ì ì— ëŒ€í•´ ë” ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ” ë¶€ë¶„ì´ ìˆìœ¼ì‹ ì§€ìš”? ê·¸ë¦¬ê³  ì¢€ ë” í° ê·¸ë¦¼ì—ì„œ ë³´ë©´, VESPER-3ì—ì„œ ì§„í–‰ë˜ëŠ” ë‘ ê°€ì§€ ìš©ëŸ‰ì„ ê³ ë ¤í–ˆì„ ë•Œ, í™•ì‹¤íˆ ê²¬ê³ í•œ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ë¥¼ ë³´ì´ê³  ì›” 1íšŒ íˆ¬ì—¬ë¼ëŠ” ì¥ì ì´ ìˆëŠ” ì•½ë¬¼ì„ ë³´ìœ í•˜ê³  ê³„ì‹  ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë™ì‹œì—, ì´ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ê°€ ì£¼ 1íšŒ íˆ¬ì—¬ ì œì œë‚˜ Zepboundì—ì„œ ë³´ì…¨ë˜ ê²ƒë³´ë‹¤ëŠ” ë‹¤ì†Œ ë‚®ì„ ìˆ˜ ìˆì„ ê²ƒ ê°™ì€ë°ìš”. ì´ëŸ¬í•œ í”„ë¡œíŒŒì¼ì´ ì‹œì¥ì—ì„œ ì–´ë–¤ ì—­í• ì„ í•  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ê·€ì‚¬ì˜ ê²¬í•´ë¥¼ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Excellent. And of course, I will start with Chris, which I suspect will be the one who will receive most of the questions today, and I love it. So -- and then maybe we'll ask also the commercial guys to speak a little bit about it. So Chris, why don't you start?</td><td>**Albert Bourla:** ì¢‹ìŠµë‹ˆë‹¤. ë¬¼ë¡  ì˜¤ëŠ˜ ê°€ì¥ ë§ì€ ì§ˆë¬¸ì„ ë°›ê²Œ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” Chrisë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì €ëŠ” ê·¸ê²Œ ì¢‹ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜ì—… ë‹´ë‹¹ìë“¤ì—ê²Œë„ ì´ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€í•´ ë‹¬ë¼ê³  ìš”ì²­í•  ì˜ˆì •ì…ë‹ˆë‹¤. Chris, ë¨¼ì € ì‹œì‘í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Yes. Thanks for the question. So obviously, we will share the full tolerability data at our oral presentation at ADA in June. We are really encouraged by the observed distribution of AEs across weekly and monthly. And you could have expected potentially that when patients switch to a 4-fold higher dose, we're going to have a higher number of sudden discontinuations and nausea and vomiting, we did not, nicely distribution between the monthly as well as the weekly. Just to remember for this study, there was -- no step-down titration was allowed, which is unusual for obesity trials. But that will obviously not happen in the Phase III study, we will allow down-titration. Regarding the different doses, as we pointed out, low and medium was presented today. The higher dose is already being tested in VESPER-4 because previous prediction models indicated that it will be well tolerated and we should test 2.4 milligrams weekly, which is happening now. And in the monthly study we'll test 9.6 as pointed out.</td><td>**Chris Boshoff:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 6ì›” ADAì—ì„œ êµ¬ë‘ ë°œí‘œ ì‹œ ì „ì²´ ë‚´ì•½ì„± ë°ì´í„°ë¥¼ ê³µìœ í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì£¼ê°„ íˆ¬ì—¬êµ°ê³¼ ì›”ê°„ íˆ¬ì—¬êµ° ì „ë°˜ì— ê±¸ì³ ê´€ì°°ëœ ì´ìƒë°˜ì‘(AE) ë¶„í¬ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™˜ìë“¤ì´ 4ë°° ë†’ì€ ìš©ëŸ‰ìœ¼ë¡œ ì „í™˜í•  ë•Œ ê°‘ì‘ìŠ¤ëŸ¬ìš´ íˆ¬ì•½ ì¤‘ë‹¨ì´ë‚˜ ì˜¤ì‹¬, êµ¬í† ê°€ ë” ë§ì´ ë°œìƒí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•  ìˆ˜ë„ ìˆì—ˆì§€ë§Œ, ì‹¤ì œë¡œëŠ” ê·¸ë ‡ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ì›”ê°„ íˆ¬ì—¬êµ°ê³¼ ì£¼ê°„ íˆ¬ì—¬êµ° ê°„ì— ì–‘í˜¸í•œ ë¶„í¬ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. <br><br>ì´ë²ˆ ì—°êµ¬ì—ì„œ ê¸°ì–µí•˜ì…”ì•¼ í•  ì ì€ ìš©ëŸ‰ ê°ëŸ‰ ì ì •(step-down titration)ì´ í—ˆìš©ë˜ì§€ ì•Šì•˜ë‹¤ëŠ” ê²ƒì¸ë°, ì´ëŠ” ë¹„ë§Œ ì„ìƒì‹œí—˜ì—ì„œëŠ” ì´ë¡€ì ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ 3ìƒ ì„ìƒì‹œí—˜ì—ì„œëŠ” ë‹¹ì—°íˆ ìš©ëŸ‰ ê°ëŸ‰ì„ í—ˆìš©í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë‹¤ì–‘í•œ ìš©ëŸ‰ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì˜¤ëŠ˜ ì €ìš©ëŸ‰ê³¼ ì¤‘ê°„ ìš©ëŸ‰ ë°ì´í„°ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ê³ ìš©ëŸ‰ì€ ì´ë¯¸ VESPER-4ì—ì„œ í…ŒìŠ¤íŠ¸ ì¤‘ì¸ë°, ì´ì „ ì˜ˆì¸¡ ëª¨ë¸ë“¤ì´ ì£¼ 2.4ë°€ë¦¬ê·¸ë¨ì´ ì¶©ë¶„íˆ ë‚´ì•½ì„±ì´ ì¢‹ì„ ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ê³ , ë”°ë¼ì„œ ì´ ìš©ëŸ‰ì„ í…ŒìŠ¤íŠ¸í•´ì•¼ í•œë‹¤ê³  íŒë‹¨í–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì›” 1íšŒ íˆ¬ì—¬ ì—°êµ¬ì—ì„œëŠ” ë§ì”€ë“œë¦° ëŒ€ë¡œ 9.6ë°€ë¦¬ê·¸ë¨ì„ í…ŒìŠ¤íŠ¸í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO All right. Why don't we go -- Aamir, how do you see this playing commercially? And then Alexandre.</td><td>**Albert Bourla:** ì¢‹ìŠµë‹ˆë‹¤. Aamir, ì´ ë¶€ë¶„ì´ ìƒì—…ì ìœ¼ë¡œ ì–´ë–»ê²Œ ì „ê°œë  ê²ƒìœ¼ë¡œ ë³´ì‹œë‚˜ìš”? ê·¸ë¦¬ê³  Alexandreë„ ë§ì”€í•´ ì£¼ì‹œì£ .</td></tr>
<tr><td>Aamir Malik: Executive VP & Chief U.S. Commercial Officer I think when you look at the clinical data, I think what it suggests to us very clearly is that '3944 from an efficacy perspective has the potential to deliver efficacy that's competitive with the standard of care and potentially best-in-class against mono-agonists. So we think when you take that efficacy and then you combine it with a lower medication burden through a monthly dose, that's a value proposition that's going to resonate with patients, with providers and with payers because persistency and simplicity matter. And it also gives us the opportunity to switch patients from weekly onto monthly therapy. So we think '3944 is going to be a compelling therapy, full stop. And then you add to that the opportunity that exists from the other assets that we have in our portfolio with our commercial capabilities to execute in U.S. and international, and I think it gives us a lot of confidence around the commercial potential.</td><td>**Aamir Malik:** ì„ìƒ ë°ì´í„°ë¥¼ ë³´ë©´ 3944ê°€ íš¨ëŠ¥ ì¸¡ë©´ì—ì„œ í‘œì¤€ ì¹˜ë£Œì œì™€ ê²½ìŸí•  ìˆ˜ ìˆëŠ” íš¨ëŠ¥ì„ ì œê³µí•  ì ì¬ë ¥ì´ ìˆê³ , ë‹¨ì¼ ì‘ìš©ì œ(mono-agonist) ëŒ€ë¹„ ë™ê¸‰ ìµœê³ (best-in-class)ê°€ ë  ê°€ëŠ¥ì„±ì´ ìˆë‹¤ëŠ” ì ì´ ë§¤ìš° ëª…í™•í•˜ê²Œ ë‚˜íƒ€ë‚©ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ íš¨ëŠ¥ì— ì›” 1íšŒ íˆ¬ì—¬ë¥¼ í†µí•œ ë‚®ì€ ë³µì•½ ë¶€ë‹´ì„ ê²°í•©í•˜ë©´, í™˜ì, ì˜ë£Œì§„, ê·¸ë¦¬ê³  ë³´í—˜ì‚¬ ëª¨ë‘ì—ê²Œ ê³µê°ì„ ì–»ì„ ìˆ˜ ìˆëŠ” ê°€ì¹˜ ì œì•ˆì´ ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ì§€ì†ì„±ê³¼ ê°„í¸ì„±ì´ ì¤‘ìš”í•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë˜í•œ ì£¼ 1íšŒ íˆ¬ì—¬ í™˜ìë“¤ì„ ì›” 1íšŒ ì¹˜ë£Œì œë¡œ ì „í™˜í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë„ ì œê³µí•©ë‹ˆë‹¤. ë”°ë¼ì„œ 3944ëŠ” ê·¸ ìì²´ë¡œ ë§¤ìš° ì„¤ë“ë ¥ ìˆëŠ” ì¹˜ë£Œì œê°€ ë  ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. ì—¬ê¸°ì— ë”í•´ ìš°ë¦¬ê°€ ë³´ìœ í•œ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ ë‹¤ë¥¸ ìì‚°ë“¤ê³¼ ë¯¸êµ­ ë° í•´ì™¸ ì‹œì¥ì—ì„œ ì‹¤í–‰í•  ìˆ˜ ìˆëŠ” ìš°ë¦¬ì˜ ìƒì—…í™” ì—­ëŸ‰ì„ ê³ ë ¤í•˜ë©´, ìƒì—…ì  ì ì¬ë ¥ì— ëŒ€í•´ ìƒë‹¹í•œ í™•ì‹ ì„ ê°€ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Yes. Thank you, Aamir. The surprise, I think, so far with this market, it is how well it is performing outside the U.S. So Alexandre, what's your take?</td><td>**Albert Bourla:** <answer>ê°ì‚¬í•©ë‹ˆë‹¤, Aamir. ì œ ìƒê°ì— ì´ë²ˆ ì‹œì¥ì—ì„œ ë†€ë¼ìš´ ì ì€ ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ ì–¼ë§ˆë‚˜ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆëŠ”ê°€ í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. Alexandre, ì–´ë–»ê²Œ ë³´ì‹­ë‹ˆê¹Œ?</answer></td></tr>
<tr><td>Alexandre de Germay: Executive VP & Chief International Commercial Officer That's right. Just -- what's really interesting in this category is actually the size of the market, ex U.S. -- is projected to be $150 billion and 40% of that is actually ex-U.S. There are two things that are really interesting in this category that are unique and that reinforce the potential of these assets. First, is the out-of-pocket category. Because in most countries, when we introduce the innovation, we have to go through reimbursement negotiation and often translate into price reduction. In this category, we see that there are high willingness to pay out of pocket across all mature markets, either be in Europe or in Australia or in Canada, and we see the price point being across $250 to $350, which is higher than what we had expected. And when we look at the latest release from our competitors in this category, we see that there is higher willingness to pay from all those geographies, including actually also emerging markets where we also see high prevalence. The second is the time to market because it's going to be mostly an out-of-pocket category, the time after approval at the EMEA will be instant and where we will be able to actually commercialize those products. So that will drive also rapid penetration in the market.</td><td>**Alexandre de Germay:** ë§ìŠµë‹ˆë‹¤. ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ì •ë§ í¥ë¯¸ë¡œìš´ ì ì€ ì‚¬ì‹¤ ë¯¸êµ­ì„ ì œì™¸í•œ ì‹œì¥ ê·œëª¨ì¸ë°ìš”, 1,500ì–µ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒë˜ê³  ìˆìœ¼ë©° ê·¸ ì¤‘ 40%ê°€ ì‹¤ì œë¡œ ë¯¸êµ­ ì™¸ ì§€ì—­ì…ë‹ˆë‹¤. ì´ ì¹´í…Œê³ ë¦¬ì—ëŠ” ìì‚°ì˜ ì ì¬ë ¥ì„ ê°•í™”í•˜ëŠ” ë…íŠ¹í•˜ê³  í¥ë¯¸ë¡œìš´ ë‘ ê°€ì§€ ìš”ì†Œê°€ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸ëŠ” ë³¸ì¸ë¶€ë‹´(out-of-pocket) ì¹´í…Œê³ ë¦¬ì…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ êµ­ê°€ì—ì„œëŠ” í˜ì‹  ì œí’ˆì„ ì¶œì‹œí•  ë•Œ ë³´í—˜ê¸‰ì—¬ í˜‘ìƒì„ ê±°ì³ì•¼ í•˜ê³ , ì´ëŠ” ì¢…ì¢… ê°€ê²© ì¸í•˜ë¡œ ì´ì–´ì§€ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ìœ ëŸ½, í˜¸ì£¼, ìºë‚˜ë‹¤ ë“± ëª¨ë“  ì„±ìˆ™ ì‹œì¥ì—ì„œ ë³¸ì¸ë¶€ë‹´ê¸ˆ(out-of-pocket) ì§€ë¶ˆ ì˜í–¥ì´ ë†’ê²Œ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ê°€ê²©ëŒ€ëŠ” 250ë‹¬ëŸ¬ì—ì„œ 350ë‹¬ëŸ¬ ì‚¬ì´ë¡œ í˜•ì„±ë˜ì–´ ìˆëŠ”ë°, ì´ëŠ” ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ê²ƒë³´ë‹¤ ë†’ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ê²½ìŸì‚¬ë“¤ì˜ ìµœê·¼ ì¶œì‹œ ì œí’ˆë“¤ì„ ì‚´í´ë³´ë©´, ì‹¤ì œë¡œ ìœ ë³‘ë¥ ì´ ë†’ì€ ì‹ í¥ì‹œì¥ì„ í¬í•¨í•œ ëª¨ë“  ì§€ì—­ì—ì„œ ì§€ë¶ˆ ì˜í–¥ì´ ë” ë†’ì•„ì§€ê³  ìˆëŠ” ê²ƒì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ëŠ” ì‹œì¥ ì¶œì‹œ ì‹œê¸°ì…ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ ë³¸ì¸ë¶€ë‹´ ì¹´í…Œê³ ë¦¬ê°€ ë  ê²ƒì´ê¸° ë•Œë¬¸ì—, EMEA ìŠ¹ì¸ ì´í›„ ì¦‰ì‹œ ìƒìš©í™”ê°€ ê°€ëŠ¥í•˜ë©° ì œí’ˆì„ ì‹¤ì œë¡œ íŒë§¤í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì‹œì¥ ì¹¨íˆ¬ë„ ë¹ ë¥´ê²Œ ì§„í–‰ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Alexandre.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì•Œë ‰ìƒë“œë¥´.</td></tr>
<tr><td>Operator: Our next question comes from Vamil Divan with Guggenheim Securities.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ êµ¬ê²í•˜ì„ ì‹œíë¦¬í‹°ì¦ˆì˜ ë°”ë°€ ë””ë°˜ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vamil Divan: Guggenheim Securities, LLC, Research Division So just maybe building off this, Chris, you just talked a little bit about this in a prior question around down-titration in Phase III. Can you just elaborate a little bit more on that kind of how you are designing your Phase IIIs and allowing for flexibility of the patient maybe dealing with any sort of side effects, and maybe that improves overall the profile you see from Phase II? And then my other question is actually just beyond VESPER-3. You mentioned this will be at ADA. I'm curious what other data we may get from either your internal programs or from the Metsera portfolio at ADA? And specifically, your internal GIPR, do you expect to provide that Phase II data there?</td><td>**Vamil Divan:** 3ìƒ ì‹œí—˜ì—ì„œì˜ ìš©ëŸ‰ ì¡°ì ˆì— ëŒ€í•´ ì¡°ê¸ˆ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? 3ìƒ ì‹œí—˜ì„ ì–´ë–»ê²Œ ì„¤ê³„í•˜ê³  ê³„ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  í™˜ìë“¤ì´ ë¶€ì‘ìš©ì— ëŒ€ì‘í•  ìˆ˜ ìˆë„ë¡ ì–´ë–¤ ìœ ì—°ì„±ì„ ì œê³µí•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ 2ìƒì—ì„œ ë³¸ í”„ë¡œíŒŒì¼ì´ ì „ë°˜ì ìœ¼ë¡œ ê°œì„ ë  ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ë‹¤ë¥¸ ì§ˆë¬¸ì€ VESPER-3 ì´í›„ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ADAì—ì„œ ë°œí‘œí•˜ì‹¤ ê±°ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°, ADAì—ì„œ ë‚´ë¶€ í”„ë¡œê·¸ë¨ì´ë‚˜ Metsera í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ì–´ë–¤ ë‹¤ë¥¸ ë°ì´í„°ë¥¼ ë³¼ ìˆ˜ ìˆì„ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. íŠ¹íˆ ë‚´ë¶€ GIPR í”„ë¡œê·¸ë¨ì˜ ê²½ìš°, 2ìƒ ë°ì´í„°ë¥¼ ì œê³µí•˜ì‹¤ ì˜ˆì •ì´ì‹ ê°€ìš”?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Thank you very much for the question. Just a reminder again for the VESPER-3 data we presented today, there's only two step-up doses. You're used to four, five step-up doses to get to the desired dose in this study, there was only two step-up doses. So the Phase III design for VESPER-6 will test different titrations as well as, as we pointed out, the additional dose of 9.6 milligrams, which is currently being tested in VESPER-4 as 2.4 milligrams weekly. Regarding the next -- the rest of the portfolio, we're obviously excited about the platform in general. It's a very differentiated platform. As you know, we previously presented data for the ultra-long-acting amylin '3945 also called MET-233, where the observed additive weight loss when combining '3944 and '3945 was 5% at day 8 and single-agent ultra-long amylin previous data showed at day 36, 8.4% placebo-adjusted weight loss. So we should share later this year, including at ADA, updated data on amylin and potential early data for the combination of the amylin plus '3944. We also, as you know, in our portfolio, are excited about the rest of the Phase II programs, which including a first in -- potential first-in-class GIPR antagonist oral that was discovered, conceptualized internally, that's currently in the randomized Phase II experience and also the more broader Phase I program of peptides, including an ultra-long GLP-1 that's potentially 3-monthly, quarterly, that's currently in Phase I as well as our additional oral portfolio, including the oral GLP-1 recently acquired from YaoPharma.</td><td>**Chris Boshoff:** ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œí•œ VESPER-3 ë°ì´í„°ì— ëŒ€í•´ ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€ë“œë¦¬ë©´, ìš©ëŸ‰ ì¦ëŸ‰ ë‹¨ê³„ê°€ ë‹¨ ë‘ ë²ˆë¿ì´ì—ˆìŠµë‹ˆë‹¤. ë³´í†µ ëª©í‘œ ìš©ëŸ‰ì— ë„ë‹¬í•˜ê¸° ìœ„í•´ 4~5ë²ˆì˜ ìš©ëŸ‰ ì¦ëŸ‰ ë‹¨ê³„ë¥¼ ê±°ì¹˜ëŠ” ê²ƒì— ìµìˆ™í•˜ì‹¤ í…ë°, ì´ë²ˆ ì—°êµ¬ì—ì„œëŠ” ë‘ ë²ˆì˜ ìš©ëŸ‰ ì¦ëŸ‰ ë‹¨ê³„ë§Œ ìˆì—ˆìŠµë‹ˆë‹¤. VESPER-6ì˜ 3ìƒ ì„ìƒ ì„¤ê³„ì—ì„œëŠ” ë‹¤ì–‘í•œ ìš©ëŸ‰ ì ì • ë°©ë²•ì„ í…ŒìŠ¤íŠ¸í•  ì˜ˆì •ì´ë©°, ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ í˜„ì¬ VESPER-4ì—ì„œ ì£¼ 1íšŒ 2.4ë°€ë¦¬ê·¸ë¨ìœ¼ë¡œ í…ŒìŠ¤íŠ¸ ì¤‘ì¸ 9.6ë°€ë¦¬ê·¸ë¨ ì¶”ê°€ ìš©ëŸ‰ë„ ì‹œí—˜í•  ê³„íšì…ë‹ˆë‹¤.<br><br>ë‚˜ë¨¸ì§€ í¬íŠ¸í´ë¦¬ì˜¤ì— ê´€í•´ì„œëŠ”, ì „ë°˜ì ìœ¼ë¡œ ì´ í”Œë«í¼ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒë‹¹íˆ ì°¨ë³„í™”ëœ í”Œë«í¼ì…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ì €í¬ëŠ” ì´ì „ì— ì´ˆì¥ê¸° ì‘ìš© ì•„ë°€ë¦°(ultra-long-acting amylin) '3945, ì¦‰ MET-233ì— ëŒ€í•œ ë°ì´í„°ë¥¼ ë°œí‘œí•œ ë°” ìˆìŠµë‹ˆë‹¤. '3944ì™€ '3945ë¥¼ ë³‘ìš©í–ˆì„ ë•Œ ê´€ì°°ëœ ì¶”ê°€ ì²´ì¤‘ ê°ì†ŒëŠ” 8ì¼ì°¨ì— 5%ì˜€ìœ¼ë©°, ë‹¨ì¼ì œì œ ì´ˆì¥ê¸° ì•„ë°€ë¦°ì˜ ì´ì „ ë°ì´í„°ì—ì„œëŠ” 36ì¼ì°¨ì— ìœ„ì•½ ëŒ€ë¹„ 8.4%ì˜ ì²´ì¤‘ ê°ì†Œë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ì— ADAë¥¼ í¬í•¨í•œ ì—¬ëŸ¬ ìë¦¬ì—ì„œ ì•„ë°€ë¦°ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ëœ ë°ì´í„°ì™€ ì•„ë°€ë¦°ê³¼ '3944 ë³‘ìš©ìš”ë²•ì— ëŒ€í•œ ì´ˆê¸° ë°ì´í„°ë¥¼ ê³µìœ í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë˜í•œ ì•„ì‹œë‹¤ì‹œí”¼, ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì—ëŠ” ë‚˜ë¨¸ì§€ 2ìƒ í”„ë¡œê·¸ë¨ë“¤ë„ ìˆì–´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë‚´ë¶€ì—ì„œ ë°œê²¬í•˜ê³  ê°œë…í™”í•œ ì ì¬ì  í¼ìŠ¤íŠ¸-ì¸-í´ë˜ìŠ¤(first-in-class) GIPR ê¸¸í•­ì œ ê²½êµ¬ì œê°€ í¬í•¨ë˜ëŠ”ë°, í˜„ì¬ ë¬´ì‘ìœ„ 2ìƒ ì„ìƒì„ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë” ê´‘ë²”ìœ„í•œ 1ìƒ í©íƒ€ì´ë“œ í”„ë¡œê·¸ë¨ë„ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” 3ê°œì›”, ì¦‰ ë¶„ê¸°ë³„ íˆ¬ì—¬ê°€ ê°€ëŠ¥í•œ ì´ˆì¥ê¸°í˜• GLP-1ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©° í˜„ì¬ 1ìƒ ë‹¨ê³„ì— ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìµœê·¼ ì•¼ì˜¤íŒŒë§ˆ(YaoPharma)ë¡œë¶€í„° ì¸ìˆ˜í•œ ê²½êµ¬ìš© GLP-1ì„ í¬í•¨í•œ ì¶”ê°€ ê²½êµ¬ì œ í¬íŠ¸í´ë¦¬ì˜¤ë„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Chris.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Chris.</td></tr>
<tr><td>Operator: Our next question comes from Steve Scala with TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Steve Scalaë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Steve Scala: TD Cowen, Research Division In the VESPER-3 data, did the placebo arm gain weight or lose weight? And the second question is not on obesity, but Pfizer has been quite adamant about no life beyond December '28 for Vyndaqel. Should we completely rule out any sort of strategy whatsoever, such as settlement with generic companies, on patents Pfizer holds?</td><td>**Steve Scala:** <response><br><br>VESPER-3 ë°ì´í„°ì—ì„œ ìœ„ì•½êµ°(placebo arm)ì˜ ì²´ì¤‘ì´ ì¦ê°€í–ˆëŠ”ì§€ ê°ì†Œí–ˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ë¹„ë§Œ ê´€ë ¨ì´ ì•„ë‹Œë°ìš”, í™”ì´ìê°€ Vyndaqelì˜ 2028ë…„ 12ì›” ì´í›„ ìƒëª…ë ¥ì— ëŒ€í•´ ìƒë‹¹íˆ ë‹¨í˜¸í•œ ì…ì¥ì„ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. í™”ì´ìê°€ ë³´ìœ í•œ íŠ¹í—ˆì™€ ê´€ë ¨í•˜ì—¬ ì œë„¤ë¦­ íšŒì‚¬ë“¤ê³¼ì˜ í•©ì˜ ê°™ì€ ì „ëµì„ ì™„ì „íˆ ë°°ì œí•´ì•¼ í• ê¹Œìš”?<br><br></response></td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Steve. Let me take the Vyndaqel because I have been asked multiple times. Right now, we are assuming that the patent will be lost at the end of 2028. And I don't have any other comments to make on that. These are very sensitive topics. So I'm moving to Chris now to talk about the placebo arm, what was the weight lost there.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤, Steve. Vyndaqel ê´€ë ¨ ì§ˆë¬¸ì„ ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì—¬ëŸ¬ ì°¨ë¡€ ì§ˆë¬¸ì„ ë°›ì•˜ëŠ”ë°ìš”. í˜„ì¬ ì €í¬ëŠ” 2028ë…„ ë§ì— íŠ¹í—ˆê°€ ë§Œë£Œë  ê²ƒìœ¼ë¡œ ê°€ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ë” ì´ìƒ ë“œë¦´ ë§ì”€ì´ ì—†ìŠµë‹ˆë‹¤. ë§¤ìš° ë¯¼ê°í•œ ì‚¬ì•ˆì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Chrisì—ê²Œ ë„˜ê²¨ì„œ ìœ„ì•½êµ°(placebo arm)ì˜ ì²´ì¤‘ ê°ì†Œì— ëŒ€í•´ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Again, the full data we will present at ADA, but in this case, VESPER-3, actually, the placebo arm was very stable, not really up or down, but you'll see the data at ADA.</td><td>**Chris Boshoff:** ì „ì²´ ë°ì´í„°ëŠ” ADAì—ì„œ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤ë§Œ, VESPER-3ì˜ ê²½ìš° ì‹¤ì œë¡œ ìœ„ì•½êµ°(placebo arm)ì´ ë§¤ìš° ì•ˆì •ì ì´ì—ˆê³ , ìƒìŠ¹ì´ë‚˜ í•˜ë½ ì—†ì´ ìœ ì§€ë˜ì—ˆìŠµë‹ˆë‹¤. ìì„¸í•œ ë°ì´í„°ëŠ” ADAì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO All right. Thank you very much.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Geoff Meacham with Citibank.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì”¨í‹°ì€í–‰ì˜ ì œí”„ ë¯¸ì²¨ ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Meacham: Citigroup Inc., Research Division Congrats on the data today. Again, a few on the new data today. So when you look at the PK/PD, are you guys set with monthly being the longest dosing interval to preserve efficacy? Or is it potentially -- is it feasible to extend to every 2-month dosing? And then on your Phase III plans, is it your sense these are likely to be the standard type of metabolic studies that we'd expect to do? Or would you pursue any maybe inflammation or neuropsych indications? Or would you pursue GLP-1 active comparator studies? Just trying to think of how you could separate yourself in a broad Phase III program.</td><td>**Geoffrey Meacham:** ì˜¤ëŠ˜ ë°œí‘œí•˜ì‹  ë°ì´í„°ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ìƒˆë¡œ ë‚˜ì˜¨ ë°ì´í„°ì— ëŒ€í•´ ëª‡ ê°€ì§€ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. PK/PDë¥¼ ë³´ë©´, íš¨ëŠ¥ì„ ìœ ì§€í•˜ê¸° ìœ„í•œ ìµœì¥ íˆ¬ì—¬ ê°„ê²©ìœ¼ë¡œ ì›” 1íšŒ íˆ¬ì—¬ê°€ í™•ì •ëœ ê±´ê°€ìš”? ì•„ë‹ˆë©´ 2ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•˜ëŠ” ê²ƒìœ¼ë¡œ ì—°ì¥í•˜ëŠ” ê²ƒë„ ê°€ëŠ¥í• ê¹Œìš”? ê·¸ë¦¬ê³  3ìƒ ê³„íšê³¼ ê´€ë ¨í•´ì„œëŠ”, ì¼ë°˜ì ìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” í‘œì¤€ì ì¸ ëŒ€ì‚¬ ê´€ë ¨ ì„ìƒì‹œí—˜ë“¤ì„ ì§„í–‰í•˜ì‹¤ ê³„íšì´ì‹ ê°€ìš”? ì•„ë‹ˆë©´ ì—¼ì¦ì´ë‚˜ ì‹ ê²½ì •ì‹ ê³¼ ì ì‘ì¦ì„ ì¶”ì§„í•˜ì‹¤ ìƒê°ë„ ìˆìœ¼ì‹ ê°€ìš”? ë˜ëŠ” GLP-1 ì•½ë¬¼ì„ ëŒ€ì¡°êµ°ìœ¼ë¡œ í•˜ëŠ” ë¹„êµ ì„ìƒì‹œí—˜ì„ ì§„í–‰í•˜ì‹¤ ê±´ê°€ìš”? ê´‘ë²”ìœ„í•œ 3ìƒ í”„ë¡œê·¸ë¨ì—ì„œ ì–´ë–»ê²Œ ì°¨ë³„í™”ë¥¼ ê¾€í•˜ì‹¤ ìˆ˜ ìˆì„ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Yes. Thank you, Geoff. So Chris, monthly or more. And then additional studies.</td><td>**Albert Bourla:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Geoff. Chris, ì›”ë³„ ë˜ëŠ” ê·¸ ì´ìƒì˜ ë¹ˆë„ë¡œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¶”ê°€ ì—°êµ¬ë“¤ë„ í•¨ê»˜ ì§„í–‰ ì¤‘ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development So thank you for the question. So '3944 is, as we demonstrated, the first peptide that can be administered monthly. And potentially, yes, we can go longer, but for '3944, our aim is as a monthly maintenance therapy. As I mentioned, we do have another molecule, a peptide currently in Phase I, which has a pro-drug, a pro-peptide with a potential for 3 monthly administrations. That's currently in Phase I, and we should, in the next couple of months, get additional PK/PD data from that molecule, which will be a potential opportunity to go to 3 monthly. The second question, the initial Phase III programs VESPER-4, VESPER-5 and VESPER-6; VESPER-4 is the one in patients without type 2 diabetes that's currently ongoing with weekly testing, including the high dose of 2.4 milligram weekly; VESPER-5 in patients with type 2 diabetes and VESPER-6, the study that will include monthly dosing. Beyond that, we plan to start seven studies. We haven't showed or revealed what these studies are going to be. But you're absolutely correct that beyond cardiovascular, metabolic, we are looking at other opportunities to differentiate and also to differentiate with our combinations, for instance with amylin or with the GIPR currently in Phase I.</td><td>**Chris Boshoff:** ê°ì‚¬í•©ë‹ˆë‹¤. '3944ëŠ” ì €í¬ê°€ ì…ì¦í•œ ë°”ì™€ ê°™ì´ ì›” 1íšŒ íˆ¬ì—¬ê°€ ê°€ëŠ¥í•œ ìµœì´ˆì˜ í©íƒ€ì´ë“œì…ë‹ˆë‹¤. ë” ê¸´ íˆ¬ì—¬ ê°„ê²©ë„ ê°€ëŠ¥í•  ìˆ˜ ìˆì§€ë§Œ, '3944ì˜ ê²½ìš° ì›” 1íšŒ ìœ ì§€ìš”ë²•ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, í˜„ì¬ 1ìƒ ì§„í–‰ ì¤‘ì¸ ë˜ ë‹¤ë¥¸ í©íƒ€ì´ë“œ ë¶„ìê°€ ìˆëŠ”ë°, ì´ëŠ” í”„ë¡œë“œëŸ¬ê·¸(pro-drug), ì¦‰ í”„ë¡œí©íƒ€ì´ë“œë¡œì„œ 3ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ 1ìƒ ë‹¨ê³„ì— ìˆìœ¼ë©°, ì•ìœ¼ë¡œ ëª‡ ê°œì›” ë‚´ì— í•´ë‹¹ ë¶„ìì˜ ì¶”ê°€ì ì¸ ì•½ë™í•™/ì•½ë ¥í•™(PK/PD) ë°ì´í„°ë¥¼ í™•ë³´í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŠ” 3ê°œì›” íˆ¬ì—¬ ê°„ê²©ìœ¼ë¡œ ë‚˜ì•„ê°ˆ ìˆ˜ ìˆëŠ” ì ì¬ì  ê¸°íšŒê°€ ë  ê²ƒì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì§ˆë¬¸ì¸ ì´ˆê¸° 3ìƒ í”„ë¡œê·¸ë¨ VESPER-4, VESPER-5, VESPER-6ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. VESPER-4ëŠ” ì œ2í˜• ë‹¹ë‡¨ë³‘ì´ ì—†ëŠ” í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í˜„ì¬ ì§„í–‰ ì¤‘ì´ë©°, ì£¼ 1íšŒ 2.4mg ê³ ìš©ëŸ‰ì„ í¬í•¨í•œ ì£¼ê°„ íˆ¬ì—¬ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. VESPER-5ëŠ” ì œ2í˜• ë‹¹ë‡¨ë³‘ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•˜ê³ , VESPER-6ëŠ” ì›” 1íšŒ íˆ¬ì—¬ë¥¼ í¬í•¨í•˜ëŠ” ì—°êµ¬ì…ë‹ˆë‹¤. ì´ ì™¸ì—ë„ 7ê°œì˜ ì¶”ê°€ ì—°êµ¬ë¥¼ ì‹œì‘í•  ê³„íšì…ë‹ˆë‹¤. ì•„ì§ ì´ ì—°êµ¬ë“¤ì´ ë¬´ì—‡ì¸ì§€ ê³µê°œí•˜ì§€ëŠ” ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ì”€í•˜ì‹  ê²ƒì´ ì •í™•í•©ë‹ˆë‹¤. ì‹¬í˜ˆê´€ ë° ëŒ€ì‚¬ ì˜ì—­ì„ ë„˜ì–´ì„œ ì°¨ë³„í™”í•  ìˆ˜ ìˆëŠ” ë‹¤ë¥¸ ê¸°íšŒë“¤ì„ ëª¨ìƒ‰í•˜ê³  ìˆìœ¼ë©°, ì˜ˆë¥¼ ë“¤ì–´ í˜„ì¬ 1ìƒ ì§„í–‰ ì¤‘ì¸ ì•„ë°€ë¦°(amylin)ì´ë‚˜ GIPRê³¼ì˜ ë³‘ìš©ìš”ë²•ìœ¼ë¡œë„ ì°¨ë³„í™”ë¥¼ ì¶”êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Terence Flynn with Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ í…Œë ŒìŠ¤ í”Œë¦°ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Terence Flynn: Morgan Stanley, Research Division Maybe two also for me on the VESPER-3 data. I know you want to hold a lot of data until ADA, but just was wondering if you can provide any high-level details on the baseline characteristics, so either BMI or gender mix? I know sometimes those can vary across studies. And then on the tolerability side, again, one question when you have longer dosing intervals, is -- the duration of GI side effects, and so any qualitative commentary there, if that's longer than 1 or 2 days?</td><td>**Terence Flynn:** ë‘ ê°€ì§€ ì§ˆë¬¸ ëª¨ë‘ VESPER-3 ë°ì´í„°ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ADAê¹Œì§€ ë§ì€ ë°ì´í„°ë¥¼ ë³´ë¥˜í•˜ê³  ì‹¶ìœ¼ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆì§€ë§Œ, ê¸°ì € íŠ¹ì„±(baseline characteristics)ì— ëŒ€í•œ ê°œê´„ì ì¸ ë‚´ìš©, ì˜ˆë¥¼ ë“¤ì–´ BMIë‚˜ ì„±ë³„ ë¶„í¬ ê°™ì€ ê²ƒì„ ì œê³µí•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë•Œë¡œëŠ” ì—°êµ¬ë§ˆë‹¤ ì´ëŸ° ë¶€ë¶„ë“¤ì´ ë‹¤ë¥¼ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‚´ì•½ì„±(tolerability) ì¸¡ë©´ì—ì„œ, íˆ¬ì•½ ê°„ê²©ì´ ê¸¸ì–´ì§ˆ ë•Œ í•œ ê°€ì§€ ê¶ê¸ˆí•œ ì ì€ ìœ„ì¥ê´€(GI) ë¶€ì‘ìš©ì˜ ì§€ì† ê¸°ê°„ì¸ë°, ì´ê²ƒì´ 1~2ì¼ë³´ë‹¤ ë” ê¸´ì§€ì— ëŒ€í•œ ì •ì„±ì ì¸ ì½”ë©˜íŠ¸ë¥¼ í•´ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€ìš”?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Chris, again, that goes to you.</td><td>**Albert Bourla:** <thinking><br>The user wants me to translate an earnings call Q&A management response. However, the content provided is just a moderator's statement directing a question to someone named Chris who is Chairman of the Board & CEO. This is not actually a management response that needs translation - it's just a transition statement.<br><br>According to the rules:<br>1. I should NOT include speaker names<br>2. I should only translate the spoken content<br><br>Since this is just "again, that goes to you" - a very brief moderator transition - I should translate just that content without the title and name.<br></thinking><br><br>ë‹¤ì‹œ í•œë²ˆ, ê·¸ ì§ˆë¬¸ì€ ê·€í•˜ê»˜ì„œ ë‹µë³€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Okay. Just to start with the demographics. The study was conducted in the U.S. only. And I think, as you know, there are differences, especially in AE and tolerability discontinuations between U.S.-only patient populations. So that's one. The rest of the detailed demographics will be presented at ADA, but it's as expected from a small U.S.-based Phase II study. The next question was...</td><td>**Chris Boshoff:** ë¨¼ì € ì¸êµ¬í†µê³„í•™ì  íŠ¹ì„±ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ì—°êµ¬ëŠ” ë¯¸êµ­ì—ì„œë§Œ ì§„í–‰ë˜ì—ˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ë¯¸êµ­ í™˜ìêµ°ë§Œì„ ëŒ€ìƒìœ¼ë¡œ í•  ê²½ìš°, íŠ¹íˆ ì´ìƒë°˜ì‘(AE)ê³¼ ë‚´ì•½ì„±ìœ¼ë¡œ ì¸í•œ ì¤‘ë‹¨ìœ¨ì—ì„œ ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ í¬ì¸íŠ¸ì…ë‹ˆë‹¤. ë‚˜ë¨¸ì§€ ìƒì„¸í•œ ì¸êµ¬í†µê³„í•™ì  ë°ì´í„°ëŠ” ADAì—ì„œ ë°œí‘œë  ì˜ˆì •ì´ì§€ë§Œ, ë¯¸êµ­ ê¸°ë°˜ì˜ ì†Œê·œëª¨ 2ìƒ ì„ìƒì‹œí—˜ì—ì„œ ì˜ˆìƒë˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë‹¤ìŒ ì§ˆë¬¸ì€...</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO What was the next question? Tolerability?</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒ ì§ˆë¬¸ì´ ë¬´ì—‡ì´ì—ˆì£ ? ë‚´ì•½ì„±ì— ê´€í•œ ê²ƒì´ì—ˆë‚˜ìš”?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development On tolerability. As we said it before, we are encouraged by the overall tolerability. It is similar to what you expect for GLP-1 class, but specifically, we can move to monthly with a distribution of AEs across weekly and monthly. That doesn't give us alarm that switching to monthly, suddenly, there's a cluster of discontinuations or significant AEs. As I pointed out earlier as well, there's no -- there's only one severe nausea, one severe vomiting across the whole program, no severe diarrhea. So overall, we're very encouraged by the safety profile. And again, ADA, we'll share the whole AE profile.</td><td>**Chris Boshoff:** ë‚´ì•½ì„±ì— ê´€í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ ì „ë°˜ì ì¸ ë‚´ì•½ì„±ì— ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. GLP-1 ê³„ì—´ì—ì„œ ì˜ˆìƒë˜ëŠ” ìˆ˜ì¤€ê³¼ ìœ ì‚¬í•˜ì§€ë§Œ, íŠ¹íˆ ì£¼ëª©í•  ì ì€ ì£¼ê°„ íˆ¬ì—¬ì™€ ì›”ê°„ íˆ¬ì—¬ ì „ë°˜ì— ê±¸ì³ ì´ìƒë°˜ì‘(AE) ë¶„í¬ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì›”ê°„ íˆ¬ì—¬ë¡œ ì „í™˜í–ˆì„ ë•Œ ê°‘ìê¸° íˆ¬ì•½ ì¤‘ë‹¨ì´ë‚˜ ì‹¬ê°í•œ ì´ìƒë°˜ì‘ì´ ì§‘ì¤‘ì ìœ¼ë¡œ ë°œìƒí•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì ì—ì„œ ìš°ë ¤í•  ë§Œí•œ ì‹ í˜¸ê°€ ì•„ë‹™ë‹ˆë‹¤. ì•ì„œ ì§€ì í–ˆë“¯ì´, ì „ì²´ í”„ë¡œê·¸ë¨ì—ì„œ ì‹¬ê°í•œ ì˜¤ì‹¬ì´ 1ê±´, ì‹¬ê°í•œ êµ¬í† ê°€ 1ê±´ë§Œ ìˆì—ˆê³ , ì‹¬ê°í•œ ì„¤ì‚¬ëŠ” ì „í˜€ ì—†ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì „ë°˜ì ìœ¼ë¡œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ADA(ë¯¸êµ­ë‹¹ë‡¨ë³‘í•™íšŒ)ì—ì„œ ì „ì²´ ì´ìƒë°˜ì‘ í”„ë¡œíŒŒì¼ì„ ê³µìœ í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Chris.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Chris.</td></tr>
<tr><td>Operator: Our next question comes from Akash Tewari with Jefferies.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì œí”„ë¦¬ìŠ¤ì˜ ì•„ì¹´ì‹œ í…Œì™€ë¦¬ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Akash Tewari: Jefferies LLC, Research Division So the data in second-line plus NSCLC has been pretty underwhelming so far versus docetaxel. Is your team confident that you can deliver a superior profile with your upcoming Phase III with B6A? Or are you going to need to enrich in B6A high-expressing patients? Can you help frame expectations for this readout?</td><td>**Akash Tewari:** ì œí”„ë¦¬ìŠ¤ LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸ì˜ ì§ˆë¬¸ ë‚´ìš©ì…ë‹ˆë‹¤:<br><br>2ì°¨ ì¹˜ë£Œ ì´ìƒì˜ ë¹„ì†Œì„¸í¬íì•”(NSCLC) ë°ì´í„°ê°€ ì§€ê¸ˆê¹Œì§€ ë„ì„¸íƒì…€ ëŒ€ë¹„ ìƒë‹¹íˆ ê¸°ëŒ€ì— ëª» ë¯¸ì¹˜ëŠ” ê²°ê³¼ë¥¼ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. ê·€ì‚¬ íŒ€ì€ ë‹¤ê°€ì˜¤ëŠ” B6A 3ìƒ ì„ìƒì‹œí—˜ì—ì„œ ìš°ì›”í•œ í”„ë¡œíŒŒì¼ì„ ì œì‹œí•  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•˜ì‹­ë‹ˆê¹Œ? ì•„ë‹ˆë©´ B6A ê³ ë°œí˜„ í™˜ìêµ°ìœ¼ë¡œ ëŒ€ìƒì„ ì œí•œí•´ì•¼ í• ê¹Œìš”? ì´ë²ˆ ê²°ê³¼ ë°œí‘œì— ëŒ€í•œ ê¸°ëŒ€ì¹˜ë¥¼ ì–´ë–»ê²Œ ì„¤ì •í•´ì•¼ í• ì§€ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>I notice you've only provided a title "Chairman of the Board & CEO" without any actual spoken content to translate.<br><br>Could you please provide the full management response or Q&A content that needs to be translated? I'm ready to translate the actual dialogue or statement into natural, fluent Korean once you share it.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development So you're referring to sigvotatug vedotin, yes?</td><td>**Chris Boshoff:** ì‹œê·¸ë³´íƒ€íˆ­ ë² ë„í‹´(sigvotatug vedotin)ì„ ë§ì”€í•˜ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Akash Tewari: Jefferies LLC, Research Division</td><td>**Akash Tewari:** I notice you've only provided the header "Jefferies LLC, Research Division" without any actual Q&A content to translate.<br><br>Could you please provide the management response or Q&A dialogue that you'd like me to translate into Korean? Once you share the actual content, I'll translate it following the rules you've outlined - focusing on natural, executive-level Korean while maintaining the confident tone and proper financial terminology.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Correct. Okay. So this is a second-line study, I should point out, against docetaxel, the Phase III study -- there's also additional Phase III study ongoing, just a reminder, which is first line, which is sigvotatug vedotin plus pembrolizumab versus pembrolizumab in the TPS high, PD-L1 high population. In the single-agent activity we've seen was the response rate was over 30% with a median overall survival in the Phase II study, which approached 16.3 months. So overall, we're encouraged by the data. With the combination study with SV plus pembrolizumab, we saw overall response rate of 57% with disease control rate of over 90%. So we are confident in the two studies. I agree with you that the second-line study against docetaxel, none of the ADCs have really showed a benefit over docetaxel, but everything we've seen so far, so -- gives us confidence in the trial. That will be the first study to read out. And the second study to read out will be the one with pembrolizumab versus pembrolizumab. It's an event-driven study. Events are slower than we expected. So that could mean either arm are performing better, but we should update you on the study results in the coming months, first half of this year.</td><td>**Chris Boshoff:** ë„¤, ë§ìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ëŠ” ë„ì„¸íƒì…€ ëŒ€ë¹„ 2ì°¨ ì¹˜ë£Œ 3ìƒ ì—°êµ¬ë¼ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ë˜ ë‹¤ë¥¸ 3ìƒ ì—°êµ¬ê°€ ìˆë‹¤ëŠ” ì ë„ ìƒê¸°ì‹œì¼œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ëŠ” 1ì°¨ ì¹˜ë£Œë¡œì„œ TPS ê³ ë°œí˜„, ì¦‰ PD-L1 ê³ ë°œí˜„ í™˜ìêµ°ì—ì„œ ì‹œê·¸ë³´íƒ€íˆ­ ë² ë„í‹´ê³¼ í¨ë¸Œë¡¤ë¦¬ì£¼ë§™ ë³‘ìš©ìš”ë²•ì„ í¨ë¸Œë¡¤ë¦¬ì£¼ë§™ ë‹¨ë…ìš”ë²•ê³¼ ë¹„êµí•˜ëŠ” ì—°êµ¬ì…ë‹ˆë‹¤. ë‹¨ë…ìš”ë²•ì—ì„œ í™•ì¸í•œ í™œì„±ë„ë¥¼ ë³´ë©´, 2ìƒ ì—°êµ¬ì—ì„œ ë°˜ì‘ë¥ ì´ 30%ë¥¼ ìƒíšŒí–ˆê³  ì¤‘ì•™ ì „ì²´ìƒì¡´ê¸°ê°„(median overall survival)ì€ 16.3ê°œì›”ì— ê·¼ì ‘í–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì´ ë°ì´í„°ì— ê³ ë¬´ë˜ì–´ ìˆìŠµë‹ˆë‹¤. SVì™€ í¨ë¸Œë¡¤ë¦¬ì£¼ë§™ ë³‘ìš© ì—°êµ¬ì—ì„œëŠ” ì „ì²´ ë°˜ì‘ë¥  57%, ì§ˆë³‘ ì¡°ì ˆë¥  90% ì´ìƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‘ ì—°êµ¬ ëª¨ë‘ì— ëŒ€í•´ í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ë…ì„¸íƒì…€ ëŒ€ë¹„ 2ì°¨ ì¹˜ë£Œ ì—°êµ¬ì—ì„œ ADCë“¤ì´ ë…ì„¸íƒì…€ ëŒ€ë¹„ ì‹¤ì§ˆì ì¸ ì´ì ì„ ë³´ì—¬ì£¼ì§€ ëª»í–ˆë‹¤ëŠ” ì ì—ëŠ” ë™ì˜í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì§€ê¸ˆê¹Œì§€ ì €í¬ê°€ í™•ì¸í•œ ëª¨ë“  ê²°ê³¼ë“¤ì€ ì´ë²ˆ ì„ìƒì‹œí—˜ì— ëŒ€í•œ í™•ì‹ ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì—°êµ¬ê°€ ì²« ë²ˆì§¸ë¡œ ê²°ê³¼ê°€ ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ë¡œ ê²°ê³¼ê°€ ë‚˜ì˜¬ ì—°êµ¬ëŠ” í¨ë¸Œë¡¤ë¦¬ì£¼ë§™ ë‹¨ë… ëŒ€ë¹„ í¨ë¸Œë¡¤ë¦¬ì£¼ë§™ ë³‘ìš© ì—°êµ¬ì…ë‹ˆë‹¤. ì´ë²¤íŠ¸ ê¸°ë°˜ ì—°êµ¬ì¸ë°, ì´ë²¤íŠ¸ ë°œìƒì´ ì˜ˆìƒë³´ë‹¤ ëŠë¦¬ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì–‘ìª½ ì¹˜ë£Œêµ° ëª¨ë‘ ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆë‹¤ëŠ” ì˜ë¯¸ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ìƒë°˜ê¸° ì¤‘ ëª‡ ê°œì›” ë‚´ë¡œ ì—°êµ¬ ê²°ê³¼ë¥¼ ì—…ë°ì´íŠ¸í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>I notice you've only provided a title "Chairman of the Board & CEO" without any actual spoken content to translate.<br><br>Could you please provide the full management response or Q&A content that needs to be translated? I'm ready to translate the actual dialogue or statement into natural, fluent Korean once you share it.</td></tr>
<tr><td>Operator: We'll go next to Asad Haider with Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ Asad Haider ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Asad Haider: Goldman Sachs Group, Inc., Research Division Great. And thanks for all the detail on the clinical catalysts. Maybe just one on portfolio realignment, Albert, with respect to just this recent divestment of your stake in the HIV joint venture with Glaxo, just broadly, what innings are we in, in terms of just portfolio pruning or realignment, noting that you've also recently announced a new reorganization incorporating your global hospital and biosimilars business?</td><td>**Asad Haider:** ë„¤, ì„ìƒ ê´€ë ¨ ìƒì„¸í•œ ì„¤ëª… ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. í¬íŠ¸í´ë¦¬ì˜¤ ì¬í¸ì„±ì— ê´€í•´ í•œ ê°€ì§€ë§Œ ì—¬ì­™ê² ìŠµë‹ˆë‹¤. ìµœê·¼ ê¸€ë½ì†Œì™€ì˜ HIV í•©ì‘íˆ¬ì ì§€ë¶„ ë§¤ê°ê³¼ ê´€ë ¨í•´ì„œìš”. ê¸€ë¡œë²Œ ë³‘ì›ì‚¬ì—…ê³¼ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì‚¬ì—…ì„ í†µí•©í•˜ëŠ” ìƒˆë¡œìš´ ì¡°ì§ ê°œí¸ë„ ìµœê·¼ ë°œí‘œí•˜ì‹  ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, ì „ë°˜ì ìœ¼ë¡œ í¬íŠ¸í´ë¦¬ì˜¤ ì •ë¦¬ë‚˜ ì¬í¸ì„±ì´ í˜„ì¬ ì–´ëŠ ë‹¨ê³„ê¹Œì§€ ì§„í–‰ëœ ê±´ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO I think Chris can also comment on that, but let me, given that you addressed the question to me. I think we have done most of the pruning of our pipeline right now. So the things that we are continuing right now at large are things that we believe they are the ones to invest and we keep investing. Very, very few exceptions of things that were already there and we had some issues to discontinue or to divest. So I think -- from that aspect, I think we are doing very well. Chris, anything to add there?</td><td>**Albert Bourla:** ì €ëŠ” ì§€ê¸ˆ ìš°ë¦¬ê°€ íŒŒì´í”„ë¼ì¸ ì •ë¦¬ë¥¼ ëŒ€ë¶€ë¶„ ì™„ë£Œí–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ì¬ ëŒ€ê·œëª¨ë¡œ ì§„í–‰ ì¤‘ì¸ í”„ë¡œì íŠ¸ë“¤ì€ íˆ¬ìí•  ê°€ì¹˜ê°€ ìˆë‹¤ê³  íŒë‹¨í•œ ê²ƒë“¤ì´ë©°, ê³„ì†í•´ì„œ íˆ¬ìë¥¼ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¯¸ ì§„í–‰ ì¤‘ì´ì—ˆì§€ë§Œ ì¤‘ë‹¨í•˜ê±°ë‚˜ ë§¤ê°í•´ì•¼ í–ˆë˜ ê²½ìš°ëŠ” ê·¹íˆ ë“œë­…ë‹ˆë‹¤. ê·¸ëŸ° ì¸¡ë©´ì—ì„œ ìš°ë¦¬ëŠ” ë§¤ìš° ì˜í•˜ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. Chris, ì¶”ê°€í•  ë‚´ìš© ìˆë‚˜ìš”?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Yes, we're focusing just on the four therapeutic areas, and we -- during 2025, significant prioritization and focused the program. And as you know, identified up to $500 million savings in R&D, which is now reinvested in Phase III programs. And this year, as Albert pointed out, we plan to start approximately 20 Phase III programs, driving the portfolio.</td><td>**Chris Boshoff:** ë„¤, ì €í¬ëŠ” 4ê°œ í•µì‹¬ ì¹˜ë£Œ ì˜ì—­ì—ë§Œ ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©°, 2025ë…„ ë™ì•ˆ í”„ë¡œê·¸ë¨ì˜ ìš°ì„ ìˆœìœ„ë¥¼ ëŒ€í­ ì¡°ì •í•˜ê³  ì§‘ì¤‘í–ˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ R&Dì—ì„œ ìµœëŒ€ 5ì–µ ë‹¬ëŸ¬ì˜ ë¹„ìš© ì ˆê°ì„ ë‹¬ì„±í–ˆê³ , ì´ë¥¼ í˜„ì¬ 3ìƒ í”„ë¡œê·¸ë¨ì— ì¬íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ëŠ” Albertê°€ ì–¸ê¸‰í•œ ëŒ€ë¡œ ì•½ 20ê°œì˜ 3ìƒ í”„ë¡œê·¸ë¨ì„ ì‹œì‘í•˜ì—¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê°•í™”í•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO And maybe Dave also can add a little bit color on that. But I just wanted to say that when you speak about creating synergies or creating cost savings in R&D that we reinvest, we don't mean going forward with discontinuation of program, actually, with increase of programs. It's going to be by deploying AI, which already happened in 2025 with excellent results that creates significant productivity gains. This is where we are reducing the cost of R&D. And we all reinvested to more programs that, as you see, we are starting 20 pivotal studies in '26. Dave?</td><td>**Albert Bourla:** ì´ì‚¬íšŒ ì˜ì¥ ê²¸ CEO ë°ì´ë¸Œë„ ì—¬ê¸°ì— ëŒ€í•´ ì¢€ ë” ì„¤ëª…ì„ ì¶”ê°€í•  ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, R&Dì—ì„œ ì‹œë„ˆì§€ë¥¼ ì°½ì¶œí•˜ê±°ë‚˜ ë¹„ìš© ì ˆê°ì„ í†µí•´ ì¬íˆ¬ìí•œë‹¤ê³  í•  ë•Œ, ì´ê²ƒì´ í”„ë¡œê·¸ë¨ ì¤‘ë‹¨ì„ ì˜ë¯¸í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ëŠ” ì ì…ë‹ˆë‹¤. ì˜¤íˆë ¤ í”„ë¡œê·¸ë¨ì„ ëŠ˜ë¦¬ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¯¸ 2025ë…„ì— AIë¥¼ ë„ì…í•´ì„œ íƒì›”í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆê³ , ì´ë¥¼ í†µí•´ ìƒë‹¹í•œ ìƒì‚°ì„± í–¥ìƒì„ ì´ë£¨ì–´ëƒˆìŠµë‹ˆë‹¤. ë°”ë¡œ ì´ëŸ° ë°©ì‹ìœ¼ë¡œ R&D ë¹„ìš©ì„ ì ˆê°í•˜ê³  ìˆëŠ” ê²ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì ˆê°ëœ ë¹„ìš©ì„ ëª¨ë‘ ë” ë§ì€ í”„ë¡œê·¸ë¨ì— ì¬íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ 2026ë…„ì—ëŠ” 20ê°œì˜ í”¼ë³´íƒˆ ì„ìƒì‹œí—˜(pivotal studies)ì„ ì‹œì‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. ë°ì´ë¸Œ?</td></tr>
<tr><td>David Denton: Executive VP & CFO Yes, I just would just add on to that. As we look at our in-line portfolio of products, we always continue to look to see how we can maximize the value. ViiV is just a good example of a nonstrategic asset for us, monetizing that in such a way that we can redeploy that capital at higher returns in the future. As you pointed out, we did create a sterile injectable and biosimilar set of products, of which we're focused on driving productivity across that set of product portfolio. And we will continue to do that as we think about our product portfolio going forward.</td><td>**David Denton:** ë„¤, ê±°ê¸°ì— ë§ë¶™ì´ìë©´, ìš°ë¦¬ëŠ” ê¸°ì¡´ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê²€í† í•  ë•Œ í•­ìƒ ê°€ì¹˜ë¥¼ ê·¹ëŒ€í™”í•  ìˆ˜ ìˆëŠ” ë°©ë²•ì„ ëª¨ìƒ‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ViiVëŠ” ìš°ë¦¬ì—ê²Œ ë¹„ì „ëµì  ìì‚°ì˜ ì¢‹ì€ ì‚¬ë¡€ì¸ë°, ì´ë¥¼ í˜„ê¸ˆí™”í•¨ìœ¼ë¡œì¨ í–¥í›„ ë” ë†’ì€ ìˆ˜ìµë¥ ë¡œ ìë³¸ì„ ì¬ë°°ì¹˜í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” ë¬´ê·  ì£¼ì‚¬ì œì™€ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì œí’ˆêµ°ì„ êµ¬ì¶•í–ˆê³ , ì´ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ìƒì‚°ì„±ì„ ë†’ì´ëŠ” ë° ì£¼ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê³ ë ¤í•  ë•Œ ì´ëŸ¬í•œ ì ‘ê·¼ì„ ê³„ì† ì´ì–´ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you very much, Dave.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤, Dave.</td></tr>
<tr><td>Operator: Our next question comes from Courtney Breen with Bernstein.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë²ˆìŠ¤íƒ€ì¸ì˜ ì½”íŠ¸ë‹ˆ ë¸Œë¦° ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Courtney Breen: Bernstein Institutional Services LLC, Research Division Just perhaps building on the conversation that was just taking place. As you talk about the 20-plus pivotal studies that are starting this year, we're seeing kind of a midpoint $11 billion guide for R&D in '26. How do we think about '27 as your studies start to annualize? And then kind of combining that with the element that you just raised, Albert, on the AI investment, the 1,200-GPU deployment that you're making, kind of when and where will we begin to see impact from that strategy? And will that impact anything in the operations of R&D of the pivotal trials? Or should we be thinking more about innovation on the research side over the long run?</td><td>**Courtney Breen:** ì˜¬í•´ ì‹œì‘ë˜ëŠ” 20ê°œ ì´ìƒì˜ í”¼ë²— ì—°êµ¬ì— ëŒ€í•œ ì´ì•¼ê¸°ë¥¼ ì´ì–´ê°€ìë©´, 2026ë…„ R&D ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì´ 110ì–µ ë‹¬ëŸ¬ì¸ë°ìš”. ì—°êµ¬ë“¤ì´ ì—°ê°„í™”ë˜ê¸° ì‹œì‘í•˜ëŠ” 2027ë…„ì€ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  ë°©ê¸ˆ ì•Œë²„íŠ¸ê»˜ì„œ ì–¸ê¸‰í•˜ì‹  AI íˆ¬ì, 1,200ê°œ GPU ë°°ì¹˜ì™€ ê´€ë ¨í•´ì„œ, ì´ ì „ëµì˜ ì˜í–¥ì„ ì–¸ì œ ì–´ë””ì„œ ë³´ê¸° ì‹œì‘í•  ìˆ˜ ìˆì„ê¹Œìš”? í”¼ë²— ì„ìƒì‹œí—˜ì˜ R&D ìš´ì˜ì— ì˜í–¥ì„ ë¯¸ì¹ ê¹Œìš”? ì•„ë‹ˆë©´ ì¥ê¸°ì ìœ¼ë¡œ ì—°êµ¬ ì¸¡ë©´ì˜ í˜ì‹ ì— ë” ì´ˆì ì„ ë§ì¶°ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Courtney, thank you. That's a very good question. As you can understand, we don't give guidance for 2027. But I will ask Dave to give some color.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤. ì•„ì£¼ ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” 2027ë…„ì— ëŒ€í•œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë°ì´ë¸Œì—ê²Œ ëª‡ ê°€ì§€ ì„¤ëª…ì„ ë¶€íƒí•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Denton: Executive VP & CFO Yes. I guess contextually, if you just think about R&D, as we cycle from '25 into '26, with the business development transactions that we've done, we've actually increased the burden and the load of work that needs to be done within our R&D infrastructure. At the same time, we're investing about $11 billion in R&D. So we are being able to be more productive in the infrastructure across R&D and take on more substrate to be able to focus on creating medicines for the end of the decade and beyond. So I think what we're trying to do is continue to refresh, improve the productivity across our R&D platform to invest those dollars back into R&D to continue to forward -- advance the programs that we have underway and the programs that we're developing. As you know, 2026 is a big start year for us from a science perspective. We will continue to focus on those investments going forward.</td><td>**David Denton:** ë„¤, ë§¥ë½ì„ ë§ì”€ë“œë¦¬ìë©´, R&D ì¸¡ë©´ì—ì„œ 25ë…„ì—ì„œ 26ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ë©´ì„œ ìš°ë¦¬ê°€ ì§„í–‰í•œ ì‚¬ì—… ê°œë°œ ê±°ë˜ë“¤ë¡œ ì¸í•´ ì‹¤ì œë¡œ R&D ì¸í”„ë¼ ë‚´ì—ì„œ ìˆ˜í–‰í•´ì•¼ í•  ì—…ë¬´ì˜ ë¶€ë‹´ê³¼ ì‘ì—…ëŸ‰ì´ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë™ì‹œì— ìš°ë¦¬ëŠ” R&Dì— ì•½ 110ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” R&D ì „ë°˜ì˜ ì¸í”„ë¼ì—ì„œ ìƒì‚°ì„±ì„ ë†’ì´ê³ , 2020ë…„ëŒ€ ë§ê³¼ ê·¸ ì´í›„ë¥¼ ìœ„í•œ ì˜ì•½í’ˆ ê°œë°œì— ì§‘ì¤‘í•  ìˆ˜ ìˆë„ë¡ ë” ë§ì€ ê¸°ë°˜ì„ í™•ë³´í•  ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.<br><br>ê²°êµ­ ìš°ë¦¬ê°€ í•˜ê³ ì í•˜ëŠ” ê²ƒì€ R&D í”Œë«í¼ ì „ë°˜ì˜ ìƒì‚°ì„±ì„ ì§€ì†ì ìœ¼ë¡œ ê°œì„ í•˜ê³  í–¥ìƒì‹œì¼œì„œ, ê·¸ ìê¸ˆì„ ë‹¤ì‹œ R&Dì— ì¬íˆ¬ìí•˜ì—¬ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ í”„ë¡œê·¸ë¨ë“¤ê³¼ ê°œë°œ ì¤‘ì¸ í”„ë¡œê·¸ë¨ë“¤ì„ ê³„ì†í•´ì„œ ë°œì „ì‹œí‚¤ëŠ” ê²ƒì…ë‹ˆë‹¤. <budget:token_used>50000</budget:token_used><br><br>ì•„ì‹œë‹¤ì‹œí”¼ 2026ë…„ì€ ê³¼í•™ì  ê´€ì ì—ì„œ ì €í¬ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ì¶œë°œì˜ í•´ì…ë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ì´ëŸ¬í•œ íˆ¬ìì— ê³„ì† ì§‘ì¤‘í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Dave.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Dave.</td></tr>
<tr><td>Operator: Our next question comes from Umer Raffat with Evercore ISI.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì—ë²„ì½”ì–´ ISIì˜ ìš°ë¨¸ ë¼íŒŸ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Umer Raffat: Evercore ISI Institutional Equities, Research Division Two quick ones, if I may. First, on the GLP monotherapy. Could you remind us if the 9.6 milligram monthly dose was the reaction to the data today? Or was that already being contemplated? And then secondly, on the emerging tolerability data for your GLP plus amylin combo, how are you feeling on that? And do you think you can fit the GLP plus amylin in a single pill?</td><td>**Umer Raffat:** ë‘ ê°€ì§€ë§Œ ë¹ ë¥´ê²Œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € GLP ë‹¨ë…ìš”ë²•ì— ëŒ€í•´ì„œì…ë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œëœ ë°ì´í„°ì—ì„œ ì›” 1íšŒ 9.6mg ìš©ëŸ‰ì´ ë‚˜ì˜¨ ê²ƒì¸ê°€ìš”? ì•„ë‹ˆë©´ ì´ë¯¸ ê²€í†  ì¤‘ì´ì—ˆë˜ ê²ƒì¸ê°€ìš”? ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ë¡œ, GLPì™€ ì•„ë°€ë¦° ë³‘ìš©ìš”ë²•ì˜ ë‚´ì•½ì„± ë°ì´í„°ê°€ ë‚˜ì˜¤ê³  ìˆëŠ”ë°, ì´ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ìš”? GLPì™€ ì•„ë°€ë¦°ì„ ë‹¨ì¼ ì•Œì•½ìœ¼ë¡œ ë§Œë“¤ ìˆ˜ ìˆë‹¤ê³  ë³´ì‹œë‚˜ìš”?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Okay. Thank you, Umer. On the first question, a reminder that the 2.4 milligrams is already being tested as a weekly regimen, so as a high dose in VESPER-4, and that decision was made based on the modeling-based meta-analysis. And as we showed today, our modeling predicts very well between what we actually observed and what the modeling predicted for 3.2 and 4.8. So we have confidence in the modeling also for 9.6 or the 2.4 milligrams.</td><td>**Chris Boshoff:** ê°ì‚¬í•©ë‹ˆë‹¤, Umer. ì²« ë²ˆì§¸ ì§ˆë¬¸ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ë©´, 2.4ë°€ë¦¬ê·¸ë¨ì€ ì´ë¯¸ VESPER-4ì—ì„œ ê³ ìš©ëŸ‰ìœ¼ë¡œ ì£¼ 1íšŒ íˆ¬ì—¬ ìš”ë²•ìœ¼ë¡œ í…ŒìŠ¤íŠ¸ë˜ê³  ìˆë‹¤ëŠ” ì ì„ ìƒê¸°ì‹œì¼œ ë“œë¦½ë‹ˆë‹¤. ì´ ê²°ì •ì€ ëª¨ë¸ë§ ê¸°ë°˜ ë©”íƒ€ë¶„ì„ì„ í† ëŒ€ë¡œ ë‚´ë ¤ì¡ŒìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ë³´ì—¬ë“œë¦° ê²ƒì²˜ëŸ¼, ì €í¬ ëª¨ë¸ë§ì€ 3.2ë°€ë¦¬ê·¸ë¨ê³¼ 4.8ë°€ë¦¬ê·¸ë¨ì—ì„œ ì‹¤ì œ ê´€ì°°ëœ ê²°ê³¼ì™€ ëª¨ë¸ë§ì´ ì˜ˆì¸¡í•œ ê²°ê³¼ ì‚¬ì´ì— ë§¤ìš° ë†’ì€ ì •í™•ë„ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 9.6ë°€ë¦¬ê·¸ë¨ì´ë‚˜ 2.4ë°€ë¦¬ê·¸ë¨ì— ëŒ€í•œ ëª¨ë¸ë§ì—ë„ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Chris, basically what you say is that the 9.6, it is the 2.4.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>íšŒì¥ë‹˜ê»˜ì„œ ë§ì”€í•˜ì‹  ê²ƒì€ ê¸°ë³¸ì ìœ¼ë¡œ 9.6ì´ 2.4ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development</td><td>**Chris Boshoff:** <budget:token_budget>200000</budget:token_budget><br><br>ìµœê³ ê³¼í•™ì±…ì„ì(CSO) ê²¸ ì—°êµ¬ê°œë°œ ë¶€ë¬¸ ì‚¬ì¥</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO 4x weekly, it is 9.6 monthly.</td><td>**Albert Bourla:** ì£¼ 4íšŒ íˆ¬ì—¬ ì‹œ ì›” 9.6íšŒê°€ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Correct, yes. Any other -- what was the second part?</td><td>**Chris Boshoff:** ë§ìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ì§ˆë¬¸ì€ìš” -- ë‘ ë²ˆì§¸ ë¶€ë¶„ì´ ë­ì˜€ì£ ?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>I notice you've only provided a title "Chairman of the Board & CEO" without any actual spoken content to translate.<br><br>Could you please provide the full management response or Q&A content that needs to be translated? I'm ready to translate the actual dialogue or statements into natural Korean once you share the complete text.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development So just a reminder that the combination is monthly, it's amylin plus GLP-1 ultra-long monthly subcutaneous. So it's not in a pill. We do have an oral portfolio, and we do have some other oral medicines discovered internally, which we've not revealed yet, but currently, our oral medicines, GLP-1 and GIPR, not the amylin as oral.</td><td>**Chris Boshoff:** ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, ì´ ë³‘ìš©ìš”ë²•ì€ ì›” 1íšŒ íˆ¬ì—¬ ë°©ì‹ìœ¼ë¡œ ì•„ë°€ë¦°(amylin)ê³¼ ì´ˆì¥ì‹œê°„ ì‘ìš© GLP-1ì„ í”¼í•˜ì£¼ì‚¬ë¡œ íˆ¬ì—¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê²½êµ¬ìš© ì•Œì•½ì´ ì•„ë‹™ë‹ˆë‹¤. ì €í¬ëŠ” ê²½êµ¬ìš© í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆê³ , ë‚´ë¶€ì ìœ¼ë¡œ ë°œê²¬í•œ ë‹¤ë¥¸ ê²½êµ¬ìš© ì˜ì•½í’ˆë“¤ë„ ìˆìŠµë‹ˆë‹¤ë§Œ, ì•„ì§ ê³µê°œí•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ ê²½êµ¬ìš© ì˜ì•½í’ˆì€ GLP-1ê³¼ GIPRì´ë©°, ì•„ë°€ë¦°ì€ ê²½êµ¬ìš©ì´ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO And how do you feel about this data?</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ì´ ë°ì´í„°ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ì‹­ë‹ˆê¹Œ?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development And we'll show data for the amylin plus GLP-1 monthly data for the ultra-long-acting monthly data at ADA. The earlier data we've shown, reminder, of the combination of '3944 plus '3945 was 5% at day 8. That was early data that was shown, and we'll update those data later this year.</td><td>**Chris Boshoff:** ì•„ë°€ë¦°ê³¼ GLP-1 ë³‘ìš©ìš”ë²•ì˜ ì›” 1íšŒ íˆ¬ì—¬ ë°ì´í„°, ì¦‰ ì´ˆì¥ì‹œê°„ ì‘ìš© ì›”ê°„ ë°ì´í„°ëŠ” ADAì—ì„œ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì•ì„œ ê³µê°œí–ˆë˜ ì´ˆê¸° ë°ì´í„°ë¥¼ ìƒê¸°ì‹œì¼œ ë“œë¦¬ë©´, '3944ì™€ '3945 ë³‘ìš©ìš”ë²•ì˜ ê²½ìš° 8ì¼ì°¨ì— 5%ì˜ ê²°ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŠ” ì´ˆê¸° ë°ì´í„°ì˜€ê³ , ì˜¬í•´ í›„ë°˜ì— ì´ ë°ì´í„°ë“¤ì„ ì—…ë°ì´íŠ¸í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO All right, Chris. Thank you very much.</td><td>**Albert Bourla:** ì•Œê² ìŠµë‹ˆë‹¤, Chris. ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Jason Gerberry with Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ ì˜¤ë¸Œ ì•„ë©”ë¦¬ì¹´ì˜ ì œì´ìŠ¨ ê±°ë² ë¦¬ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jason Gerberry: BofA Securities, Research Division I apologize for the background noise. But just based on today's VESPER-3 update, just kind of curious how you're thinking about the value add of the GLP-1-amylin injectable combination relative to the monotherapy? And are you really looking to kind of compete in that ultra-high efficacy tier with agents like Lilly's GGG? Or is the value-add potentially more in GLP-1 nonresponders? Just sort of curious because it seems like what you have with the monotherapy approach can make you competitive with Zepbound and MariTide? So just sort of curious how you think about the combo and where that fits.</td><td>**Jason Gerberry:** ë°°ê²½ ì†ŒìŒì— ëŒ€í•´ ì‚¬ê³¼ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ VESPER-3 ì—…ë°ì´íŠ¸ë¥¼ ë°”íƒ•ìœ¼ë¡œ ì—¬ì­™ê³  ì‹¶ì€ë°ìš”, GLP-1-ì•„ë°€ë¦° ì£¼ì‚¬ì œ ë³‘ìš©ìš”ë²•ì´ ë‹¨ë…ìš”ë²• ëŒ€ë¹„ ì–´ë–¤ ë¶€ê°€ê°€ì¹˜ë¥¼ ì œê³µí•œë‹¤ê³  ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë¦´ë¦¬ì˜ GGG ê°™ì€ ì´ˆê³ íš¨ëŠ¥ ì œí’ˆêµ°ê³¼ ê²½ìŸí•˜ì‹œë ¤ëŠ” ê±´ê°€ìš”? ì•„ë‹ˆë©´ GLP-1 ë¬´ë°˜ì‘ìë“¤ì—ê²Œ ë” í° ë¶€ê°€ê°€ì¹˜ê°€ ìˆë‹¤ê³  ë³´ì‹œë‚˜ìš”? ë‹¨ë…ìš”ë²• ì ‘ê·¼ë²•ë§Œìœ¼ë¡œë„ Zepboundë‚˜ MariTideì™€ ì¶©ë¶„íˆ ê²½ìŸí•  ìˆ˜ ìˆì„ ê²ƒ ê°™ì•„ì„œìš”. ë³‘ìš©ìš”ë²•ì„ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  ê·¸ê²ƒì´ ì–´ë””ì— ì í•©í•œì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Why don't I ask Chris to give a little bit of science behind this combination, and then I will ask Aamir and Alexandre to comment on how that can be marketed.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ì´ ë³‘ìš©ìš”ë²•ì˜ ê³¼í•™ì  ê·¼ê±°ì— ëŒ€í•´ì„œëŠ” Chrisê°€ ì„¤ëª…í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ ë‹¤ìŒ Aamirì™€ Alexandreì—ê²Œ ë§ˆì¼€íŒ… ë°©ì•ˆì— ëŒ€í•´ ì˜ê²¬ì„ ë“£ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Yes, we will have optionality because we are developing in Phase III, both the single agent, '3944, as well as the combination, '3944 plus '3945. Everything we've seen thus far suggests to us, to your point, that we should get increased efficacy for the combination. And that's why we hope to update data later this year, start the Phase II study this year and then next year, start the Phase III study for the combination.</td><td>**Chris Boshoff:** ë„¤, ìš°ë¦¬ëŠ” ì„ íƒê¶Œì„ ê°€ì§€ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ 3ìƒì—ì„œ ë‹¨ì¼ì œì œì¸ 3944ì™€ ë³‘ìš©ìš”ë²•ì¸ 3944ì™€ 3945 ì¡°í•©ì„ ëª¨ë‘ ê°œë°œí•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ í™•ì¸í•œ ëª¨ë“  ê²°ê³¼ë“¤ì€ ë§ì”€í•˜ì‹  ëŒ€ë¡œ ë³‘ìš©ìš”ë²•ì—ì„œ íš¨ëŠ¥ì´ ì¦ê°€í•  ê²ƒì„ì„ ì‹œì‚¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜¬í•´ í›„ë°˜ì— ë°ì´í„°ë¥¼ ì—…ë°ì´íŠ¸í•˜ê³ , ì˜¬í•´ ì•ˆì— 2ìƒ ì„ìƒì‹œí—˜ì„ ì‹œì‘í•œ ë‹¤ìŒ, ë‚´ë…„ì—ëŠ” ë³‘ìš©ìš”ë²•ì— ëŒ€í•œ 3ìƒ ì„ìƒì‹œí—˜ì„ ê°œì‹œí•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO And then Aamir, how do you see this playing as portfolio?</td><td>**Albert Bourla:** <budget:token_used>50000</budget_used><br><br>ê·¸ë¦¬ê³  Aamir, ì´ê²ƒì´ í¬íŠ¸í´ë¦¬ì˜¤ë¡œì„œ ì–´ë–»ê²Œ ì „ê°œë  ê²ƒìœ¼ë¡œ ë³´ì‹œë‚˜ìš”?</td></tr>
<tr><td>Aamir Malik: Executive VP & Chief U.S. Commercial Officer Yes, Jason. So I think the quick answer would be, look, I think we're in the very early innings of a large market where there is still significant unmet need, right? There's more convenient dosing that's needed, higher weight loss for certain BMI patients, GI tolerabilities need to improve, maintenance strategies, friction in the patient journey. So our belief is that there's not going to be one single asset that serves all those patients. People are going to have different starting points, goals, preferences on their dosing and route of administration, comorbidities, their willingness to pay. And what you need to win in a market like that is, one, you need a great portfolio of products that can serve all those patient needs. And two, you need really differentiated capabilities. And I think with Chris describing not only our data today, but some of the other things that we have in our portfolio, we have the first piece in place and emerging. And we feel very confident about our commercial capabilities, whether it's our field forces that are the top ranked in the U.S. and already are seeing the majority of GLP-1 prescribers or the digital platforms that we're building like PfizerForAll that have touched over 25 million patients. So when you put that all together, we have a lot of confidence in our ability to win commercially in this market with these assets.</td><td>**Aamir Malik:** ë„¤, Jason. ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” ì•„ì§ ìƒë‹¹í•œ ë¯¸ì¶©ì¡± ìˆ˜ìš”ê°€ ì¡´ì¬í•˜ëŠ” ëŒ€ê·œëª¨ ì‹œì¥ì˜ ì´ˆê¸° ë‹¨ê³„ì— ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë” í¸ë¦¬í•œ íˆ¬ì—¬ ë°©ì‹ì´ í•„ìš”í•˜ê³ , íŠ¹ì • BMI í™˜ìë“¤ì—ê²ŒëŠ” ë” ë†’ì€ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ê°€ í•„ìš”í•˜ë©°, ìœ„ì¥ê´€ ë‚´ì•½ì„±ë„ ê°œì„ ë˜ì–´ì•¼ í•˜ê³ , ìœ ì§€ ì „ëµê³¼ í™˜ì ì—¬ì •ì—ì„œì˜ ë§ˆì°° ìš”ì†Œë“¤ë„ í•´ê²°í•´ì•¼ í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ëª¨ë“  í™˜ìë¥¼ ì¶©ì¡±ì‹œí‚¬ ìˆ˜ ìˆëŠ” ë‹¨ì¼ ì œí’ˆì€ ì—†ì„ ê²ƒì´ë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. í™˜ìë“¤ì€ ê°ê¸° ë‹¤ë¥¸ ì¶œë°œì ê³¼ ëª©í‘œë¥¼ ê°€ì§€ê³  ìˆê³ , íˆ¬ì—¬ ë°©ì‹ê³¼ íˆ¬ì—¬ ê²½ë¡œì— ëŒ€í•œ ì„ í˜¸ë„ê°€ ë‹¤ë¥´ë©°, ë™ë°˜ ì§ˆí™˜ê³¼ ì§€ë¶ˆ ì˜í–¥ë„ ë‹¤ë¦…ë‹ˆë‹¤. ì´ëŸ° ì‹œì¥ì—ì„œ ì„±ê³µí•˜ë ¤ë©´, ì²«ì§¸ë¡œ ì´ ëª¨ë“  í™˜ì ë‹ˆì¦ˆë¥¼ ì¶©ì¡±ì‹œí‚¬ ìˆ˜ ìˆëŠ” í›Œë¥­í•œ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ê°€ í•„ìš”í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ë¡œ, ì •ë§ ì°¨ë³„í™”ëœ ì—­ëŸ‰ì´ í•„ìš”í•©ë‹ˆë‹¤. í¬ë¦¬ìŠ¤ê°€ ì„¤ëª…í•œ í˜„ì¬ ìš°ë¦¬ì˜ ë°ì´í„°ë¿ë§Œ ì•„ë‹ˆë¼ í¬íŠ¸í´ë¦¬ì˜¤ì— ìˆëŠ” ë‹¤ë¥¸ ìš”ì†Œë“¤ì„ ê³ ë ¤í•˜ë©´, ìš°ë¦¬ëŠ” ì²« ë²ˆì§¸ ìš”ì†Œë¥¼ í™•ë³´í–ˆê³  ê³„ì† ë°œì „ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ìƒì—…ì  ì—­ëŸ‰ì— ëŒ€í•´ì„œë„ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ìµœê³  ìˆœìœ„ë¥¼ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©° ì´ë¯¸ ëŒ€ë‹¤ìˆ˜ì˜ GLP-1 ì²˜ë°© ì˜ì‚¬ë“¤ì„ ë§Œë‚˜ê³  ìˆëŠ” ìš°ë¦¬ ì˜ì—… ì¡°ì§ì´ë“ , 2,500ë§Œ ëª… ì´ìƒì˜ í™˜ìë“¤ì—ê²Œ ë„ë‹¬í•œ PfizerForAllê³¼ ê°™ì€ ë””ì§€í„¸ í”Œë«í¼ì´ë“  ë§ì…ë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì„ ì¢…í•©í•´ë³´ë©´, ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ìì‚°ë“¤ì„ ê°€ì§€ê³  ì´ ì‹œì¥ì—ì„œ ìƒì—…ì ìœ¼ë¡œ ì„±ê³µí•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ëŒ€í•´ í° í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you. And Alexandre, any additional?</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Alexandre, ì¶”ê°€ë¡œ í•˜ì‹¤ ë§ì”€ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Alexandre de Germay: Executive VP & Chief International Commercial Officer</td><td>**Alexandre de Germay:** <budget:token_budget>200000</budget:token_budget><br><br>I notice you've only provided a title/position, not actual spoken content from an earnings call Q&A session. <br><br>Could you please provide the actual management response or answer that needs to be translated? I'm ready to translate the spoken content once you share it.<br><br>For reference, the title you provided would be:<br>**ë¶€ì‚¬ì¥ ê²¸ ìµœê³  êµ­ì œìƒì—…ì±…ì„ì (Executive VP & Chief International Commercial Officer)**<br><br>But I need the actual dialogue/response content to provide a proper translation.</td></tr>
<tr><td>Operator: Our next question comes from Michael Yee with UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Michael Yeeë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Yee: Two questions, one for Chris and one for Dave. On the oral GLP-1 that you guys recently in-licensed, can you just remind us how much information you knew or what data you already had? I believe there's already a large Phase I ongoing. So that should add some comfort there, but tell us about what you knew already on that molecule. And then for Dave, you reiterated $7 billion of capacity. Can you just talk about the ability to do more in the context of the recent dividend pause -- or at least dividend growth pause recently given that, that does not happen very often and how you think about your dividend?</td><td>**Michael Yee:** ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í•˜ë‚˜ëŠ” Chrisê»˜, ë‹¤ë¥¸ í•˜ë‚˜ëŠ” Daveê»˜ ë“œë¦½ë‹ˆë‹¤. ìµœê·¼ ë„ì…í•˜ì‹  ê²½êµ¬ìš© GLP-1 ê´€ë ¨í•´ì„œ, ë„ì… ì „ì— ì–¼ë§ˆë‚˜ ë§ì€ ì •ë³´ë¥¼ ì•Œê³  ê³„ì…¨ëŠ”ì§€, ì–´ë–¤ ë°ì´í„°ë¥¼ ì´ë¯¸ í™•ë³´í•˜ê³  ê³„ì…¨ëŠ”ì§€ ìƒê¸°ì‹œì¼œ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì œ ìƒê°ì—ëŠ” ì´ë¯¸ ëŒ€ê·œëª¨ 1ìƒ ì„ìƒì´ ì§„í–‰ ì¤‘ì¸ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, ì´ê²ƒì´ ì–´ëŠ ì •ë„ í™•ì‹ ì„ ì¤„ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤ë§Œ, í•´ë‹¹ ë¬¼ì§ˆì— ëŒ€í•´ ì´ë¯¸ ì•Œê³  ê³„ì…¨ë˜ ë‚´ìš©ì„ ë§ì”€í•´ ì£¼ì‹­ì‹œì˜¤. ê·¸ë¦¬ê³  Daveê»˜ëŠ”, 70ì–µ ë‹¬ëŸ¬ì˜ ì—¬ë ¥ì„ ì¬í™•ì¸í•´ ì£¼ì…¨ëŠ”ë°, ìµœê·¼ ë°°ë‹¹ ë™ê²° - ì ì–´ë„ ë°°ë‹¹ ì„±ì¥ ë™ê²° - ìƒí™©ì—ì„œ ì¶”ê°€ì ì¸ í™œë™ ëŠ¥ë ¥ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ì´ëŸ° ì¼ì€ ìì£¼ ì¼ì–´ë‚˜ì§€ ì•ŠëŠ”ë°, ë°°ë‹¹ ì •ì±…ì„ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Let me start with Dave for a change this time and then we go to Chris.</td><td>**Albert Bourla:** ì´ë²ˆì—ëŠ” Daveë¶€í„° ì‹œì‘í•˜ê³  ê·¸ ë‹¤ìŒ Chrisì—ê²Œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Denton: Executive VP & CFO Yes. So clearly, our focus is maintaining our dividend at the moment and growing our dividend over time. So it's a very important and critical structure and component of our capital allocation program. And again, we do have -- coming into this year, we had $6 billion in BD capacity. It's actually gone up a bit as we've announced the pending liquidation of the ViiV asset. So that actually is a good example of how we're looking at the set of assets that we have within Pfizer and understanding how we can best monetize them over time. So with that, I'll turn it over to Chris.</td><td>**David Denton:** ë„¤, ë¶„ëª…íˆ ì €í¬ì˜ ì´ˆì ì€ í˜„ì¬ ë°°ë‹¹ì„ ìœ ì§€í•˜ê³  ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ë°°ë‹¹ì„ ëŠ˜ë ¤ê°€ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ìë³¸ ë°°ë¶„ í”„ë¡œê·¸ë¨ì—ì„œ ë§¤ìš° ì¤‘ìš”í•˜ê³  í•µì‹¬ì ì¸ ìš”ì†Œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¬í•´ ì´ˆ ì €í¬ëŠ” 60ì–µ ë‹¬ëŸ¬ì˜ ì‚¬ì—…ê°œë°œ(BD) ì—¬ë ¥ì„ ë³´ìœ í•˜ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ViiV ìì‚°ì˜ ì²­ì‚° ê³„íšì„ ë°œí‘œí•˜ë©´ì„œ ê·¸ ì—¬ë ¥ì´ ì¡°ê¸ˆ ë” ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” í™”ì´ìê°€ ë³´ìœ í•œ ìì‚° í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê²€í† í•˜ê³  ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì–´ë–»ê²Œ ìµœì„ ì˜ ë°©ì‹ìœ¼ë¡œ í˜„ê¸ˆí™”í•  ìˆ˜ ìˆëŠ”ì§€ íŒŒì•…í•˜ê³  ìˆëŠ” ì¢‹ì€ ì‚¬ë¡€ì…ë‹ˆë‹¤. ê·¸ëŸ¼ í¬ë¦¬ìŠ¤ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Thank you very much. 5002 is the YaoPharma oral small molecule, which is not on a [ Lupron Scaffold. ] It's currently in Phase I, and we've acquired it through an exclusive global collaboration and license agreement with YaoPharma. And we plan to conduct Phase I studies and also combination studies with our GIPR antagonist that's currently in the randomized experience in Phase II. And we're currently transitioning all the work to the U.S. to start Phase I studies in the U.S., including manufacturing in the...</td><td>**Chris Boshoff:** 5002ëŠ” ì•¼ì˜¤íŒŒë§ˆ(YaoPharma)ì˜ ê²½êµ¬ìš© ì €ë¶„ì í™”í•©ë¬¼ë¡œ, ë£¨í”„ë¡  ìŠ¤ìºí´ë“œ(Lupron Scaffold) ê¸°ë°˜ì´ ì•„ë‹™ë‹ˆë‹¤. í˜„ì¬ 1ìƒ ë‹¨ê³„ì— ìˆìœ¼ë©°, ì•¼ì˜¤íŒŒë§ˆì™€ì˜ ë…ì ì  ê¸€ë¡œë²Œ í˜‘ë ¥ ë° ë¼ì´ì„ ìŠ¤ ê³„ì•½ì„ í†µí•´ í™•ë³´í–ˆìŠµë‹ˆë‹¤. 1ìƒ ì„ìƒì‹œí—˜ì„ ì§„í–‰í•  ê³„íšì´ë©°, í˜„ì¬ 2ìƒ ë¬´ì‘ìœ„ ì‹œí—˜ ì¤‘ì¸ GIPR ê¸¸í•­ì œì™€ì˜ ë³‘ìš© ì—°êµ¬ë„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ë¯¸êµ­ì—ì„œ 1ìƒ ì„ìƒì‹œí—˜ì„ ì‹œì‘í•˜ê¸° ìœ„í•´ ì œì¡°ë¥¼ í¬í•¨í•œ ëª¨ë“  ì‘ì—…ì„ ë¯¸êµ­ìœ¼ë¡œ ì´ê´€í•˜ëŠ” ì¤‘ì…ë‹ˆë‹¤...</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: We'll go next to Alex Hammond with Wolfe Research.</td><td>**Operator:** ë‹¤ìŒì€ ìš¸í”„ ë¦¬ì„œì¹˜ì˜ ì•Œë ‰ìŠ¤ í•´ë¨¼ë“œ ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wolfe Research, LLC: So one of the key readouts guided for '26 is that Lyme disease vaccine VALOR study. I have a few on this. When could we expect an update and what are expectations for the launch if positive? What does vaccine contracting look like and what channels will be the key target for you? And I guess, finally, how big could this opportunity really be?</td><td>**Wolfe Research, LLC:** 2026ë…„ì— ê°€ì´ë“œëœ ì£¼ìš” ë°ì´í„° ì¤‘ í•˜ë‚˜ê°€ ë¼ì„ë³‘ ë°±ì‹  VALOR ì—°êµ¬ì…ë‹ˆë‹¤. ì´ì™€ ê´€ë ¨í•´ì„œ ëª‡ ê°€ì§€ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì–¸ì œì¯¤ ì—…ë°ì´íŠ¸ë¥¼ ê¸°ëŒ€í•  ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ê¸ì •ì ì¸ ê²°ê³¼ê°€ ë‚˜ì˜¬ ê²½ìš° ì¶œì‹œì— ëŒ€í•œ ê¸°ëŒ€ì¹˜ëŠ” ì–´ë–»ê²Œ ë˜ë‚˜ìš”? ë°±ì‹  ê³„ì•½ì€ ì–´ë–¤ ë°©ì‹ìœ¼ë¡œ ì´ë£¨ì–´ì§€ë©°, ì£¼ìš” íƒ€ê²Ÿ ì±„ë„ì€ ì–´ë””ê°€ ë ê¹Œìš”? ë§ˆì§€ë§‰ìœ¼ë¡œ, ì´ ê¸°íšŒê°€ ì‹¤ì œë¡œ ì–¼ë§ˆë‚˜ í´ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO</td><td>**Albert Bourla:** <answer>I notice that you've only provided a title/role ("Chairman of the Board & CEO") without any actual spoken content to translate.<br><br>Could you please provide the full management response or spoken content that you'd like me to translate? Once you share the complete text, I'll translate it into natural, fluent Korean following all the guidelines you've specified.<br><br>For example, if you have a response like:<br>"Thank you for the question. Our Q3 results exceeded expectations due to strong performance in our core business segments..."<br><br>Please share the complete content, and I'll provide an accurate Korean translation.</answer></td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Yes. Thank you. I'll start. So thank you very much. This could be a first-in-class vaccine for Lyme disease, the Phase III VALOR trial. It's a multivalent protein subunit vaccine targeting all 6 outer surface proteins of Borrelia burgdorferi. The study we expect to read-out first half of this year. Just a reminder, approximately 400,000 people in the U.S. and 132,000 people in Europe are affected by Lyme disease. And as you know, significant long-term morbidity and long-term sequelae. So a vaccine specifically in certain regions of the world could be very, very important.</td><td>**Chris Boshoff:** ê°ì‚¬í•©ë‹ˆë‹¤. ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¼ì„ë³‘ ë°±ì‹  3ìƒ VALOR ì„ìƒì‹œí—˜ì€ ë™ê¸‰ ìµœì´ˆ(first-in-class) ë°±ì‹ ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ë°±ì‹ ì€ ë³´ë ë¦¬ì•„ ë¶€ë¥´ê·¸ë„ë¥´í˜ë¦¬ê· ì˜ 6ê°€ì§€ ì™¸ë§‰ í‘œë©´ ë‹¨ë°±ì§ˆì„ ëª¨ë‘ í‘œì ìœ¼ë¡œ í•˜ëŠ” ë‹¤ê°€ ë‹¨ë°±ì§ˆ ì„œë¸Œìœ ë‹› ë°±ì‹ ì…ë‹ˆë‹¤. ì„ìƒì‹œí—˜ ê²°ê³¼ëŠ” ì˜¬í•´ ìƒë°˜ê¸°ì— ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì°¸ê³ ë¡œ ë§ì”€ë“œë¦¬ë©´, ë¯¸êµ­ì—ì„œëŠ” ì•½ 40ë§Œ ëª…, ìœ ëŸ½ì—ì„œëŠ” ì•½ 13ë§Œ 2ì²œ ëª…ì´ ë¼ì„ë³‘ì˜ ì˜í–¥ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ë¼ì„ë³‘ì€ ì‹¬ê°í•œ ì¥ê¸° ì´í™˜ìœ¨ê³¼ ì¥ê¸° í›„ìœ ì¦ì„ ë™ë°˜í•©ë‹ˆë‹¤. ë”°ë¼ì„œ íŠ¹ì • ì§€ì—­ì—ì„œëŠ” ì´ ë°±ì‹ ì´ ë§¤ìš° ì¤‘ìš”í•œ ì˜ë¯¸ë¥¼ ê°€ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Chris. We are eagerly awaiting to see the data of that. That could be a huge solution for an unmet medical need.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤, Chris. ì €í¬ë„ ê·¸ ë°ì´í„°ë¥¼ ê°„ì ˆíˆ ê¸°ë‹¤ë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¶©ì¡±ë˜ì§€ ì•Šì€ ì˜ë£Œ ìˆ˜ìš”(unmet medical need)ì— ëŒ€í•œ íšê¸°ì ì¸ ì†”ë£¨ì…˜ì´ ë  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: We'll go next to Mohit Bansal with Wells Fargo.</td><td>**Operator:** ë‹¤ìŒì€ Wells Fargoì˜ Mohit Bansal ì• ë„ë¦¬ìŠ¤íŠ¸ ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Mohit Bansal: Wells Fargo Securities, LLC, Research Division And one more on the VESPER program here. Would like to understand what kind of target profile you are looking at from the Phase III trial? I'm asking because with the GLP-1, you kind of see mid- to high teens kind of weight loss with an optimized GLP-1. And if you try to push it beyond that, you could probably start to run into tolerability issues. What makes you think that this longer-acting GLP-1 could provide higher weight loss than that with better tolerability? Or you think that monthly is probably the biggest differentiator here?</td><td>**Mohit Bansal:** VESPER í”„ë¡œê·¸ë¨ì— ëŒ€í•´ í•œ ê°€ì§€ ë” ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 3ìƒ ì„ìƒì‹œí—˜ì—ì„œ ì–´ë–¤ ëª©í‘œ í”„ë¡œíŒŒì¼ì„ ë³´ê³  ê³„ì‹ ì§€ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì™œëƒí•˜ë©´ GLP-1ì˜ ê²½ìš°, ìµœì í™”ëœ GLP-1ë¡œ 10%ëŒ€ ì¤‘í›„ë°˜ ì •ë„ì˜ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ë¥¼ ë³´ê²Œ ë˜ëŠ”ë°ìš”. ê·¸ ì´ìƒìœ¼ë¡œ ë°€ì–´ë¶™ì´ë ¤ê³  í•˜ë©´ ì•„ë§ˆë„ ë‚´ì•½ì„± ë¬¸ì œê°€ ë°œìƒí•˜ê¸° ì‹œì‘í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ì¥ê¸° ì§€ì†í˜• GLP-1ì´ ë” ë‚˜ì€ ë‚´ì•½ì„±ìœ¼ë¡œ ê·¸ë³´ë‹¤ ë” ë†’ì€ ì²´ì¤‘ ê°ëŸ‰ì„ ì œê³µí•  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•˜ì‹œëŠ” ì´ìœ ê°€ ë¬´ì—‡ì¸ê°€ìš”? ì•„ë‹ˆë©´ ì›” 1íšŒ íˆ¬ì—¬ê°€ ì•„ë§ˆë„ ê°€ì¥ í° ì°¨ë³„í™” ìš”ì†Œë¼ê³  ë³´ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO</td><td>**Albert Bourla:** <answer>I notice you've provided the role "Chairman of the Board & CEO" but haven't included the actual content that needs to be translated. <br><br>Could you please provide the management response or spoken content from the earnings call Q&A session that you'd like me to translate into Korean? Once you share the actual dialogue or response, I'll translate it following all the rules you've specified.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Thank you very much. So it's both. We expect competitive weight loss and the data we showed today, including with the predictions, what to expect from the 9.6 milligrams at 16 milligrams (sic) [ 16% ] weight loss, we are -- predicted at week 28. It's highly competitive, tolerable to be highly competitive. And then, of course, monthly dosing, which will be highly differentiated. Just to point out, we are also planning a Phase III study which will evaluate switching. So patients already on weekly therapy doing well, to switch those patients to monthly dosing.</td><td>**Chris Boshoff:** ê°ì‚¬í•©ë‹ˆë‹¤. ë‘ ê°€ì§€ ëª¨ë‘ì…ë‹ˆë‹¤. ê²½ìŸë ¥ ìˆëŠ” ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì˜¤ëŠ˜ ì œì‹œí•œ ë°ì´í„°ë¥¼ ë³´ì‹œë©´ 9.6ë°€ë¦¬ê·¸ë¨ íˆ¬ì—¬ ì‹œ 28ì£¼ì°¨ì— 16% ì²´ì¤‘ ê°ëŸ‰ì´ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ê²½ìŸë ¥ ìˆê³  ë‚´ì•½ì„±ë„ ìš°ìˆ˜í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  ì›” 1íšŒ íˆ¬ì—¬ë¼ëŠ” ì ì—ì„œ ë†’ì€ ì°¨ë³„ì„±ì„ ê°€ì§€ê²Œ ë©ë‹ˆë‹¤. í•œ ê°€ì§€ ë” ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ ì£¼ 1íšŒ ì¹˜ë£Œì œë¥¼ ë³µìš© ì¤‘ì´ê³  íš¨ê³¼ê°€ ì¢‹ì€ í™˜ìë“¤ì„ ì›” 1íšŒ íˆ¬ì—¬ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì„ í‰ê°€í•˜ëŠ” 3ìƒ ì„ìƒì‹œí—˜ë„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Chris. And this is not only ours, of course, weekly to monthly, but also any other GLP-1s that are in the market and they want to move after they achieve a weight loss into a maintenance with only one injection rather than with four. Of course, there is also the oral solutions, but that's going for one weekly to one daily pill. Some will do it, but I think our research shows that most would like -- if they are already used needle, and they would like to switch mostly to a more convenient needle, which is once a month.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤, Chris. ê·¸ë¦¬ê³  ì´ê²ƒì€ ë¬¼ë¡  ìš°ë¦¬ ì œí’ˆë¿ë§Œ ì•„ë‹ˆë¼ ì‹œì¥ì— ë‚˜ì™€ ìˆëŠ” ë‹¤ë¥¸ GLP-1 ì œí’ˆë“¤ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì²´ì¤‘ ê°ëŸ‰ì„ ë‹¬ì„±í•œ í›„ 4íšŒ ì£¼ì‚¬ê°€ ì•„ë‹Œ 1íšŒ ì£¼ì‚¬ë§Œìœ¼ë¡œ ìœ ì§€ ìš”ë²•ìœ¼ë¡œ ì „í™˜í•˜ê³ ì í•˜ëŠ” ê²½ìš° ë§ì…ë‹ˆë‹¤. ë¬¼ë¡  ê²½êµ¬ìš© ì†”ë£¨ì…˜ë„ ìˆì§€ë§Œ, ê·¸ê±´ ì£¼ 1íšŒì—ì„œ 1ì¼ 1íšŒ ë³µìš©ìœ¼ë¡œ ê°€ëŠ” ê²ƒì…ë‹ˆë‹¤. ì¼ë¶€ëŠ” ê·¸ë ‡ê²Œ í•  ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ ì—°êµ¬ ê²°ê³¼ë¥¼ ë³´ë©´ ëŒ€ë¶€ë¶„ì˜ í™˜ìë“¤ì€ ì´ë¯¸ ì£¼ì‚¬ì— ìµìˆ™í•´ì§„ ê²½ìš°, ì›” 1íšŒë¼ëŠ” ë” í¸ë¦¬í•œ ì£¼ì‚¬ ë°©ì‹ìœ¼ë¡œ ì „í™˜í•˜ê¸°ë¥¼ ì›í•˜ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: We'll go next to Evan Seigerman with BMO Capital Markets.</td><td>**Operator:** ë‹¤ìŒì€ BMO ìºí”¼íƒˆ ë§ˆì¼“ì˜ ì—ë°˜ ì„¸ì´ê±°ë¨¼ ë‹˜ ì§ˆë¬¸ ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Evan Seigerman: BMO Capital Markets Equity Research I just wanted to touch on your comments around investment in AI. How -- what are the metrics you're putting around that? And more broadly, I just want to ensure that this is going to drive a good return on your adjustment versus just kind of feeding into the hype?</td><td>**Evan Seigerman:** AI íˆ¬ìì— ëŒ€í•œ ë§ì”€ê³¼ ê´€ë ¨í•´ì„œ ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì–´ë–¤ ì§€í‘œë“¤ì„ ì„¤ì •í•˜ê³  ê³„ì‹ ê°€ìš”? ê·¸ë¦¬ê³  ë” ë„“ê²ŒëŠ”, ë‹¨ìˆœíˆ ê³¼ëŒ€ê´‘ê³ ì— í¸ìŠ¹í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ íˆ¬ì ëŒ€ë¹„ ì‹¤ì§ˆì ì¸ ìˆ˜ìµì„ ì°½ì¶œí•  ìˆ˜ ìˆì„ì§€ í™•ì¸í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO It's a very good question, and let me start, but then I will ask -- specific marketing achievements and R&D achievements through AI. In general, there are things in AI, but the technology is ready now. And those are deploying very, very fast. And certainly, I cannot do everything, but certainly can do more than what it is used right now to do. And that has to do with how successful you are in implementing it, embedding it into your organizational footprint, embedding it into your business processes and also creating AI literacy among the employees that eventually are using this AI. With that clearly affects everything from enabling functions, and maybe Dave can speak a little bit about the things that we are doing there. I mean, when I say enabling functions from finance, HR, legal, you name it. And of course, in R&D, where we have seen already significant productivity enhancements. In marketing that it is helping us to maximize the ROI right now. And in manufacturing were a very big part of the savings that were achieved of a successful deployment of AI use case that is called the [ Golden Pass ]. Chris, do you want to give some specific examples?</td><td>**Albert Bourla:** ë§¤ìš° ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦¬ê³ , AIë¥¼ í†µí•œ êµ¬ì²´ì ì¸ ë§ˆì¼€íŒ… ì„±ê³¼ì™€ R&D ì„±ê³¼ì— ëŒ€í•´ì„œëŠ” ì¶”ê°€ë¡œ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¼ë°˜ì ìœ¼ë¡œ AI ê¸°ìˆ ì€ ì´ë¯¸ ì¤€ë¹„ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§¤ìš° ë¹ ë¥´ê²Œ ë°°í¬ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ëª¨ë“  ê²ƒì„ ë‹¤ í•  ìˆ˜ëŠ” ì—†ì§€ë§Œ, í˜„ì¬ í™œìš©ë˜ê³  ìˆëŠ” ê²ƒë³´ë‹¤ í›¨ì”¬ ë” ë§ì€ ì¼ì„ í•  ìˆ˜ ìˆëŠ” ê²ƒì€ ë¶„ëª…í•©ë‹ˆë‹¤. ì´ëŠ” AIë¥¼ ì–¼ë§ˆë‚˜ ì„±ê³µì ìœ¼ë¡œ êµ¬í˜„í•˜ëŠëƒ, ì¡°ì§ êµ¬ì¡°ì— ì–¼ë§ˆë‚˜ ì˜ ë‚´ì¬í™”í•˜ëŠëƒ, ë¹„ì¦ˆë‹ˆìŠ¤ í”„ë¡œì„¸ìŠ¤ì— ì–¼ë§ˆë‚˜ ì˜ í†µí•©í•˜ëŠëƒ, ê·¸ë¦¬ê³  ê¶ê·¹ì ìœ¼ë¡œ AIë¥¼ ì‚¬ìš©í•˜ê²Œ ë  ì§ì›ë“¤ ì‚¬ì´ì—ì„œ AI ë¦¬í„°ëŸ¬ì‹œë¥¼ ì–¼ë§ˆë‚˜ ì˜ êµ¬ì¶•í•˜ëŠëƒì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì§€ì› ê¸°ëŠ¥ë¶€í„° ëª¨ë“  ê²ƒì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ”ë°, Daveê°€ ìš°ë¦¬ê°€ ì§„í–‰í•˜ê³  ìˆëŠ” ì‚¬í•­ë“¤ì— ëŒ€í•´ ì¡°ê¸ˆ ë” ë§ì”€ë“œë¦´ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì œ ë§ì€ ì¬ë¬´, HR, ë²•ë¬´ ë“± ì§€ì› ê¸°ëŠ¥ë“¤ì„ ë§ì”€ë“œë¦¬ëŠ” ê²ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  R&Dì—ì„œë„ ì´ë¯¸ ìƒë‹¹í•œ ìƒì‚°ì„± í–¥ìƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë§ˆì¼€íŒ…ì—ì„œëŠ” í˜„ì¬ ROIë¥¼ ê·¹ëŒ€í™”í•˜ëŠ” ë° ë„ì›€ì„ ì£¼ê³  ìˆê³ ìš”. ì œì¡° ë¶€ë¬¸ì—ì„œëŠ” 'Golden Pass'ë¼ê³  ë¶ˆë¦¬ëŠ” AI ìœ ìŠ¤ì¼€ì´ìŠ¤ì˜ ì„±ê³µì ì¸ ë„ì…ìœ¼ë¡œ ë‹¬ì„±í•œ ë¹„ìš© ì ˆê°ì˜ ìƒë‹¹ ë¶€ë¶„ì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. Chris, êµ¬ì²´ì ì¸ ì‚¬ë¡€ ëª‡ ê°€ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Yes. Thank you very much for the question. So as you pointed out, in R&D, we're embedding AI in each function, meaning in discovery, medical, regulatory, safety, pharmacovigilance, clinical trial execution, and we're recruiting and embedding AI engineers in each of those functions to work with the scientists and the clinicians, how to measure success, productivity. Productivity is speed and cost. We bring costs down by embedding AI and obviously, accelerating speed.</td><td>**Chris Boshoff:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ R&D ë¶€ë¬¸ì—ì„œëŠ” ê° ê¸°ëŠ¥ë³„ë¡œ AIë¥¼ ë‚´ì¬í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹ ì•½ ë°œê²¬, ë©”ë””ì»¬, ê·œì œ, ì•ˆì „ì„±, ì•½ë¬¼ê°ì‹œ(pharmacovigilance), ì„ìƒì‹œí—˜ ì‹¤í–‰ ë“± ëª¨ë“  ì˜ì—­ì— AIë¥¼ ì ìš©í•˜ê³  ìˆìœ¼ë©°, ê° ê¸°ëŠ¥ ë¶€ì„œë§ˆë‹¤ AI ì—”ì§€ë‹ˆì–´ë¥¼ ì±„ìš©í•˜ì—¬ ê³¼í•™ì ë° ì„ìƒì˜ë“¤ê³¼ í˜‘ì—…í•˜ë„ë¡ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì„±ê³µ ì¸¡ì • ê¸°ì¤€ì€ ìƒì‚°ì„±ì…ë‹ˆë‹¤. ìƒì‚°ì„±ì€ ì†ë„ì™€ ë¹„ìš©ìœ¼ë¡œ ì¸¡ì •ë©ë‹ˆë‹¤. AIë¥¼ ë‚´ì¬í™”í•¨ìœ¼ë¡œì¨ ë¹„ìš©ì„ ì ˆê°í•˜ê³ , ë‹¹ì—°íˆ ì†ë„ë„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO What about in commercial?</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ìƒì—…ìš© ë¶€ë¬¸ì€ ì–´ë–¤ê°€ìš”?</td></tr>
<tr><td>Aamir Malik: Executive VP & Chief U.S. Commercial Officer Yes. Evan, I think metrics are at the heart of everything that we're doing with AI. I'll give you two very specific examples. One is our field force productivity. We're using AI to not only help train our field forces, but also help make their time with physicians maximize. So we invest more time with physicians rather than behind screens. Second is on the marketing side, we measure MROI. And you've seen us be very disciplined, as Dave alluded to, in our SI&A spend, particularly as we're trying to grow revenue for a lot of our launch and acquired brands, and AI has absolutely helped us increase our MROIs by being much, much more targeted about where we invest.</td><td>**Aamir Malik:** ë„¤, Evan. ì§€í‘œëŠ” ìš°ë¦¬ê°€ AIë¡œ í•˜ê³  ìˆëŠ” ëª¨ë“  ì¼ì˜ í•µì‹¬ì…ë‹ˆë‹¤. ë‘ ê°€ì§€ êµ¬ì²´ì ì¸ ì˜ˆë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ì˜ì—… ì¸ë ¥ ìƒì‚°ì„±ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” AIë¥¼ í™œìš©í•´ì„œ ì˜ì—… ì¸ë ¥ì„ êµìœ¡í•  ë¿ë§Œ ì•„ë‹ˆë¼, ì˜ì‚¬ë“¤ê³¼ì˜ ë©´ë‹´ ì‹œê°„ì„ ê·¹ëŒ€í™”í•˜ë„ë¡ ë•ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í™”ë©´ ì•ì— ì•‰ì•„ìˆëŠ” ì‹œê°„ë³´ë‹¤ ì˜ì‚¬ë“¤ê³¼ í•¨ê»˜í•˜ëŠ” ì‹œê°„ì— ë” ë§ì´ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ë§ˆì¼€íŒ… ì¸¡ë©´ì¸ë°, ìš°ë¦¬ëŠ” MROI(ë§ˆì¼€íŒ… íˆ¬ììˆ˜ìµë¥ )ë¥¼ ì¸¡ì •í•©ë‹ˆë‹¤. Daveê°€ ì–¸ê¸‰í–ˆë“¯ì´, íŠ¹íˆ ë§ì€ ì‹ ì œí’ˆê³¼ ì¸ìˆ˜ ë¸Œëœë“œì˜ ë§¤ì¶œì„ ì„±ì¥ì‹œí‚¤ë ¤ëŠ” ê³¼ì •ì—ì„œ ìš°ë¦¬ê°€ SI&A(íŒë§¤ ë° ê´€ë¦¬ë¹„) ì§€ì¶œì— ë§¤ìš° ê·œìœ¨ ìˆê²Œ ì ‘ê·¼í•˜ëŠ” ê²ƒì„ ë³´ì…¨ì„ ê²ë‹ˆë‹¤. AIëŠ” íˆ¬ìì²˜ë¥¼ í›¨ì”¬ ë” íƒ€ê²ŸíŒ…í•¨ìœ¼ë¡œì¨ MROIë¥¼ ë†’ì´ëŠ” ë° í™•ì‹¤íˆ ë„ì›€ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you. Alexandre, you did fantastic things also in international with AI.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤. Alexandre, ë‹¹ì‹ ë„ AI ë¶„ì•¼ì—ì„œ êµ­ì œì ìœ¼ë¡œ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ëƒˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Alexandre de Germay: Executive VP & Chief International Commercial Officer Yes, that's right. I mean every step of the way when we interact with our customer is subject to an improvement with AI. Let me give you an example, pre-call planning for our rep is actually done better when it is done with AI. The quality of the interaction is listened, so that we can rerun those interactions, so that we can improve the quality of the interaction. We can also do targeting in a better way so that we have advanced targeting, thanks to AI. And finally, imagine that operating globally with very different regulatory requirements require every country to redo and reassess every promotional pieces. With AI, we can do that instantly in all those markets. We don't need to rerun all those activities at every country. So that has massive impact on productivity and speed to market.</td><td>**Alexandre de Germay:** ë„¤, ë§ìŠµë‹ˆë‹¤. ê³ ê°ê³¼ì˜ ëª¨ë“  ì ‘ì ì—ì„œ AIë¥¼ í†µí•´ ê°œì„ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ ì˜ˆë¥¼ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤. ì˜ì—… ë‹´ë‹¹ìì˜ ì‚¬ì „ ë°©ë¬¸ ê³„íš(pre-call planning)ì€ AIë¥¼ í™œìš©í•  ë•Œ í›¨ì”¬ ë” íš¨ê³¼ì ìœ¼ë¡œ ìˆ˜ë¦½ë©ë‹ˆë‹¤. ê³ ê°ê³¼ì˜ ìƒë‹´ ë‚´ìš©ì„ ë¶„ì„í•´ì„œ ë‹¤ì‹œ ê²€í† í•  ìˆ˜ ìˆê¸° ë•Œë¬¸ì— ìƒë‹´ì˜ ì§ˆì„ ì§€ì†ì ìœ¼ë¡œ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ AI ë•ë¶„ì— ê³ ê¸‰ íƒ€ê²ŸíŒ… ê¸°ë²•ì„ í™œìš©í•´ ë” ì •êµí•œ ê³ ê° íƒ€ê²ŸíŒ…ì´ ê°€ëŠ¥í•©ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì „ ì„¸ê³„ì ìœ¼ë¡œ ì‚¬ì—…ì„ ìš´ì˜í•˜ë‹¤ ë³´ë©´ ê°êµ­ì˜ ê·œì œ ìš”ê±´ì´ ëª¨ë‘ ë‹¤ë¥´ê¸° ë•Œë¬¸ì— ëª¨ë“  í”„ë¡œëª¨ì…˜ ìë£Œë¥¼ êµ­ê°€ë³„ë¡œ ì¬ê²€í† í•˜ê³  ì¬í‰ê°€í•´ì•¼ í•©ë‹ˆë‹¤. AIë¥¼ í™œìš©í•˜ë©´ ì´ëŸ¬í•œ ì‘ì—…ì„ ëª¨ë“  ì‹œì¥ì—ì„œ ì¦‰ì‹œ ì²˜ë¦¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë” ì´ìƒ ê° êµ­ê°€ì—ì„œ ì´ëŸ° ì‘ì—…ë“¤ì„ ë°˜ë³µí•  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ì´ëŠ” ìƒì‚°ì„±ê³¼ ì‹œì¥ ì¶œì‹œ ì†ë„ì— ì—„ì²­ë‚œ ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO</td><td>**Albert Bourla:** <answer>I notice that you've only provided a title/role ("Chairman of the Board & CEO") without any actual spoken content to translate.<br><br>Could you please provide the full management response or Q&A content that you'd like me to translate? Once you share the complete text, I'll translate it into natural, fluent Korean following all the guidelines you've specified.<br><br>For example, if you have content like:<br>- Management's response to analyst questions<br>- CEO's remarks during the earnings call<br>- CFO's explanation of financial results<br><br>Please share that content and I'll provide an accurate Korean translation.</answer></td></tr>
<tr><td>David Denton: Executive VP & CFO Yes. Maybe just two points. From an enabling functions perspective, I think about AI in us leveraging our vendors because we have big vendor technology platforms across our enterprise. And as they make investments in their platform, we're taking advantage of those and embedding those within our process, which is increasing our productivity. And then secondly, think about our business model, we have routine transactions, but we have a large number of products that are across literally hundreds of markets. So AI is allowing us to use those datasets to essentially automate some of those transactions to make it very efficient that -- today, we deploy resources to be able to do that. So now the technology is enabling us to be a lot more productive.</td><td>**David Denton:** ë‘ ê°€ì§€ ì¸¡ë©´ì—ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§€ì› ê¸°ëŠ¥ ê´€ì ì—ì„œ ë³´ë©´, ì €í¬ëŠ” ì „ì‚¬ì ìœ¼ë¡œ ëŒ€ê·œëª¨ ë²¤ë” ê¸°ìˆ  í”Œë«í¼ì„ í™œìš©í•˜ê³  ìˆëŠ”ë°, AIì™€ ê´€ë ¨í•´ì„œëŠ” ì´ëŸ¬í•œ ë²¤ë”ë“¤ì„ ì ê·¹ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë²¤ë”ë“¤ì´ ìì‚¬ í”Œë«í¼ì— íˆ¬ìë¥¼ ì§„í–‰í•˜ë©´, ì €í¬ëŠ” ê·¸ê²ƒì„ ìš°ë¦¬ í”„ë¡œì„¸ìŠ¤ì— ë‚´ì¬í™”í•˜ì—¬ ìƒì‚°ì„±ì„ ë†’ì´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ë¡œ, ì €í¬ ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ì„ ë³´ë©´ ì¼ìƒì ì¸ ê±°ë˜ë“¤ì´ ìˆì§€ë§Œ, ë§ ê·¸ëŒ€ë¡œ ìˆ˜ë°± ê°œ ì‹œì¥ì— ê±¸ì³ ë°©ëŒ€í•œ ìˆ˜ì˜ ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. AIë¥¼ í†µí•´ ì´ëŸ¬í•œ ë°ì´í„°ì…‹ì„ í™œìš©í•˜ì—¬ ê±°ë˜ì˜ ìƒë‹¹ ë¶€ë¶„ì„ ìë™í™”í•˜ê³  íš¨ìœ¨ì„±ì„ í¬ê²Œ ë†’ì¼ ìˆ˜ ìˆê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ê³¼ê±°ì—ëŠ” ì´ëŸ° ì—…ë¬´ë¥¼ ì²˜ë¦¬í•˜ê¸° ìœ„í•´ ì¸ë ¥ì„ íˆ¬ì…í•´ì•¼ í–ˆì§€ë§Œ, ì´ì œëŠ” ê¸°ìˆ ì´ ìƒì‚°ì„±ì„ ëŒ€í­ í–¥ìƒì‹œì¼œì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Yes. So in closing, Evan, that's why we put it as one of the four imperative strategic priorities we plan to do, which is to scale up because we have so big success. Many people are asking us, how is possible that Pfizer was able to take so much cost out of its operations without affecting the top line. And the answer is AI. We didn't just cut cost, what we did is we improved productivity. And the main lever -- of course, there was simplification efforts that also took place. But the main lever was the successful deployment of AI, where basically we are reducing the cost without that being seen in the activity. So very excited about the prospects of AI.</td><td>**Albert Bourla:** ë„¤, ë§ˆë¬´ë¦¬í•˜ìë©´ ì—ë°˜, ê·¸ë˜ì„œ ìš°ë¦¬ê°€ ì´ê²ƒì„ ì‹¤í–‰í•˜ê³ ì í•˜ëŠ” 4ëŒ€ í•µì‹¬ ì „ëµ ê³¼ì œ ì¤‘ í•˜ë‚˜ë¡œ ì„¤ì •í•œ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ê°€ í° ì„±ê³µì„ ê±°ë‘ì—ˆê¸° ë•Œë¬¸ì— í™•ëŒ€í•˜ë ¤ëŠ” ê²ƒì´ì£ . ë§ì€ ë¶„ë“¤ì´ ìš°ë¦¬ì—ê²Œ ë¬»ìŠµë‹ˆë‹¤. ì–´ë–»ê²Œ í™”ì´ìê°€ ë§¤ì¶œì— ì˜í–¥ì„ ì£¼ì§€ ì•Šìœ¼ë©´ì„œ ìš´ì˜ë¹„ë¥¼ ê·¸ë ‡ê²Œ ë§ì´ ì ˆê°í•  ìˆ˜ ìˆì—ˆëŠëƒê³ ìš”. ê·¸ ë‹µì€ ë°”ë¡œ AIì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ ë¹„ìš©ì„ ì‚­ê°í•œ ê²ƒì´ ì•„ë‹ˆë¼ ìƒì‚°ì„±ì„ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹¤. ë¬¼ë¡  ë‹¨ìˆœí™” ë…¸ë ¥ë„ í•¨ê»˜ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹¤ë§Œ, í•µì‹¬ ë™ë ¥ì€ AIì˜ ì„±ê³µì ì¸ ë„ì…ì´ì—ˆìŠµë‹ˆë‹¤. ê¸°ë³¸ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” í™œë™ì—ëŠ” ì˜í–¥ì„ ì£¼ì§€ ì•Šìœ¼ë©´ì„œ ë¹„ìš©ì„ ì ˆê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. AIì˜ ì „ë§ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Dave Risinger with Leerink Partners.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Leerink Partnersì˜ Dave Risingerë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Risinger: Leerink Partners LLC, Research Division Yes. So my question is for Chris. Chris, could you talk a little bit more about MET-233i, which I believe is now numbered '3945. Specifically, the bias of amylin relative to calcitonin, the implications for the efficacy and tolerability profile and the data we should expect at ADA?</td><td>**David Risinger:** ë„¤, í¬ë¦¬ìŠ¤ì—ê²Œ ë“œë¦¬ëŠ” ì§ˆë¬¸ì…ë‹ˆë‹¤. í¬ë¦¬ìŠ¤, MET-233i, í˜„ì¬ '3945ë¡œ ë²ˆí˜¸ê°€ ë§¤ê²¨ì§„ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°ìš”, ì´ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? íŠ¹íˆ ì¹¼ì‹œí† ë‹Œ(calcitonin) ëŒ€ë¹„ ì•„ë°€ë¦°(amylin)ì˜ í¸í–¥ì„±, ì´ê²ƒì´ íš¨ëŠ¥ê³¼ ë‚´ì•½ì„± í”„ë¡œíŒŒì¼ì— ë¯¸ì¹˜ëŠ” ì˜í–¥, ê·¸ë¦¬ê³  ADAì—ì„œ ê¸°ëŒ€í•  ìˆ˜ ìˆëŠ” ë°ì´í„°ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Thank you very much for the question. So this is an ultra-long-acting amylin, which was previously shown to have a monotherapy efficacy of 8.4% placebo-adjusted weight loss at day 36. It's a [ dual ] molecule, so it's not biased to the one. It's placebo-like tolerability was previously shown with the monotherapy. And that gave confidence for the -- starting the combination of '3944 and '3945. Previously, early data shown at day 8, 5% weight loss, but obviously, that's very early. So we will update those data later this year. This is an important combination for us because we believe with this combination, we can have best-in-class efficacy with a monthly dosing, which will be highly differentiated for this combination.</td><td>**Chris Boshoff:** ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ ì•½ë¬¼ì€ ì´ˆì¥ê¸° ì‘ìš© ì•„ë°€ë¦°(ultra-long-acting amylin)ìœ¼ë¡œ, ì´ì „ì— ë‹¨ë…ìš”ë²•ìœ¼ë¡œ 36ì¼ì°¨ì— ìœ„ì•½ ëŒ€ë¹„ 8.4%ì˜ ì²´ì¤‘ ê°ì†Œ íš¨ê³¼ë¥¼ ë³´ì—¬ì¤€ ë°” ìˆìŠµë‹ˆë‹¤. ì´ì¤‘ ì‘ìš© ë¶„ì(dual molecule)ì´ê¸° ë•Œë¬¸ì— ì–´ëŠ í•œìª½ìœ¼ë¡œ í¸í–¥ë˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë‹¨ë…ìš”ë²•ì—ì„œ ìœ„ì•½ ìˆ˜ì¤€ì˜ ë‚´ì•½ì„±ì„ ë³´ì˜€ê³ , ì´ê²ƒì´ '3944ì™€ '3945 ë³‘ìš©ìš”ë²•ì„ ì‹œì‘í•  ìˆ˜ ìˆëŠ” í™•ì‹ ì„ ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ˆê¸° ë°ì´í„°ì—ì„œ 8ì¼ì°¨ì— 5% ì²´ì¤‘ ê°ì†Œë¥¼ ë³´ì˜€ì§€ë§Œ, ì•„ì‹œë‹¤ì‹œí”¼ ì´ëŠ” ë§¤ìš° ì´ˆê¸° ë‹¨ê³„ì…ë‹ˆë‹¤. ì˜¬í•´ ë§ì— í•´ë‹¹ ë°ì´í„°ë¥¼ ì—…ë°ì´íŠ¸í•  ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ì´ ë³‘ìš©ìš”ë²•ì€ ì €í¬ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì´ ì¡°í•©ì„ í†µí•´ ì›” 1íšŒ íˆ¬ì—¬ë¡œ ë™ê¸‰ ìµœê³ (best-in-class) íš¨ëŠ¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ì´ ë³‘ìš©ìš”ë²•ì„ í¬ê²Œ ì°¨ë³„í™”ì‹œí‚¬ ê²ƒì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Chris.</td><td>**Albert Bourla:** <budget:token_budget>200000</budget:token_budget><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Chris.</td></tr>
<tr><td>Operator: Our final question comes from Louise Chen with Scotiabank.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ìŠ¤ì½”ìƒ¤ë±…í¬ì˜ Louise Chenìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Louise Chen: Scotiabank Global Banking and Markets, Research Division I wanted to ask you first, it's been a couple of years since you completed the acquisition of Seagen. And I'm just curious how that integration has gone? And then how is that deal really increased your leadership in oncology? And then just a second quick question on your PD-1-VEGF. It's becoming a more crowded market. So just curious where you expect to stand out with respect to your pipeline? I mean there's some indications that are coming before you, but is there anything special that you would like to call out?</td><td>**Louise Chen:** ì‹œì   ì¸ìˆ˜ë¥¼ ì™„ë£Œí•œ ì§€ 2ë…„ ì •ë„ ì§€ë‚¬ëŠ”ë°ìš”, í†µí•©ì´ ì–´ë–»ê²Œ ì§„í–‰ë˜ê³  ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë²ˆ ì¸ìˆ˜ê°€ ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œì˜ ë¦¬ë”ì‹­ì„ ì‹¤ì§ˆì ìœ¼ë¡œ ì–´ë–»ê²Œ ê°•í™”ì‹œì¼°ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? <br><br>ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ë¡œ ê°„ë‹¨í•œ ì§ˆë¬¸ì¸ë°ìš”, PD-1-VEGF ê´€ë ¨í•´ì„œìš”. ì‹œì¥ì´ ì ì  ë” ê²½ìŸì´ ì¹˜ì—´í•´ì§€ê³  ìˆëŠ”ë°, íŒŒì´í”„ë¼ì¸ì—ì„œ ì–´ë–¤ ì°¨ë³„ì ì„ ë³´ì—¬ì¤„ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ì‹œëŠ”ì§€ìš”? ì¼ë¶€ ì ì‘ì¦ë“¤ì´ ë¨¼ì € ë‚˜ì˜¤ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆëŠ”ë°, íŠ¹ë³„íˆ ê°•ì¡°í•˜ê³  ì‹¶ìœ¼ì‹  ë¶€ë¶„ì´ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Louise. And clearly Seagen has been integrated on research, commercial, manufacturing and multiple other levels. But given that Chris was the leader that drove the integration during the first sensitive year, Chris, maybe you want to make a comment on how the integration of Seagen went and is continuing.</td><td>**Albert Bourla:** <response><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Louise. ë§ì”€í•˜ì‹  ëŒ€ë¡œ Seagenì€ ì—°êµ¬ê°œë°œ, ì˜ì—…, ì œì¡° ë° ì—¬ëŸ¬ ë¶„ì•¼ì—ì„œ í†µí•©ì´ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ Chrisê°€ ì²« í•´ì˜ ë¯¼ê°í•œ ì‹œê¸° ë™ì•ˆ í†µí•©ì„ ì´ëˆ ë¦¬ë”ì˜€ë˜ ë§Œí¼, Chris, Seagen í†µí•©ì´ ì–´ë–»ê²Œ ì§„í–‰ë˜ì—ˆê³  í˜„ì¬ ì–´ë–»ê²Œ ê³„ì†ë˜ê³  ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br></response></td></tr>
<tr><td>Chris Boshoff: Chief Scientific Officer and President of Research & Development Thank you very much for the question. So firstly, we have a vibrant community of scientists and clinicians in Seattle. I believe we're one of the biggest employers for -- in the biotech or biopharma industry in that region. Most of the colleagues actually remained at Pfizer, which is just a testament of our culture and the success of the integration. A number of programs have started and being accelerated, including, as you've seen, the readout with 303 and 304 for Padcev. We are planning an additional Phase III study for Padcev. It will start later this year. It's an important study for us and for patients because that is to -- study to potentially replace cystectomy, which, as you know, leads to significant morbidity and mortality. We also accelerated a number of other programs into Phase III, including SV with two Phase III studies ongoing, an additional Phase III study that's going to start. PD-L1V, another Phase III program ongoing in non-small cell lung cancer and a number of Phase I ADCs that's differentiated, including using the integrin beta-6 antigen as a marker with new payloads, including TOPO2 and new auristatin-based payload. So integration, overall of Seagen going very, very well. Regarding '4404, it is a differentiated molecule. What we've seen in the preclinical data was a 100-fold increase for the affinity for PD-1 in the presence of VEGF and binding to all isoforms of VEGF-A. So preclinical data highly encouraging. Overall encouraged by the field now. As you know, we've recently seen from China first-line non-small cell lung data that was positive. The data we've seen with a combination of '4404 with chemotherapy are highly encouraging. And as we accelerate the program, as you've seen, we started Phase III programs already for colorectal cancer. And earlier this year, we'll also start with first-line Phase III with non-small cell lung cancer and then endometrial cancer and bladder cancer, including combinations with our ADC portfolio.</td><td>**Chris Boshoff:** ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë¨¼ì €, ì‹œì• í‹€ì—ëŠ” í™œê¸°ì°¬ ê³¼í•™ì ë° ì„ìƒì˜ ì»¤ë®¤ë‹ˆí‹°ê°€ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í•´ë‹¹ ì§€ì—­ì—ì„œ ë°”ì´ì˜¤í…Œí¬ ë˜ëŠ” ë°”ì´ì˜¤íŒŒë§ˆ ì—…ê³„ ìµœëŒ€ ê³ ìš©ì£¼ ì¤‘ í•˜ë‚˜ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ë™ë£Œë“¤ì´ ì‹¤ì œë¡œ í™”ì´ìì— ë‚¨ì•„ìˆëŠ”ë°, ì´ëŠ” ìš°ë¦¬ì˜ ê¸°ì—…ë¬¸í™”ì™€ í†µí•©ì˜ ì„±ê³µì„ ë³´ì—¬ì£¼ëŠ” ì¦ê±°ì…ë‹ˆë‹¤. ì—¬ëŸ¬ í”„ë¡œê·¸ë¨ë“¤ì´ ì‹œì‘ë˜ê³  ê°€ì†í™”ë˜ê³  ìˆìœ¼ë©°, ë³´ì…¨ë‹¤ì‹œí”¼ Padcevì˜ 303 ë° 304 ì„ìƒê²°ê³¼ ë°œí‘œë„ í¬í•¨ë©ë‹ˆë‹¤. Padcevì— ëŒ€í•œ ì¶”ê°€ 3ìƒ ì„ìƒì‹œí—˜ì„ ê³„íší•˜ê³  ìˆìœ¼ë©°, ì˜¬í•´ í›„ë°˜ì— ì‹œì‘í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ê²ƒì€ ì €í¬ì™€ í™˜ìë“¤ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ì„ìƒì‹œí—˜ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ë°©ê´‘ì ˆì œìˆ (cystectomy)ì„ ì ì¬ì ìœ¼ë¡œ ëŒ€ì²´í•  ìˆ˜ ìˆëŠ” ì—°êµ¬ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ë°©ê´‘ì ˆì œìˆ ì€ ìƒë‹¹í•œ ì´í™˜ìœ¨ê³¼ ì‚¬ë§ë¥ ì„ ì´ˆë˜í•©ë‹ˆë‹¤. ë˜í•œ ì—¬ëŸ¬ ë‹¤ë¥¸ í”„ë¡œê·¸ë¨ë“¤ë„ 3ìƒìœ¼ë¡œ ê°€ì†í™”í–ˆìŠµë‹ˆë‹¤. SVì˜ ê²½ìš° í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ë‘ ê±´ì˜ 3ìƒ ì„ìƒì‹œí—˜ì´ ìˆê³ , ì¶”ê°€ë¡œ í•œ ê±´ì˜ 3ìƒ ì„ìƒì‹œí—˜ì´ ì‹œì‘ë  ì˜ˆì •ì…ë‹ˆë‹¤. PD-L1VëŠ” ë¹„ì†Œì„¸í¬íì•”(non-small cell lung cancer)ì—ì„œ ì§„í–‰ ì¤‘ì¸ ë˜ ë‹¤ë¥¸ 3ìƒ í”„ë¡œê·¸ë¨ì´ê³ , ì°¨ë³„í™”ëœ ì—¬ëŸ¬ 1ìƒ ADCë“¤ë„ ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì¸í…Œê·¸ë¦° ë² íƒ€-6 í•­ì›(integrin beta-6 antigen)ì„ ë§ˆì»¤ë¡œ ì‚¬ìš©í•˜ê³  TOPO2ì™€ ìƒˆë¡œìš´ ì•„ìš°ë¦¬ìŠ¤íƒ€í‹´ ê¸°ë°˜ í˜ì´ë¡œë“œ(auristatin-based payload)ë¥¼ í¬í•¨í•œ ì‹ ê·œ í˜ì´ë¡œë“œë“¤ì´ í¬í•¨ë©ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ Seagenì˜ í†µí•©ì€ ë§¤ìš° ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. '4404ì™€ ê´€ë ¨í•´ì„œëŠ”, ì´ê²ƒì€ ì°¨ë³„í™”ëœ ë¶„ìì…ë‹ˆë‹¤. ì „ì„ìƒ ë°ì´í„°ì—ì„œ í™•ì¸í•œ ë°”ë¡œëŠ” VEGF ì¡´ì¬ í•˜ì—ì„œ PD-1ì— ëŒ€í•œ ì¹œí™”ë„ê°€ 100ë°° ì¦ê°€í–ˆê³ , VEGF-Aì˜ ëª¨ë“  ì´ì†Œí¼(isoform)ì— ê²°í•©í•˜ëŠ” ê²ƒì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì „ì„ìƒ ë°ì´í„°ëŠ” ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì´ ë¶„ì•¼ì— ëŒ€í•´ ê³ ë¬´ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ìµœê·¼ ì¤‘êµ­ì—ì„œ 1ì°¨ ì¹˜ë£Œ ë¹„ì†Œì„¸í¬íì•” ë°ì´í„°ê°€ ê¸ì •ì ìœ¼ë¡œ ë‚˜ì™”ìŠµë‹ˆë‹¤. '4404ì™€ í™”í•™ìš”ë²• ë³‘ìš©ì—ì„œ ë‚˜ì˜¨ ë°ì´í„°ë„ ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. í”„ë¡œê·¸ë¨ì„ ê°€ì†í™”í•˜ë©´ì„œ ì´ë¯¸ ëŒ€ì¥ì•”ì— ëŒ€í•œ 3ìƒ í”„ë¡œê·¸ë¨ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ ì´ˆì—ëŠ” ë¹„ì†Œì„¸í¬íì•” 1ì°¨ ì¹˜ë£Œ 3ìƒë„ ì‹œì‘í•  ì˜ˆì •ì´ê³ , ì´ì–´ì„œ ìê¶ë‚´ë§‰ì•”ê³¼ ë°©ê´‘ì•”, ê·¸ë¦¬ê³  ìš°ë¦¬ ADC í¬íŠ¸í´ë¦¬ì˜¤ì™€ì˜ ë³‘ìš©ìš”ë²•ë„ ì§„í–‰í•  ê³„íšì…ë‹ˆë‹¤.</td></tr>
<tr><td>Albert Bourla: Chairman of the Board & CEO Thank you, Chris. Very exciting. So thank you very much, everyone. Clearly, I'm very proud of what we achieved in 2025 in multiple horizons. The last piece of the puzzle was revealed today with the fourth quarter results, which were stellar. We beat with a significant margin, revenues and earnings in the face of the lowest-ever COVID season that generated the lowest-ever revenues because of the way that this strain was mild. Now we are already in 2026. And this is a pivotal year because it marks the first year of an LOE cycle but already started this year. And we've been preparing for that for many years with the acquisitions we have done, strategic and licensing agreements, while also we were sharpening our focus on the most impactful internal programs. Our U.S. and international commercial organizations have refined models to strengthen leadership with key product portfolios, streamlining and financial discipline are, of course, ongoing priorities. We will continue strategic investment in future growth and value creation for our shareholders, including by maintaining and over the long term, growing our dividend. Our 2026 strategic agenda is clear, and I'm confident in the progress we will achieve. Thank you for your interest in Pfizer, and we look forward to continuing to share our progress with you in the year ahead. Thank you.</td><td>**Albert Bourla:** ê°ì‚¬í•©ë‹ˆë‹¤, Chris. ì •ë§ í¥ë¯¸ì§„ì§„í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ ëª¨ë‘ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì €ëŠ” 2025ë…„ì— ì—¬ëŸ¬ ë°©ë©´ì—ì„œ ì´ë£¬ ì„±ê³¼ì— ëŒ€í•´ ë§¤ìš° ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. í¼ì¦ì˜ ë§ˆì§€ë§‰ ì¡°ê°ì€ ì˜¤ëŠ˜ ë°œí‘œëœ 4ë¶„ê¸° ì‹¤ì ìœ¼ë¡œ ì™„ì„±ë˜ì—ˆìœ¼ë©°, ê·¸ ê²°ê³¼ëŠ” ì •ë§ í›Œë¥­í–ˆìŠµë‹ˆë‹¤. ì—­ëŒ€ ìµœì € ìˆ˜ì¤€ì˜ ì½”ë¡œë‚˜ ì‹œì¦Œì„ ë§ì´í–ˆê³ , ë³€ì´ ë°”ì´ëŸ¬ìŠ¤ê°€ ê²½ë¯¸í–ˆë˜ íƒ“ì— ì—­ëŒ€ ìµœì € ë§¤ì¶œì„ ê¸°ë¡í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ìš°ë¦¬ëŠ” ë§¤ì¶œê³¼ ìˆ˜ìµ ëª¨ë‘ì—ì„œ ìƒë‹¹í•œ ì°¨ì´ë¡œ ì˜ˆìƒì¹˜ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ ìš°ë¦¬ëŠ” ì´ë¯¸ 2026ë…„ì— ì ‘ì–´ë“¤ì—ˆìŠµë‹ˆë‹¤. ì˜¬í•´ëŠ” íŠ¹í—ˆë§Œë£Œ(LOE) ì‚¬ì´í´ì˜ ì²« í•´ë¥¼ ë§ì´í•˜ëŠ” ì¤‘ìš”í•œ ì „í™˜ì ì´ ë  ê²ƒì´ë©°, ì´ëŠ” ì‚¬ì‹¤ ì˜¬í•´ë¶€í„° ì´ë¯¸ ì‹œì‘ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìˆ˜ë…„ê°„ ì´ë¥¼ ëŒ€ë¹„í•´ì™”ìŠµë‹ˆë‹¤. ì „ëµì  ì¸ìˆ˜í•©ë³‘ê³¼ ë¼ì´ì„ ì‹± ê³„ì•½ì„ ì§„í–‰í•˜ëŠ” ë™ì‹œì—, ê°€ì¥ ì˜í–¥ë ¥ ìˆëŠ” ë‚´ë¶€ í”„ë¡œê·¸ë¨ë“¤ì— ì§‘ì¤‘ë„ë¥¼ ë†’ì—¬ì™”ìŠµë‹ˆë‹¤. ë¯¸êµ­ê³¼ í•´ì™¸ ìƒì—… ì¡°ì§ì€ í•µì‹¬ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ë¦¬ë”ì‹­ì„ ê°•í™”í•˜ê¸° ìœ„í•´ ëª¨ë¸ì„ ê°œì„ í–ˆìœ¼ë©°, í•©ë¦¬í™”ì™€ ì¬ë¬´ ê±´ì „ì„±ì€ ë¬¼ë¡  ì§€ì†ì ì¸ ìš°ì„ ìˆœìœ„ì…ë‹ˆë‹¤. ë°°ë‹¹ê¸ˆ ìœ ì§€ì™€ ì¥ê¸°ì  ì„±ì¥ì„ í¬í•¨í•˜ì—¬ ë¯¸ë˜ ì„±ì¥ê³¼ ì£¼ì£¼ ê°€ì¹˜ ì°½ì¶œì„ ìœ„í•œ ì „ëµì  íˆ¬ìë¥¼ ê³„ì†í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ì „ëµì  ì–´ì  ë‹¤ëŠ” ëª…í™•í•˜ë©°, ìš°ë¦¬ê°€ ë‹¬ì„±í•  ì§„ì „ì— ëŒ€í•´ í™•ì‹ í•©ë‹ˆë‹¤. í™”ì´ìì— ëŒ€í•œ ê´€ì‹¬ì— ê°ì‚¬ë“œë¦¬ë©°, ì•ìœ¼ë¡œë„ ì—¬ëŸ¬ë¶„ê³¼ ìš°ë¦¬ì˜ ì§„ì „ì„ ê³„ì† ê³µìœ í•˜ê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ íšŒì˜ë¥¼ ë§ˆì¹˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ì‹œê°„ ë‚´ì£¼ì‹œê³  ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Pfizer Q4 2025 ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **VESPER-3 ì„ìƒ ê²°ê³¼ ë°œí‘œ**: ì›” 1íšŒ íˆ¬ì—¬ GLP-1 ì œì œ '3944ê°€ 28ì£¼ì°¨ì— 16% ì²´ì¤‘ ê°ì†Œ íš¨ê³¼ë¥¼ ë³´ì˜€ìœ¼ë©°, ë‚´ì•½ì„±ì€ ì£¼ 1íšŒ íˆ¬ì—¬ì™€ ìœ ì‚¬í•œ ìˆ˜ì¤€. ì¤‘ì¦ ì˜¤ì‹¬/êµ¬í† ëŠ” ê° 1ê±´ì— ë¶ˆê³¼í•˜ë©°, ë‹¨ê³„ì  ìš©ëŸ‰ ê°ì†Œ ì˜µì…˜ì„ Phase IIIì— ì¶”ê°€ ì˜ˆì •. 9.6mg ì›” 1íšŒ ìš©ëŸ‰ì„ VESPER-6 ì—°êµ¬ì—ì„œ í…ŒìŠ¤íŠ¸í•  ê³„íš<br><br>â€¢ **2026ë…„ ì „ëµì  ìš°ì„ ìˆœìœ„**: ì˜¬í•´ ì•½ 20ê°œì˜ Phase III ì„ìƒì‹œí—˜ ê°œì‹œ ì˜ˆì •. R&D íˆ¬ìëŠ” ì•½ 110ì–µ ë‹¬ëŸ¬ ê°€ì´ë˜ìŠ¤ ìœ ì§€í•˜ë©°, AI í™œìš©ì„ í†µí•œ ìƒì‚°ì„± í–¥ìƒìœ¼ë¡œ ë¹„ìš© ì ˆê°ë¶„ì„ ì¬íˆ¬ì. ViiV Healthcare ì§€ë¶„ ë§¤ê° ë“± ë¹„ì „ëµì  ìì‚° í˜„ê¸ˆí™”ë¡œ BD ì—¬ë ¥ í™•ë³´ (ì•½ 70ì–µ ë‹¬ëŸ¬)<br><br>â€¢ **ë¹„ë§Œì¹˜ë£Œì œ í¬íŠ¸í´ë¦¬ì˜¤ ì „ëµ**: ì›” 1íšŒ GLP-1 ë‹¨ë…ìš”ë²• ì™¸ì—ë„ ì´ˆì¥ê¸° ì‘ìš© ì•„ë°€ë¦°('3945)ê³¼ì˜ ë³‘ìš©ìš”ë²• ê°œë°œ ì¤‘. ê²½êµ¬ìš© GLP-1(YaoPharma ë„ì…), GIPR ê¸¸í•­ì œ ë“± ë‹¤ì–‘í•œ ì œí˜•ê³¼ ê¸°ì „ì˜ íŒŒì´í”„ë¼ì¸ êµ¬ì¶•. ìƒì—…íŒ€ì€ ì›” 1íšŒ íˆ¬ì—¬ì˜ í¸ì˜ì„±ê³¼ ê²½ìŸë ¥ ìˆëŠ” íš¨ëŠ¥ì´ ì‹œì¥ì—ì„œ ì°¨ë³„í™” ìš”ì†Œê°€ ë </p>
    <hr style="margin:50px 0;">
    
</body></html>